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RÉSUMÉ 
Le chitosane (CS) est un polymère cationique naturel qui s’associe aux acides nucléiques (AN), 
tels que les ARN interférents courts (siRNA), l’ADN plasmidique (pDNA) ou l’ARN messager 
(mRNA), pour former des complexes polyélectrolytes ou polyplexes non-solubles. Au cours des 
dernières années, les formulations de polyplexes à base de chitosane ont suscité un intérêt croissant 
en tant que systèmes de livraison d’acides nucléiques efficaces et sécuritaires, et ce pour des 
applications in vitro et in vivo. Les polyplexes CS/AN se forment par association électrostatique 
lorsque des solutions de CS et NA sont mélangées l’une avec l’autre. On utilise généralement le 
CS en excès par rapport aux AN, de telle sorte que les polyplexes portent une charge nette positive 
et suffisante pour assurer leur stabilité colloïdale. Malgré leur grand potentiel thérapeutique, les 
polyplexes à base de chitosane et leurs méthodes de production doivent être développés/optimisés 
davantage avant de pouvoir être utilisés pour des applications cliniques.  
Le mélange manuel est la méthode de production la plus courante des polyplexes CS/NA. Une telle 
méthode ne permet cependant pas un contrôle précis du processus de formation des complexes, 
pose donc des problèmes de variabilité/répétabilité entre utilisateurs/expérimentateurs et ne peut 
évidemment pas être utilisée à grande échelle. D’un autre côté, une fraction significative du CS 
utilisé en excès lors de la préparation des polyplexes demeure libre (non-lié aux polyplexes). Cette 
fraction de chitosane libre ainsi que la charge électrique positive des polyplexes favorisent les 
interactions avec les composants du sang et des systèmes physiologiques qui sont chargés 
négativement, ce qui limite la dose applicable de ces systèmes de livraison. L’application clinique 
de cette technologie de livraison par voie intravasculaire requièrt donc le développement de 
formulations avec une hémocompatibilité accrue. Le développement de telles formulations 
nécessite l’élimination de la fraction de CS libre et la modification des polyplexes avec, par 
exemple, le recouvrement de leur surface avec des polymères hydrophiles neutres ou des 
polyanions, de façon à neutraliser ou inverser le signe de la charge de ces complexes et ainsi 
éliminer/limiter les interactions avec les composantes du sang et améliorer leur pharmacocinétique. 
Dans le cadre de ce projet de doctorat, un système de mélange en ligne automatisé (SMLA) pour 
la production contrôlée et reproductible de larges volumes de polyplexes CS/AN a d’abord été 
développé. Le SMLA a permis la production de polyplexes CS/siRNA plus petits et plus 
homogènes par rapport à ceux obtenus par mélange manuel. Les polyplexes CS/siRNA produits à 
vii 
 
l’aide du SMLA en utilisant la vitesse de mélange maximale de 300 mL/min et une concentration 
de siRNA de 0.2 mg/mL, sont sphériques, plus petits et homogènes avec un diamètre 
hydrodynamique (Z-average) et un indice de polydispersite (PdI) de 47 nm et 0.12, respectivement, 
comparativement à des complexes préparés manuellement dont la taille est de l’ordre de 100 nm et 
le PdI de l’ordre de 0.2. Ces travaux de recherche ont permis de démontrer que les polyplexes 
CS/siRNA préparés à l’aide du SMLA ont une efficacité de silençage du gene de l’apolipoprotéine 
B (ApoB) in vitro équivalente ou supérieure à celle des polyplexes préparés par mélange manuel. 
Cette plate-forme de production à grande échelle automatisée permet de surmonter les limitations 
associées au mélange manuel des polyplexes et rend possible leur production contrôlée en grandes 
quantités pour des applications précliniques/cliniques. 
Afin de purifier de grands volumes de polyplexes à base de CS préparés à l’aide du SMLA, la 
filtration à flux tangentiel (TFF) basée sur l’utilisation de la technologie de fibres creuses a été 
adoptée et optimisée. Les paramètres d’opération optimaux de la TFF opérée en mode diafiltration 
ont été déterminés en utilisant des fibres creuses de polyethersulfone modifié (mPES) avec un poids 
moléculaire de coupure (MWCO) de 100 kDa: pression transmembranaire (TMP) de 0.9-1.0 psi, 
taux de cisaillement relativement faible allant de 7000 à 11000 s-1. Le rendement du procédé 
optimisé est de l’ordre de 85% avec une élimination du chitosane libre de plus de 98% et les 
résultats démontrent que les propriétés physico-chimiques des complexes ne sont pas altérées par 
la diafiltration. Les complexes de CS/siRNA ainsi purifiés ont été recouverts avec une librairie de 
molécules d’acide hyaluronique (HA) afin d’accroitre leur hémocompatibilité. Des HAs de masse 
molaire et degré de sulfatation (densité de charge) différents ont été utilisés. Les résultats 
démontrent que l’utilisation de HAs sulfatés ou non-sulfatés dans des proportions molaires de 
charges négatives du HA : charges négatives du siRNA supérieures ou égales à 2 :1 permet la 
production de polyplexes homogènes de faible taille et chargés négativement. De plus, l’utilisation 
de HA sulfatés permet d’obtenir des complexes plus stables par rapport à ceux préparés avec des 
HAs non-sulfatés. Finalement, nous avons déterminé que les polyplexes recouverts avec de HA 
non-sulfaté de masse molaire 10 kDa et de HA sulfaté de masse molaire 12 kDa (diamètres 
hydrodynamiques de 125 – 129 nm, PdI de 0.09 – 0.18 et potentiel zeta de 17 mV) possèdent une 
efficacité de silençage in vitro aussi élevée que celle de polyplexes CS/siRNA non recouverts de 
HA (non modifiés) et présentent une hémocompatibilité accrue par rapport aux complexes non-
recouverts.  
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Globalement, ce travail de recherche a mené au développement d’une méthode contrôlée et 
reproductible de production à grande échelle de polyplexes à base de chitosane. Ces polyplexes 
possèdent une bioactivité équivalente ou supérieure en comparaison à celle de polyplexes préparés 
par mélange manuel. La purification de larges volumes de polyplexes par TFF, tout en préservant 
leurs propriétés physico-chimiques et leur bioactivité, constitue une autre réalisation importante de 
ce projet. L’ajout de molécules de HA à la surface de polyplexes suite à leur purification par TFF 
a mené au développement d’une nouvelles classe de complexes bioactifs avec une 
hémocompatibilité accrue. L’ensemble des résultats et développements de ce travail de recherche 
représentent un pas important pour l’utilisation future de polyplexes CS/AN dans des applications 
précliniques et cliniques. 
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ABSTRACT 
Chitosan (CS) is a naturally derived cationic polysaccharide which simply self-assembles with 
nucleic acids (NAs) to form non-soluble polyelectrolyte complexes. In recent years, CS-based 
polyplex formulations have gained increasing interest as safe and efficient non-viral gene delivery 
systems both in vitro and in vivo. CS/NA polyplexes are produced by electrostatic-mediated 
association upon mixing of CS and NA solutions while CS is in excess versus NA. Thus, the final 
polyplexes bear a net positive charge that electrostatically stabilize them. Despite their great 
therapeutic potential, CS-based polyplexes must be further improved before transferring for 
clinical applications. Manual mixing is the most common method to produce CS-based polyplexes. 
However, this method varies in implementation, which raises concerns regarding comparability of 
the final polyplexes. Nonetheless, independent of the adopted approach, the conventional manual 
mixing is not only a poorly controlled method that results in irreproducibility but it is also restricted 
to relatively small volumes, which poses risks of batch to batch and inter-user variability. On the 
other hand, upon mixing of CS and NA, a significant portion of CS remains unbound to polyplexes. 
Due to interactions with negatively charged blood components, the unbound CS as well as the 
positive surface of polyplexes limit the applicable dosage of these therapeutics. Hence, clinical 
application of this technology requires development of hemocompatible formulations for 
intravenous (IV) delivery systems. Development of formulations with increased 
hemocompatibility involves coating the polyplexes either with another hydrophilic neutral 
polymer, e.g. polyethylene glycol (PEG), or with another polyanion, e.g. Hyaluronic Acid (HA), 
to switch the surface charge in order to eliminate the interactions with blood cells, and finally 
enhance the pharmacokinetics of CS-based polyplexes. Before these polyplexes can be used for 
further surface modifications, and studied clinically for IV administration they must be purified. 
Purification of CS-based polyplexes relies on elimination of the unbound CS molecules from the 
polyplexes. 
This work initially established a fully automated in-line mixing system (AIMS) for production of 
large batches of CS-based polyplexes. CS/siRNA polyplexes produced via AIMS were 
predominantly spherical, with z-average diameter as small as 47 nm, polydispersity index (PDI) as 
low as 0.12, and zeta potential of +16 mV, when prepared at the highest possible mixing speed 
(300mL/min), and siRNA concentration of 0.2mg/mL. Thus, AIMS was capable to deliver even 
smaller and more monodisperse CS/siRNA polyplexes compared to manual polyplexes with z-
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average of 100 nm and PDI of 0.20). It was also demonstrated that the in-line mixed CS/siRNA 
polyplexes have equivalent or higher silencing efficiency of Apolipoprotein B (ApoB) in HepG2 
cells, compared to manually prepared polyplexes. This scaled-up platform addressed the risk of 
batch to batch inter-user and intra-user variability, resulting in a controlled quality of large 
quantities of polyplexes intended for pre-clinical and clinical applications.  
Furthermore, to concentrate and purify large batches of CS-based polyplexes, tangential flow 
filtration (TFF) was adopted based on hollow fiber technology. Optimal TFF operational conditions 
were established using 100kD modified polyethersulfone (mPES) hollow fibers: trans-membrane 
pressure (TMP) of 0.9-1.0 psid, and relatively low shear rates of 7000-11000 s-1. Upon 
establishment of the operational conditions, it was demonstrated that TFF is capable in 
concentration of polyplexes up to sevenfold while preserving their physico-chemical properties. 
Optimal number of diafiltration volumes (DV) for diafiltration of polyplexes was also studied. Our 
data showed that when system ran at the shear rate of 7000 s-1, more than 98% of the unbound CS 
was removed with a DV of 5, while recovery yield was as high as 85%. Moreover, no marked 
changes in physico-chemical properties and morphology of polyplexes were observed post-
diafiltration. Purified CS/siRNA eGFP polyplexes were then coated by a library of HA molecules 
to enhance their hemocompatibility. HAs with different molecular weights and degrees of sulfation, 
at different phosphate to carboxyl ratios (C:P) were tested. It was found that a high molecular 
weight HA (866 kDa) results in macroscopic flocculations at every C:P ratio tested. Moreover, for 
low molecular weight HA (10-40 kDa) or moderate molecular weight HA (148-168 kDa), C:P≥ 2 
is needed to effectively coat the polyplexes and switch the surface charge of complexes. Our data 
showed that polyplexes coated with lower molecular weight HAs, non-sulfated 10kDa and sulfated 
12 kDa have have even higher knockdown efficiency of eGFP in H1299 cells (75-82%), compared 
to the uncoated polyplexes (53-63%). Furthermore, it was shown that although both sulfated and 
non-sulfated HAs result in small sized, homogenous and bioactive complexes, sulfated HA 
molecules present higher stability during filtration process. However, for both non-sulfated and 
sulfated HAs, coated formulations demonstrated improved hemocompatibility compared to the 
uncoated polyplexes. 
This work allowed to develop a controlled method for reproducible production of large batches of 
CS-based polyplexes with equivalent bioactivity as compared to manually prepared polyplexes. 
Purification of large batches of polyplexes via TFF while preserving their physicochemical 
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properties, and their biological activity was another accomplishment of this work. Moreover, 
adding a HA-coating to polyplexes led to the development of a new class of bioactive complexes 
with increased hemocompatibility. These results represent an important step towards future clinical 
use of CS-based intravenous gene therapies.   
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CHAPTER 1 INTRODUCTION 
Gene therapy involves introduction of nucleic acids (NAs) into cells to either promote or inhibit 
expression of a protein. While deoxyribonucleic acids (DNA) and messenger ribonucleic acids 
(mRNA) are used to express proteins, short interfering ribonucleic acids (siRNA) are used to inhibit 
the expression of a specific protein in host cells. Suppressing or promoting a gene expression 
requires successful delivery of NA into the cells. However, several extracellular and intracellular 
barriers limit the effectiveness of the delivery of an unprotected genetic material. For instance, the 
NA must be protected from nucleases; it must penetrate various structures including the 
endothelium and the plasma membrane; it must resist degradation during endolysosomal transit, 
and then be released into the cytoplasm; and, in the case of DNA, it must even migrate into the 
nucleus (Al-Dosari & Gao, 2009a). Therefore, for a successful delivery of a gene, an appropriate 
carrier is required. Depending on the nature of the carrier, delivery of NA can be accomplished 
using two major approaches: viral and non-viral. Viral gene delivery uses a virus as a vehicle to 
deliver therapeutic NAs. Although viral vectors show higher efficiency, they involve safety 
concerns such as immunogenicity, possible toxicity, inflammatory potential (Lim et al., 2006), and 
insertional mutagenesis (Dewey et al., 1999; Fox, 2000). In spite of a relatively large number of 
trials for viral products, only a few are marketed which is due to the safety issues. Therefore, viral-
based vectors need to be carefully assessed with regard to their safety for human gene therapy (S. 
R. Mao, W. Sun, & T. Kissel, 2010). On the other hand, non-viral vectors can present certain 
advantages over viral vectors such as large scale production and low host immunogenicity as well 
as formulation flexibility and lower manufacturing cost. Non-viral gene delivery mainly relies on 
the use of cationic compounds binding to negatively charged NAs by means of electrostatic 
interactions. Interest in this field has risen due to the lack of delivery systems for siRNA. Non-viral 
vectors are broadly classified into two categories: i) cationic lipids such as DOTAP (N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium) (Tousignant et al., 2000); and ii) cationic 
polymers such as polyethylenimine (PEI) and chitosan (CS) that form electrostatic complexes with 
NA. Complexes formed with cationic lipids and cationic polymers are referred to as lipoplexes and 
polyplexes, respectively. Lipoplexes are the most studied non-viral gene delivery systems, and 
have demonstrated ability for delivering siRNA, however, they are still associated with in vitro and 
in vivo toxicity issues (Basha et al., 2011; Ewert et al., 2004; M. C. Filion & Phillips, 1998; Lee et 
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al., 2012; Lv, Zhang, Wang, Cui, & Yan, 2006; Mortimer et al., 1999). On the other hand, cationic 
polymers present less toxicity compared to their cationic lipid counterparts (Al-Dosari & Gao, 
2009b), and have been shown to be particularly promising vectors and demonstrated successful 
nucleotide delivery both in vitro and in vivo (Aliabadi, Landry, Sun, Tang, & Uludag, 2012; Boussif 
et al., 1995; Chaturvedi et al., 2011; Davis et al., 2004; Heidel, Hu, Liu, Triche, & Davis, 2004; 
Howard, 2009; Howard et al., 2006b; Ikonen, Murtomaki, & Kontturi, 2008; Ishii, Okahata, & 
Sato, 2001; Issa et al., 2006; Pun et al., 2004). Hence, significant effort has been devoted to develop 
biomolecular conjugates and cationic polymers as delivery systems (Al-Dosari & Gao, 2009a; 
Prakash, Malhotra, & Rengaswamy, 2010; Winkler, 2013). There is also an increasing interest in 
cationic polymers as a non-viral carrier because of the virtually unlimited size of genes that they 
can complex and the possibility to easily functionalize such vectors. Among the cationic polymers, 
CS has gained interest for the safe delivery of NA in the past decade.  
CS is a naturally derived polycation, and a biocompatible and biodegradable linear polysaccharide. 
It has been demonstrated that CS-based delivery systems are efficient for the delivery of plasmid 
DNA, pDNA (Buschmann et al., 2013; Jean, Alameh, Buschmann, & Merzouki, 2011; Jean et al., 
2009; Lavertu, Methot, Tran-Khanh, & Buschmann, 2006; Mao et al., 2001; Nimesh, Thibault, 
Lavertu, & Buschmann, 2010a; Thibault, Nimesh, Lavertu, & Buschmann, 2010b) and siRNA 
(Alameh et al., 2012; Alameh et al., 2017; Corbet et al., 2016; Gao et al., 2014; Holzerny et al., 
2012; Howard et al., 2006a; X. Liu et al., 2007; Malhotra et al., 2009; Malhotra, Tomaro-
Duchesneau, Saha, Kahouli, & Prakash, 2013; Malmo, Sorgard, Varum, & Strand, 2012a; S. Mao, 
W. Sun, & T. Kissel, 2010; Ragelle et al., 2014; Ragelle, Vandermeulen, & Preat, 2013; Raja, 
Katas, & Jing Wen, 2015; Yang et al., 2015) both in vitro and in vivo. CS/NA polyplexes can be 
simply produced by electrostatic-mediated association upon mixing of CS and NA solutions in 
dilute conditions, while CS is used in excess versus NA. Thus, the final polyplexes bear a net 
positive charge which electrostatically stabilize them. Despite the promising potential of CS-based 
polyplexe formulations, some factors currently limit the use of these complexes in the clinic.  
Preparation of CS-based polyplexes is most commonly done by simple manual addition of CS and 
NA. However, this method is not established between research groups, which raises some concerns 
regarding comparability of the properties of such complexes. On the other hand, independent of 
the adopted approach, manual mixing is not only a poorly controlled method, which can result in 
formation of inconsistent complexes (C. Ankerfors, Ondaral, Wagberg, & Odberg, 2010a; Lu et 
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al., 2014), but is also restricted to relatively small preparation volumes, which seriously limit their 
applicability. Small scale day to day preparation of complexes poses the risk of batch to batch and 
inter-user variability of these polyplexes (Kasper, Schaffert, Ogris, Wagner, & Friess, 2011; Lu et 
al., 2014; Zelphati et al., 1998). Thus, a controlled and reproducible production process (ideally, 
an automated platform) is a prerequisite to tackle the drawbacks of manual method before 
transferring CS-based polyplexes to clinical applications. To date, there is no report on 
establishment of an automated platform for production of large batches of CS-based polyplexes. 
Here, we introduced an automated in-line mixing system for reproducible production of CS-based 
polyplexes in large batches, as we hypothesized that by controlling the process parameters, it is 
possible to control the physico-chemical properties and bioactivity of the polyplexes. 
On the other hand, in order to produce stable colloidal suspensions of relatively small sized and 
homogeneous polyplexes, preparation must take place in dilute conditions, ~50 to 100 μg nucleic 
acid/mL (MacLaughlin et al., 1998a; Xu & Anchordoquy, 2011a). The low concentration regime 
limits the concentration of the final product in such systems. However, higher doses of polyplexes 
per injection are required for clinical applications. Thus, it is necessary to increase the 
concentration of polyplexes post-mixing. In addition, being in excess during mixing, a significant 
portion of CS remains free (unbound to polyplexes) in the final polyplex solution. It was reported 
that in CS/NA formulations prepared at an N:P ratio of 5, around 70% of added CS stays free in 
the final soluiton (P. L. Ma, Lavertu, Winnik, & Buschmann, 2009). Moreover, in almost all of the 
reported studies, a very high N:P ratio (>25) was used to produce CS/siRNA formulations. The 
unbound CS as well as the cationic surface of the polyplexes limit in vivo application of these 
formulations due to interaction with negatively charged blood components, e.g. proteins and red 
blood cells (RBCs). Despite promising results for different administration routes (i.e. 
intramuscular, oral, intranasal, etc.), intravenous (IV) administration of high doses of CS-based 
polyplexes remains problematic due to the interactions with blood components, which cause 
hemolysis and hemagglutination (Carreno-Gomez & Duncan, 1997; Rao & Sharma, 1997). To 
overcome this challenge, several types of surface modification can be used to eliminate the 
hemotoxicity of these polyplexes. 
Effective approach involves either PEGylation of CS before mixing with NA (Malhotra, Lane, 
Tomaro-Duchesneau, Saha, & Prakash, 2011; Pickenhahn et al., 2015), or PEGylation of 
polyplexes (Corbet et al., 2016), where the polyplexes become neutralized by addition of PEG 
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though chemical modification of CS on the surface of the polyplexes. PEG not only provides 
nanoparticles (NPs) with a hydrophilic layer that stablizes and protects them from further intractions 
due to steric repulsions, but also increases the circulation time of NPs in the blood (Buschmann et al., 
2013; Torchilin & Trubetskoy, 1995). However, PEGylation of polyplexes involves several chemical 
modifications that potentiates toxicity concerns. A relatively simple approach involves coating the 
CS/NA polyplexes with another biocompatible polyanion, i.e. hyaluronic acid (HA). Hyaluronic 
acid is a highly hydrophilic glycosaminoglycan with a broad range of molecular weight 
(Karbownik & Nowak, 2013; Tripodo et al., 2015). HA is a polyanion formed of N-acetyl-D-
glucosamine and D-glucuronic acid units, which are linked by alternating β-(1,4) and β-(1,3) 
glycosidic bonds. HA is involve in several biological functions including maintenance of the 
elastoviscosity of joint liquids, hydration and water transport to tissues, as well as numerous 
receptor-mediated roles (Hascall et al., 2004; Necas, Bartosikova, Brauner, & Kolar, 2008; Turley, 
Noble, & Bourguignon, 2002), e.g. HA binds to the CD44 receptor, which is overexpressed in a wide 
variety of cancer cells (Dosio, Arpicco, Stella, & Fattal, 2016; Karbownik & Nowak, 2013; Platt & 
Szoka, 2008). HA can be used to modify the surface of CS-based complexes to improve their 
hemocompatibility. The carboxyl functions of the D-glucuronic acid units have an acidic pKa of 
~3-4. Thus, HA is negatively charged at physiological pHs (Dosio et al., 2016), and therefore can 
bind spontaneously to the cationic amine groups of CS by electrostatic interactions. However, 
before CS-based polyplexes can be either studied clinically for IV administration, or used for 
further surface modifications, they must be concentrated and purified. Purification of CS-based 
NPs relies on elimination of the unbound chitosan molecules from the polyplex solution. Several 
conventional techniques have been reported for the purification of NPs such as ultracentrifugation 
(Correa et al., 2016; Dalwadi, Benson, & Chen, 2005), dialysis (Kwon, Lee, Choi, Jang, & Kim, 
2001), and gel separation (Beck, Scherer, & Kreuter, 1990; Hanauer, Pierrat, Zins, Lotz, & 
Sonnichsen, 2007). However, these traditional techniques are either invasive, expensive, or time-
consuming and relatively inefficient, or difficult to scale-up. Ultracentrifugation is associated with 
irreversible aggregation due to the high centrifugal forces, and particle loss in the supernatant 
during the washing steps (Dalwadi et al., 2005). Such drawbacks become much more problematic 
when transitioning from small scale to large scale purifications (Correa et al., 2016). Dialysis 
involves the risk of product loss through manual manipulations of the dialysis bags, requires a large 
amount of exchange buffer, which produces large volumes of aqueous waste, and can take up to 
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several days (Sweeney, Woehrle, & Hutchison, 2006). Moreover, due to the lengthy process, 
dialysis can result in release of NP’s payload (Dalwadi et al., 2005). Gel filtration is relatively, a 
faster purification technique, however, irreversible adsorption of molecules onto the column, and 
not a perfect selectivity of small and bigger NPs can restrict the application of this technique for 
purification of drug or gene-loaded particulates. Moreover, gel separation is not scalable since only 
a small volume of NP solution can be processed at a time (Dalwadi et al., 2005). Tangential flow 
filtration (TFF), on the other hand, is a rapid and efficient method which is used for purification 
and concentration of biomolecules, and NPs. TFF overcomes the main limitations of the other 
conventional purification techniques. The exceptional feature of TFF is its capablility to purify and 
concentrate polyplexes in a single process. During TFF, molecules smaller than membrane pores 
pass through the membrane (generating the permeate) and larger molecules are retained and re-
circulated in the system (generating the retentate) until the desired purity is reached. Diafiltration 
is a TFF process that involves washing out the original buffer by continuously adding water (or a 
new buffer) to the sample at the same rate as permeate is being removed from the system (Larry 
Schwartz, 2003). In the past decade diafiltration has been applied frequently for purification and 
buffer exchange purposes. It has been used to purify pDNA (Kahn et al., 2000), indomethacin 
loaded NPs (Limayem, Charcosset, & Fessi, 2004), poly(lactide-co-glycolide) (PLGA) NPs 
containing polyvinyle alcohol (PVA) (Dalwadi et al., 2005), DNA-loaded nanospheres (Hammady, 
Nadeau, & Hildgen, 2006), hyaluronic acid (Zhoua, Ni, Huanga, & Zhang, 2006), Gold NPs 
(Sweeney et al., 2006), PEGylated NPs (Dalwadi & Sunderland, 2007), Silver NPs (Anders et al., 
2012; Trefry et al., 2010), lauric acid/albumin-coated iron oxide NPs (Zaloga et al., 2015), and 
polymersome NPs (Robertson et al., 2016). Recently, Correa et al. applied TFF to synthesize layer 
by layer (LBL) NPs (Correa et al., 2016). They managed the intermediate purification steps by 
using TFF in diafiltration mode to produce nanoscale LbL formulations. Despite its widespread 
use, to date, there is no report on using TFF to purify and concentrate CS-based polyplexes. 
Therefore, it would be relevant to validate and establish TFF technique for processing these 
polyplexes. We hypothesized that TFF is capable to remove the unbound CS, and to concentrate 
the polyplexes as well. Another hypothesis of this study is that HA-coating improves 
hemocompatibility and targeting capability of CS-based polyplexes. 
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1.1 Objectives 
The first objective of the thesis is to set up an automated mixing system for reproducible production 
of large batches of CS-based polyplexes, while preserving their physicochemical properties and 
biological activity. Another objective is to establish TFF technique and optimize its operational 
conditions for purification and concentration of CS-based polyplexes. The final objective of the 
thesis is to develop HA-coated complexes, upon purification of polyplexes, to enhance their 
hemocompatibility for intravenous clinical applications. 
1.2 Architecture of the thesis   
The thesis begins with a critical literature review, presented in Chapter 2, which covers topics 
relevant to different mixing strategies for scaled up production of nanoparticles, and drug 
formulations. This chapter continues with a literature review of several conventional purification 
techniques as well as TFF which have been used for purification of various biomolecules and 
nanoparticles. Chapter 3 presents the approach to all the work carried out in order to achieve the 
objectives of the thesis mentioned in section 1.1. The following two chapters constitute the body 
of the thesis; they are presented in the form of a published article summarizing the in-line mixing 
system for large scale production of chitosan-based polyplexes (chapter 4), and a chapter describing 
purification of polyplexes via TFF, and finally coating of the chitosan-based polyplexes using 
hyaluronic acid (chapter 5). A general discussion of the results is then presented in chapter 6, 
followed by a conclusion and recommendations (chapter 7). 
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CHAPTER 2 LITERATURE REVIEW 
2.1 Polyelectrolyte complexes (PECs) 
Mixing of anionic and cationic polyelectrolytes results in the formation of polyelectrolyte 
complexes (PECs) as a consequence of attractive electrostatic interactions. The formation of PECs 
is associated with an increase in entropy due to liberation of low molecular counter-ions (C. B. 
Bucur, Z. Sui, & J. B. Schlenoff, 2006; Claudiu B. Bucur, Zhijie Sui, & Joseph B. Schlenoff, 2006; 
Ou & Muthukumar, 2006). Figure 2.1 displays a schematic diagram of the complexation of two 
oppositely charged polyelectrolytes. The simple formation mechanism of PECs avoids the use of 
chemical manipulations, therefore minimizes the possible toxicity and other undesirable effects of 
the reagents (Lankalapalli & Kolapalli, 2009). These advantages represent a great potential for 
PECs in gene therapy and drug delivery applications. Complexes of cationic polymers and NA (as 
the polyanion) are called polyplexes which are considered as a type of PECs. There are two 
different types of PECs, soluble and non-soluble (colloidal) that are described further below.  
 
Figure 2.1 Polyelectrolyte formation as the consequence of attractive electrostatic interactions, 
which is associated with an increase in entropy due to liberation of low molecular counter-ions. 
2.1.1 Soluble and colloidal PECs 
Depending on the nature of the polyelectrolytes and mixing conditions such as media composition, 
mixing stoichiometry, and concentration of polyelectrolytes, water-soluble PECs (on a molecular 
level) or non-soluble PECs (on a colloidal level) may be formed. The first synthetic PEC was 
prepared by Michaels and Miekka dealing with the stoichiometry of PECs (Michaels & Miekka, 
1961). They investigated the formation of non-soluble PECs resulting from the mixing of two 
oppositely charged polyelectrolytes at a 1:1 charge ratio. Later, preparation of nonstoichiometric 
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water-soluble PECs was studied and developed by groups of Kabanov and Tsuchida and 
Dautzenberg (Bindig et al., 1998; Tsuchida, 1994). Soluble complexes can be formed under special 
conditions: 1) one component has weak ionic groups, 2) there is a significant difference in the 
molecular weight of the oppositely charged chains, 3) the mixture contains a high excess of the 
long chain component, and 4) a minimal amount of salt is present in mixing medium (Thunemann, 
Muller, Dautzenberg, Joanny, & Lowen, 2004b). If one or more of the above conditions are not 
met, complex formation results in particles in the colloidal range (Dautzenberg et al., 2001; 
Shovsky, Varga, Makuska, & Claesson, 2009; Zintchenko, Rother, & Dautzenberg, 2003). The 
structure of colloidal PECs is in fact aggregated particles comprising many polyelectrolytes. While 
in very dilute solutions, the formed PECs stop at colloidal level and resist secondary aggregation, 
PEC formation between strong polyelectrolytes in a concentrated regime continues with 
association of more polyelectrolytes into the previously formed PEC and creates highly aggregated 
or macroscopic flocculated systems. In highly diluted solutions (<0.1 mg/mL) PEC formation leads 
to non-aggregated, quasi-soluble particles on a colloidal level with nearly spherical morphology 
(Dautzenberg, Hartmann, Grunewald, & Brand, 1996; Muller, 1974; Muller, Kessler, Frohlich, 
Poeschla, & Torger, 2011; Thunemann, Muller, Dautzenberg, Joanny, & Lowen, 2004a). 
Aggregation, flocculation and macroscopic phase separation take place at higher concentrations 
(>1 mg/mL) (Dautzenberg et al., 1996). 
2.1.2 Polyelectrolyte complex structure 
Depending on the characteristics of the polyelectrolyte groups and external conditions, PEC 
formation leads to two different structural models known as ladder-like and scrambled egg 
structure (Michaels & Miekka, 1961). The ladder-like structure (Figure 2.2a) in which complex 
formation takes place on a molecular level consists of hydrophilic single-stranded and hydrophobic 
double-stranded segments. This structure results from the mixing of two polyelectrolytes with weak 
ionic groups and large differences in molecular weights in nonstoichiometric systems. In the ladder-
like architecture, the two polyelectrolyte are relatively stiff and have low charge densities (Chen, 
Heitmann, & Hubbe, 2003).  The ladder-like structure corresponds to the soluble PECs and was 
found as a successful model in explaining the behaviour of certain PECs formed from a “guest” 
polyelectrolyte added into a “host” polyelectrolyte with much higher molecular weight (Chen et 
al., 2003; Kabanov et al., 2003; Philipp, Dautzenberg, Linow, Kotz, & Dawydoff, 1989). However, 
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the scrambled-egg model Figure 2.2d), where a large number of chains are incorporated into a 
particle, is formed from mixing of polyelectrolytes with relatively strong charge densities (or at 
least one of the two polyelectrolytes with strong charge density) and similar molecular weights. 
Ankerfors et al. showed that mixing polyelectrolytes at 1:1 stoichiometry yields in insoluble and 
highly aggregated complexes (Caroline Ankerfors, 2008). When the two polyions are very dilute, 
the complex will be controlled at the colloidal level. While the ladder-like structure is realized in 
the case of relatively stiff chains, ﬂexible chains form globular scrambled-egg structure with 
disordered position of monomer units (Lazutin, Semenov, & Vasilevskaya, 2012). 
 
Figure 2.2 Snapshots of PECs with different levels of stiffness: from very stiff chains (a), relatively 
stiff (b), relatively flexible (c), and completely flexible (d). PECs were derived from two identical 
polyions: equal degree of polymerization and equal numbers of charged groups. Taken from 
(Lazutin et al., 2012). Copyright 2017, with Elsevier’s permission. 
2.2 Chitosan as a polycation for gene delivery applications 
As mentioned previously, the simple formation mechanism of PECs makes them great candidates 
for gene delivery systems when a NA is condensed by a suitable polycation as the carrier. A 
positively charged polymeric carrier should have well defined physicochemical properties, enough 
NA packaging capacity, a high molecular weight diversity that allows multiple formulations to 
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potentially overcome extracellular and intracellular obstacles of gene delivery (Jeong, Kim, & 
Park, 2007), and form stable complexes in physiological conditions. In addition, it should have the 
potential to avoid the host surveillance systems, and deliver the therapeutic NA to the desired cell 
population and provide appropriate functionalities to escape from endolysosomal pathways, after 
being localized within the cells (S. R. Mao et al., 2010). Chitosan (CS) is a naturally derived 
polycation obtained by deacetylation of chitin, which is a structural element in the exoskeleton of 
crustaceans (crabs, shrimp, etc.) and cell walls of fungi (S. R. Mao et al., 2010). Composed of β-
(1-4)-linked D-glucosamine (D unit) and N-acetyl-D-glucosamine (A unit) (Figure 2.3), CS is a 
biocompatible and biodegradable polymer (Garcia-Fuentes & Alonso, 2012; Kean & Thanou, 
2010) with positive charge groups.  
 
Figure 2.3 Chemical structure of chitosan (A and D units represent N-acetyl-D-glucosamine and 
D-glucosamine, respectively). Adapted from (Buschmann et al., 2013). Copyright 2017, with 
Elsevier’s permission. 
CS is characterized by its physicochemical properties such as molecular weight (MW) and degree 
of deacetylation (DDA). DDA corresponds to the molar fraction of D unit in the linear chain of 
chitosan, calculated as below: 
DDA = (D/(D+A)×100            Eq. 2.1 
The solubility of CS is greatly influenced by the DDA, MW, as well as pH and ionic strength of 
the solution. Each deacetylated unit of chitosan (D unit) contains an amine group with an intrinsic 
dissociation constant, pKa, near 6.5 (D. Filion, Lavertu, & Buschmann, 2007). CS is soluble in 
acidic conditions where sufficient protonation of D units occurs and is insoluble at neutral and 
alkaline pH values. CS can be hydrolyzed either by lysozymes or by chitinases and chitosanases 
that are produced by human intestine (Aiba, 1992; Zhang & Neau, 2002), or exist in the blood 
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(Escott & Adams, 1995). Furthermore, the protonated amine functions of CS also allow it to 
interact spontaneously with negatively charged phosphate groups of NAs, thus, forming a PEC, 
namely a polyplex. Due to its NA packaging capability, CS has been widely used in biomedical 
and pharmaceutical research as a safe alternative to other non-viral vectors such as cationic lipids 
for gene delivery applications (W. G. Liu & De Yao, 2002; S. R. Mao et al., 2010). In recent years, 
CS-based polyplexes have gained increasing interest for safe delivery of gene materials including 
pDNA and siRNA (Alameh et al., 2012; Alameh et al., 2017; Buschmann et al., 2013; Corbet et 
al., 2016; Gao et al., 2014; Holzerny et al., 2012; Howard et al., 2006a; Jean et al., 2012b; Katas & 
Alpar, 2006; Lavertu et al., 2006; X. Liu et al., 2007; MacLaughlin et al., 1998a; Malhotra et al., 
2009; Malhotra et al., 2013; Malmo et al., 2012a; Mao et al., 2001; S. Mao et al., 2010; Ragelle et 
al., 2014; Ragelle et al., 2013; Raja et al., 2015; Thibault et al., 2010b; Veilleux, 2016; Yang et al., 
2015). 
Due to the intrinsic high charge density of NAs and relatively high charge density of CS (at low 
pHs where it is fully ionized), PECs prepared by addition of CS and NA are non-soluble and 
expected to have the scrambled-egg structure when mixed in dilute conditions. At low 
concentrations, the non-soluble particles can be stable at the colloidal level and protected from 
flocculation (Dautzenberg et al., 1996; Muller, 1974; Muller et al., 2011; Thunemann et al., 2004a). 
2.2.1 Influential factors on CS/NA polyplex formation and its properties 
Generally, several parameters influence the properties of PECs such as polyelectrolyte 
concentration, structural properties (i.e. length and charge spacing), molar mixing ratio 
(Dautzenberg et al., 1996), pH of the medium (Rungsardthong et al., 2003), and ionic strength 
(Dautzenberg, 1997; Oupicky, Konak, Ulbrich, Wolfert, & Seymour, 2000). In the case of CS/NA 
polyplexes, the influential parameters could be described by the formulation parameters such as 
molecular weight of NA, molecular weight and DDA of CS, as well as the molar ratio of amine 
groups of CS to the phosphate group of NA (N:P ratio) as the indicators of length, charge spacing 
and the mixing ratio, respectively. Reducing the ionization degree of the polyelectrolytes by 
changing pH reduces the binding affinity and influences the structure of the PECs (Rungsardthong 
et al., 2003; Strand, Danielsen, Christensen, & Varum, 2005). In CS/NA polyplex formation, 
lowering the pH of the solution increases the degree of ionization for the aminated cationic polymer 
of CS leading to greater binding affinity with NA (P. L. Ma et al., 2009). For example, the variation 
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in pH at the time of transfection can influence the size, charge, colloidal stability, and transfection 
efficiency of CS/pDNA polyplexes (Lavertu et al., 2006). In the pH range from 4 to 8, DNA has a 
constant anionic charge density since the pKa of its phosphate group is near 1. Therefore, adjusting 
the solution pH only influences the degree of ionization of CS due to the pKa (~6.5) of the amine 
group in the glucosamine units (D. Filion et al., 2007). According to Ma et al., there is a stronger 
interaction of CS and DNA at low pH compared to that at high pH. A lower binding affinity is 
found at pH of 7.4 versus 6.5 and 5.5 due to a lower level of CS ionization and lower electrostatic 
attraction between CS and NA (P. L. Ma et al., 2009). The MW of CS is another important factor 
that influences the size, stability, the dissociation of DNA from the complex after endocytosis, and 
therefore the transfection efficiency of the CS/NA polyplexes (MacLaughlin et al., 1998b; Sato, 
Ishii, & Okahata, 2001). There is a contradiction for the relationship between the MW of chitosan 
and the size of polyplexes. Many reports show that the size of CS/pDNA polyplexes increase as 
chitosan MW increases (M. Huang, Fong, Khor, & Lim, 2005; Q. G. Huang, Zhu, Wu, & Lin, 
2001; MacLaughlin et al., 1998b) as they found an increase from about 100 nm to 500 nm when 
CS’s MW goes from a few kDa to around 500 kDa. In contrast, in few reports it is shown that by 
increasing CS’s MW, the size of polyplexes is decreased (M. Huang et al., 2005; Romoren, 
Pedersen, Smistad, Evensen, & Thu, 2003) or remained unchanged (Lavertu et al., 2006; Romoren 
et al., 2003). Transfection efficiency of CS/DNA polyplexes may depend on the size of the particles 
(M. Huang et al., 2005; Nafee, Taetz, Schneider, Schaefer, & Lehr, 2007). CS’s degree of 
deacetylation (DDA) corresponds to the percentage of deacetylated amine groups and thus the 
fraction of glucosamine monomers versus total glucosamine and N-acetyl glucosamine, along the 
molecular chain of CS. DDA is proportional to the positive charge density when CS is dissolved 
and ionized in strong acidic conditions. The DDA of CS influences its solubility, crystallinity, and 
degradation (Aiba, 1989). A higher DDA results in an increased charge density enabling a greater 
DNA binding capacity and cellular uptake (Kiang, Wen, Lim, & Leong, 2004). According to 
Koping-Hoggard et. al., in order to obtain stable complexes with pDNA that transfect target cells 
in vitro the DDA of chitosan must exceed 65% (Koping-Hoggard et al., 2001). According to 
Lavertu et al., the in vitro transgene expression of CS/pDNA polyplexes is maximized either by 
reducing the DDA and increasing MW, or by increasing the DDA and decreasing MW. This could 
be described by the desired intermediate level of stability of NPs, that should be high enough to 
condense and protect DNA extracellularly but low enough to allow intracellular DNA release from 
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the vector for gene expression (Lavertu et al., 2006). Also, Jean et al. found higher pDNA 
transfection efficiency using chitosan of 92% DDA compared to 80% in vitro (Jean et al., 2012a). 
The influence of DDA of CS on its binding affinity to DNA was studied by Ma et al. (P. L. Ma et 
al., 2009). They showed that an increase in the DDA of chitosan results in an increase in the charge 
density along the molecular chain of CS and increased affinity for DNA that also results in fewer 
chitosan chains bound to DNA at saturation of the binding sites. The N:P ratio is defined as the 
mixing molar ratio of amine groups of chitosan to the phosphate of NA. At a sufficient N:P charge 
ratio, CS can condense DNA and siRNA to the sizes compatible with cellular uptake while 
preventing nucleases from accessing the enclosed NA by steric protection (M. Huang et al., 2005). 
However, it should be noted that when the DDA of CS is high, using very high N:P ratio may lead 
to difficulties of NA release once the polyplex arrives at the site of action because of the strong 
electrostatic interaction (Thibault, Nimesh, Lavertu, & Buschmann, 2010a); therefore, a good 
balance needs to be chosen for appropriate cellular uptake. It has been proven that an excess CS 
versus NA (Thibault et al., 2010a) is needed for an efficient transfection. Part of the excess CS 
creates a positive charge to the polyplex surface and an additional part of the excess CS remains 
free and unassociated with the polyplexes. It has been demonstrated that an N:P ratio of 5 is 
generally optimal for a highly efficient transfection of NAs (Lavertu et al., 2006; Thibault et al., 
2010a). In addition to the above-mentioned parameters, concentration of the two polyelectrolytes 
to be mixed (CS and NA) plays a very important role on the size and the transfection efficiency of 
the produced polyplexes. In fact, there is a very significant difference between the characteristics 
of a dilute polymer solution (where polymer chains are completely separate) and a concentrated 
solution (where polymer chains are overlapped). When the distance between polyelectrolyte chains 
becomes on the order of their size, they begin to overlap. Generally, the transition concentration of 
polyelectrolyte solutions from dilute to semi-dilute regimes is defined as the overlap concentration 
(de Gennes, 1979). It is well established that for production of non-aggregated PECs, the mixing 
of the two polyions has to be done in dilute regime. Accordingly, for producing stable and non-
aggregated CS-NA polyplexes, the formation of PECs should take place in dilute regime (Klausner, 
Zhang, Chapman, Multack, & Volin, 2010; Lavertu et al., 2006; Malmo, Sorgard, Varum, & 
Strand, 2012b; Mao et al., 2001). It is reported that the diameter of the polyplexes increased as the 
plasmid concentration increased (MacLaughlin et al., 1998b). Also, the transfection efficiency will 
increase when the dosage of NA increased up to a critical point, thereafter; the transfection will 
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decrease significantly (S. R. Mao et al., 2010), which can be described by a sharp increase in the 
size of polyplexes and aggregation of NPs, resulting in impaired cell uptake. Although, according 
to the literature the maximum concentration of NA for preparation of non-aggregated and uniform 
CS/NA polyplexes is roughly 0.1 mg/mL (Xu & Anchordoquy, 2011b), it is important to be aware 
of the overlap concentration (C*) of the two polyions to have an estimation of the applicable range 
of mixing concentrations of polyions and how far the mixing conditions are from the semi-dilute 
regime. C* of a polymer solution could be either measured or calculated. Several techniques are 
used to determine the overlap concentration of polymeric solutions, such as small angle light 
scattering, osmometry, viscometry, light scattering and nuclear magnetic resonance (Wandrey, 
1999; Zhu & Choo, 2008). For example, Calero et. al. measured the overlap concentration of 
chitosan with the molecular weight of 200 kDa by viscometry technique and reported a C* of 2.6 
mg/mL. C* depends on the degree of polymerization of polyelectrolye (N, number of monomers 
in a chain), mass of a monomer (Mmon) and the radius of gyration (Rg, chain size in salt-free 
solution) (de Gennes, 1979): 
C*≈ (N × Mmon)/Rg
3             Eq. 2.2 
2.3 Chitosan-based polyplexes 
CS/NA polyplexes are generally prepared by fast addition of CS to NA solutions under dilute 
conditions (~0.1 mg/mL or below). NPs prepared this way constitute a colloidal type of PEC 
(Klausner et al., 2010; Lavertu et al., 2006; Malmo et al., 2012b; Mao et al., 2001). Studies of 
colloidal PEC formation indicate that such PECs are mainly spherical and consist of a neutral 
stoichiometric core that is surrounded by a charged stabilizing shell composed of the excess polyion 
(Dautzenberg et al., 1996; Philipp et al., 1989; Rungsardthong et al., 2003). CS-based polyplexes 
have been shown to be efficient for the delivery of pDNA (Buschmann et al., 2013; Jean et al., 
2012b; Jean et al., 2009; Lavertu et al., 2006; Mao et al., 2001; Nimesh et al., 2010a; Thibault et 
al., 2010b) and siRNA (Alameh et al., 2012; Alameh et al., 2017; Corbet et al., 2016; Gao et al., 
2014; Holzerny et al., 2012; Howard et al., 2006a; X. Liu et al., 2007; Malhotra et al., 2011; Malmo 
et al., 2012a; S. Mao et al., 2010; Ragelle et al., 2014; Ragelle et al., 2013; Raja et al., 2015; Yang 
et al., 2015) both in vitro and in vivo.  
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Despite the potential of these polyplexes in vivo, intravenous (IV) administration remains 
problematic for high doses due to hemolysis and haemagglutination of erythrocytes in contact with 
CS (Carreno-Gomez & Duncan, 1997). In fact, CS binds to the red blood cells (RBCs), and causes 
haemagglutination, even at very low concentrations (Rao & Sharma, 1997). The interactions 
between the cationic charges of CS molecules and the anionic charges on the surface of the 
erythrocytes results in haemagglutination, thus inducing stresses on the cell membranes which 
eventually leads to their rupture (Carreno-Gomez & Duncan, 1997; Rao & Sharma, 1997). 
2.3.1 Chitosan/pDNA polyplexes 
As mentioned above, molecular weight (MW in kDa) and the degree of deacetylation (DDA in %) 
of CS together with the concentration and molar ratio of amine group of CS to the phosphate group 
of NAs (N:P ratio) are the key factors in preparation of CS/NA complexes (M. Huang et al., 2005; 
Lavertu et al., 2006; S. R. Mao et al., 2010). It has been shown that while CS with relatively high 
MW is needed to achieve the extracellular NA protection, efficient intracellular unpackaging of 
NAs inside the cells is obtainable using relatively low MW chitosan (Koping-Hoggard et al., 2004). 
Lavertu et al. also reported that the transgene expression of CS/pDNA polyplexes is maximized in 
vitro by either reducing the DDA and increasing MW, or increasing the DDA and decreasing MW 
(Lavertu et al., 2006). It has been reported that the 10 kDa chitosan with DDA of 92% at N:P of 5 
(CS 92-10-5 DDA-MW-N:P ratio) form stable complexes and also dissociates effectively upon 
release from lysosomes, maximizing the level of transfection (Thibault et al., 2010a). Transfection 
in a slightly acidic medium (pH 6.5) can also maximize the in vitro transfection of CS92-10-
5/pDNA complexes (Ishii et al., 2001; Lavertu et al., 2006; Nimesh, Thibault, Lavertu, & 
Buschmann, 2010b; Sato et al., 2001). This can be explained by the fact that in the media of lower 
pH the zeta potential of the polyplexes increases, due to ionization of CS, which improves their 
affinity to the negatively charged cell membranes and consequently enhance cellular uptake 
(Lavertu et al., 2006). In another study, Veilleux et al. demonstrated that CS/pDNA polyplexes 
prepared at pH=6.5 maintained their physico-chemical properties and transfection efficiency post 
freeze-drying and (Veilleux, Nelea, Biniecki, Lavertu, & Buschmann, 2016). 
16 
 
2.3.2 Chitosan/siRNA polyplexes 
In recent years, chitosan/siRNA formulations have gained momentum as a safe and efficient 
delivery system (Alameh et al., 2012; Corbet et al., 2016; Gao et al., 2014; Holzerny et al., 2012; 
Howard et al., 2006a; X. Liu et al., 2007; Malmo et al., 2012a; S. Mao et al., 2010; Ragelle et al., 
2014; Ragelle et al., 2013; Raja et al., 2015; Yang et al., 2015). Several groups studied key factors 
(i. e. DDA and MW of CS, as well as N:P ratio) to produce CS/siRNA polyplexes with highest 
bioactivity. In one of the early studies, Liu et al. showed that using CS with MW of 65-170 kDa 
(78 to 84% DDA) results in CS/siRNA polyplexes of around 200 nm. It was demonstrated that the 
zeta potential of CS/siRNA polyplexes increases with the DDA, and they are more efficient when 
DDA≥ 80% (X. D. Liu et al., 2007). It was shown that CS/siRNA polyplexes prepared at N:P=50 
with different CSs had a silencing efficiency of 45 to 65% 48 h after transfection of EGFP+ H1299 
cells with 50 nM of siRNA (X. D. Liu et al., 2007). Moreover, as observed previously for CS/pDNA 
polyplexes, Howard et al. demonstrated that the size of the CS/siRNA polyplexes increases with 
the final concentration of siRNA in the formulations (Howard et al., 2006a). However, producing 
small polyplexes at low concentrations limits the injectable doses (1 mg of siRNA/mL) for clinical 
administrations. It was demonstrated that CS/siRNA polyplexes prepared by CS with MW of 
114kDa (DDA=84%) have in vitro silencing efficiency as high as ~ 80% (Howard et al., 2006a).  
Malmo et al. showed that when CS is fully deacetylated, MW and N:P ratio have not a marked 
impact on the silencing efficiency of the CS/siRNA polyplexes (Malmo et al., 2012a). They 
reported that the size of polyplexes increased from 34 nm to 95 nm with increasing the MW of CS 
from 16.4 kDa to 141.6 kDa, and increasing the N:P ratio from 10 to 60. Generally, DDA of CS 
was found to have a low impact on silencing efficiency of CS/siRNA polyplexes (Holzerny et al., 
2012; Howard et al., 2006a; Ji et al., 2009; X. Liu et al., 2007; Malmo et al., 2012a). Therefore, 
most of the studies involving CS/siRNA polyplexes were conducted at moderate DDA (80-85 %) 
(Holzerny et al., 2012; Howard et al., 2006a; Katas & Alpar, 2006; X. Liu et al., 2007; Ragelle et 
al., 2014). 
2.3.3 Coated polyplexes: surface modification using hyaluronic acid 
Hyaluronic Acid (HA) is a member of glycosaminoglycans. As a natural polyelectrolyte, HA is 
constituted by alternating and repeating units of D-glucuronic acid and N-acetyld-glucosamine 
linked at 1, 3 and 1, 4 position to form a linear chain (Figure 2.4) (Kakehi, Kinoshita, & Yasueda, 
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2003). HA is a non-toxic and non-immunogenic material, and is generally associated with anti-
inflammatory properties (Necas et al., 2008). The pharmacokinetics of HA upon intravenous (IV) 
injection in human adults was documented by Necas et al. It was demonstrated that HA has a 
circulating half-life of 2 to 6 min, and it is mainly eliminated in the liver by a mechanism of 
endocytosis (Necas et al., 2008). HA is also an important CD44 receptor ligand, which is expressed 
in almost every cell type in human and in mouse (Liang, Jiang, & Noble, 2016; Sherman, Sleeman, 
Herrlich, & Ponta, 1994; Tripodo et al., 2015) and overexpressed in several cancer cells, and has 
been extensively studied as a therapeutic targeting agent (Dosio et al., 2016; Karbownik & Nowak, 
2013; Platt & Szoka, 2008).  
 
Figure 2.4  Chemical structure of hyaluronic acid. Adapted from (Dosio et al., 2016). Copyright 
2017, with Elsevier’s permission. 
The distributions of the molecular size of HA are of wide range (Karbownik & Nowak, 2013; 
Tripodo et al., 2015). HA can also be modified by the insertion of ionic sulfate (SO3–) groups in 
the polysaccharide chain. Sulfated HAs have been reported with different degrees of sulfation, 
ranging from 1 to 4 sulfate groups per disaccharide (Magnani, Silvestri, & Barbucci, 1999). While 
non-sulfated HA contains only one ionizable group per disaccharide (carboxylate moiety, COO–, 
of the D-glucuronic acid units with pKa of ~3-4), sulfated HAs have ionic groups that are charged 
negatively. In one of the very early studies, Magnani et al. showed that compared to non-sulfated 
HA, the sulfate groups provide with stronger electrostatic attraction to the metal ions (Cu2+ and 
Zn2+), which is due to increased negative charge along the polymer chain (Magnani et al., 1999). 
In another study, recently, Feng et al. demonstrated a stronger binding affinity of sulfated HA with 
proteins due to higher charged density of the HA chains. Moreover, they demonstrated that sulfated 
HA has significantly slower degradation by hyaluronidase compared to the non-sulfated HA (Feng 
et al., 2017). HA is highly hydrophilic, and the charged groups of this anionic glycosaminoglycan 
can form electrostatic bonds with the amine functions of CS on the surface of the polyplexes. Since 
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the binding constant of HA and CS is ~200 fold lower than that of CS and NA, HA would not cause 
NA release when it is added to the CS/NA polyplexes (Pei Lian Ma, 2010). The presence of HA 
would promote the formation of more hemocompatible formulations with increased solubility at 
higher pHs. Moreover, since HA binds to the CD44 receptor, which is often overexpressed on the 
surface and in the matrix of cancer cells, it can act as the addressing molecule of polyplexes (Platt 
& Szoka, 2008). 
2.4 Techniques used for mixing NA with polycations 
NA and CS solutions are miscible aqueous solutions. Mixing miscible liquids can be simply seen 
as blending two fluids to get a specified degree of homogeneity. Aiming to develop a method to 
reproducibly mix large volumes of CS and NA solutions, this part of the thesis reviews different 
methods reported in the literature through which a NA solution was mixed with a polycation 
solution. 
2.4.1 Manual mixing 
Direct manual mixing is the simplest method that can be used to mix two miscible liquids. This is 
the most often used technique to produce CS-based polyplexes. However, this method is not 
established between research groups (varies from a lab to another and from paper to another) which 
raises some concerns regarding comparability of the properties of such complexes. Order of 
addition of the two solutions, experience of the user, speed of mixing are among the factors that 
affect the properties of the prepared polyplexes. The most frequently reported mixing method 
involves manual addition of CS solution into the NA solution followed by homogenization by 
pipetting the mixture up and down (Alameh et al., 2012; Jean et al., 2011; Lavertu et al., 2006; 
MacLaughlin et al., 1998a; Malmo et al., 2012a; Mao et al., 2001; Nimesh et al., 2010a; Veilleux 
et al., 2016). Independent of the method used, manual mixing is restricted to relatively small 
preparation volumes and seriously limits the quantity and applicability of the prepared complexes. 
Small scale day to day preparation by manual mixing poses the risk of batch to batch and inter-user 
variability. Aside from the manual mixing, a few mixing techniques or devices have been proposed 
in the literature to prepare large volumes of polyplexes. These techniques rely on in-line mixing of 
the two polyelectrolyte solutions in jet mixers via Y or T-shaped connectors or in a static mixer 
coupled to a dual syringe. 
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2.4.2 Jet mixer 
A jet mixer generates two opposing high velocity linear jets of polyelectrolyte solutions which 
collide in a chamber in a few milliseconds. Johnson and Prud’homme invented a novel Confined 
Impinging Jet mixing (CIJ mixer) apparatus for the preparation of nanoparticles (NPs) through 
which rapid mixing takes place in a time less than the nucleation and growth time of NPs (Brian 
K. Johnson & Prud'homme, 2003). Ankerfors et al. applied the CIJ system to investigate the 
influence of mixing time on the size of PECs produced by mixing of two low MW polyelectrolytes 
in dilute regime (C. Ankerfors, Ondaral, Wagberg, & Odberg, 2010b). PECs were prepared at pH=7 
using NaCl concentration of 10 mM. For polyacrylic acid (PAA) and polyallyl amine hydrochloride 
(PAH), smaller particles were obtained (ranging from 45 nm to 60 nm prepared in very short time 
of 20 and 65 ms, respectively), as compared to larger particles when the two solutions were added 
slowly, ranging from 80 to 140nm (C. Ankerfors et al., 2010b). Although CIJ resulted in very small 
PECs, it is a very sophisticated device. 
2.4.3 Y or T-shaped mixer 
The easier and probably the most basic design for in-line mixing of two solutions is mixing in a Y 
or T-shaped connector, where mixing takes place by pumping the two solutions simultaneously to 
contact each other and mix in the connector. Clement et al. designed an in-line mixing platform 
based on two peristaltic pumps, and a Y-connector. (Clement, Kiefer, Kimpfler, Garidel, & 
Peschka-Suss, 2005). They showed that in-line mixed pDNA lipoplexes retained their full 
biological function in vivo. Also, they investigated the influence of mixing speed and reported no 
marked change in the size and surface charge of NPs in moderate flow rates. In 2011, Kasper et. 
al. claimed reproducible production of small and homogeneous polyethyleneimine (PEI)/pDNA 
polyplexes by means of an up-scaled micro-mixer system (Kasper et al., 2011). Kasper et al. 
showed that small and homogeneous PEI/pDNA polyplexes could be reproducibly prepared using 
this technique. They developed a micro-mixer consisting of two syringes that are connected to each 
other heading oppositely by a T-connector. They also investigated the influence of mixing flow 
rate and concentration of NA solution on the size and polydispersity of the polyplexes.  It has been 
shown that by increasing the mixing speed (from 0.1 to 1.0 cm/min, using 2.5 mL syringes), the 
size of polyplexes is reduced (from 197 to 59nm), however, polydispersity index (PDI) increased 
significantly (from 0.05 to 0.19). Moreover, by increasing the concentration of pDNA (20-400 
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μg/mL), the z-average diameter (65-170 nm) and PDI (0.05-0.22) of the polyplexes increased 
(Kasper et al., 2011). 
 
Figure 2.5 Y and T shaped connectors, used in several studies for in-line mixing of two solutions. 
2.4.4 Static mixer 
A static mixer, also known as a motionless mixer, is a mixing device consisting of a series of 
identical, motionless elements. The purpose of the elements is to redistribute fluid in directions 
transverse to the main flow (since in a simple empty cylinder, there is no radial mixing). The 
effectiveness of static mixers is due to its ability to perform radial mixing so that mass transfer 
become rapid. Static mixers can be coupled to Y connectors or a jet mixer to increase the 
homogeneity of polyplexes. Davies et al. used dual syringes attached to a static mixer driven by a 
cylindrical pneumatic actuator for preparation of PEI/pDNA polyplexes for gene therapy 
application (Davies et al., 2010). They obtained small and homogeneous polyplexes using a static 
mixer in both laminar and turbulent regimes. They also found that by increasing the mixing flow 
rate (from 1 to 20 mL/sec), the hydrodynamic diameter of produced polyplexes increased slightly 
from 70 to 95 nm. 
2.4.5 Staggered herringbone micromixer 
A very recently introduced device used for in-line mixing of two solutions is a micro-mixer called 
“staggered herringbone microfluidic mixing device”. Staggered herringbone micromixer (SHM) is 
a chaotic mixer that works based on rapid microfluidic mixing in a laminar regime to produce well-
defined NPs (Belliveau et al., 2012; A. K. K. Leung et al., 2012; Zhigaltsev et al., 2012b). The 
device comes with two inlets which are connected to each other through a Y connector, where the 
output is a herringbone shape channel with asymmetric grooves on its floor. This mixing method 
makes continuous rotational and extensional flows resulting in a high speed mixing of the two 
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fluids that are injected through syringes driven by a dual syringe pump. Zhigaltsev et al. used the 
SHM device to drive lipid nanoparticle (LNP) formation (consisting of 1-palmitoyl, 2-oleoyl 
phosphatidylcholine (POPC), cholesterol and the triglyceride triolein) by high speed mixing of 
lipids dissolved in ethanol, injecting into the first inlet, with an aqueous buffer stream (saline, 154 
mM NaCl), injected into the second inlet of the micromixer, using 1 to 5 mL syringes and 
connections with inner diameters of 1/32" (Zhigaltsev et al., 2012b). They found two factors 
influencing the size of the produced LNP:  the mixing flow rate and the volumetric ratio of aqueous 
to ethanol solutions that are being mixed. They reported that as the mixing flow rate increased 
(0.5−4.5 mL/min), polydispersity of the produced LNP decreased that could be described by the 
fact that at a very high speed, mixing time (approximately 3 ms) is much shorter than the time for 
mass transfer that causes heterogeneous lipid aggregation. In addition, by increasing the volumetric 
flow ratio (VFR) of the aqueous stream to the ethanol solution, the size of LNP decreases as the 
final concentration of ethanol decreases which results in reduced production of larger LNP at the 
output (the size reduced from 120nm to around 30nm for both POPC and POPC/cholesterol mixture 
by changing the VFR from 1 to 7, and from 65 nm to 15 nm for the POPC/triolein by changing the 
VFR from 1 to 9). The staggered herringbone microfluidic mixing technique is a reproducible 
method that produces NPs in the sub-100 nm size range which are stable after purification for 
several months (Zhigaltsev et al., 2012b). In another study, Belliveau et. al. investigated the ability 
of SHM in preparation of monodisperse LNP/siRNA complexes in different flow rates of the range 
0.02 to 4 mL/min (in laminar flow regime, 2<Re<500) (Belliveau et al., 2012). They reported that 
although the size of LNP remained constant (at ~55 nm) over the range of the tested flow rates, by 
increasing the mixing flow rate the PDI of produced LNP-siRNA decreases. In addition, reducing 
the concentration of siRNA results in a decrease in polydispersity. They showed that the lowest 
polydispersity was obtained at the highest mixing flow rate (4 mL/min), with a PDI of 0.03 over 
the concentration range of siRNA from 0.25 to 0.59 mg/mL.  
Each of the above-mentioned methods might produce particles that have different physico-
chemical properties, but there is no clear indication to date that any of these techniques can produce 
CS-based polyplexes that are reproducible and approperiate in terms of their physico-chemical 
characteristics and transfection efficiency. 
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2.5 Purification and concentration techniques 
As mentioned before, in order to produce stable colloidal suspensions of relatively small and 
homogeneous polyplex NPs, the mixing process must take place i) in excess chitosan versus NA, 
and ii) in dilute conditions. However, for further surface modifications and clinical applications, 
these polyplexes must be purified (to remove the unbound chitosan), and concentrated (to achieve 
higher doses per injection). Hence, investigation of an appropriate technique is required to treat 
polyplexes post-mixing. The following section summarizes techniques used for purification and 
concentration of NPs in biopharmaceuticals. 
2.5.1 Dialysis 
Dialysis is one of the methods used for purification and concentration of NPs and proteins (Andrew, 
Titus, & Zumstein, 2001; Degerli & Akpinar, 2001; Shire, Shahrokh, & Liu, 2004). In dialysis, the 
concentration of NP suspensions is performed using a dialysis bag against a counter-dialysing 
(concentrator) solution. Concentrator solution could be an aqueous polymer solution that can be 
supplemented with additives, including buffering agents, denaturants, salts and detergents to 
maintain the integrity of the sample during concentration by dialysis. Due to osmotic pressure, 
water is displaced from the inside of the dialysis bag towards the concentrator solution until 
equilibrium is achieved. Once the desired volume of the solution is achieved, the excess 
concentrator solution is removed from the dialysis membrane and the sample is recovered. 
Concentration of NPs using dialysis against a polymer solution, dextran (Stella et al., 2007; 
Vauthier, Cabane, & Labarre, 2008), and Aquacide II, sodium salt of carboxymethyl cellulose, 
(Andrew, Titus, & Zumstein, 2002) has been reported. Concentration of NPs in pharmaceutical 
suspensions can be done via dialysis without causing any aggregation of NPs (Vauthier et al., 
2008). As a low-shear rate method, dialysis prevents DNA degradation and protein denaturation 
during the concentration process (Shire et al., 2004). However, dialysis requires preparation of an 
appropriate counter-dialysing solution at an optimized concentration to obtain the desired 
concentration factor. Dialysis procedures require large volumes of exchange buffer for 
equilibration which can take up to several days and involve the risk of product loss through manual 
manipulations of the dialysis bags (Sweeney et al., 2006). These drawbacks limit the applicability 
of this method for purification of large volumes of NPs. 
23 
 
2.5.2 Gel filtration chromatography 
Compared to dialysis, gel filtration is a relatively faster process; however, only a small volume of 
NP solution can be processed at a time which makes it difficult to scale-up. Moreover, selectivity 
of small and bigger NPs, and irreversible adsorption of molecules onto the column can restrict the 
application of this approach in pharmaceuticals (Dalwadi et al., 2005). In addition, gel filtration 
results in a dilution of the sample and often requires an additional step to concentrate it back. While 
time consuming, gel filtration is not scalable since only a small volume of NP solution can be 
processed at a time (Dalwadi et al., 2005). 
2.5.3 Ultracentrifugation 
Ultracentrifugation is probably the most common approach to remove impurities. This process is 
typically followed by a subsequent resuspension in a fresh buffer. Although simple, this technique 
is time-intensive and results in aggregation of NPs due to high centrifugal forces (Correa et al., 
2016). Moreover, resuspension as a following step might also cause loss of smaller NPs in the 
supernatant liquid, resulting in a low recovery (Chiellini, Orsini, & Solaro, 2003; Dalwadi et al., 
2005). Ultracentrifugation is considered as a simple and relatively fast approach to remove 
impurities from small batches of NPs, however, is not a suitable for large scale applications (Correa 
et al., 2016). 
2.5.4 Freeze-drying 
Freeze-drying (FD), also known as lyophilization, is a technique used to attain long term stability 
of pharmaceutical and biological products preserving their original properties. The principle of FD 
is to remove water content of a sample from its frozen form by sublimation and desorption under 
vacuum (Abdelwahed, Degobert, Stainmesse, & Fessi, 2006; Hirsjarvi, Peltonen, & Hirvonen, 
2009; Vauthier & Bouchemal, 2009). FD is not a purification technique, but can be used for 
producing concentrated NPs by rehydration in a volume smaller than the original volume. 
Anchordoquy et al. demonstrated that PEI/DNA complexes can be concentrated tenfold (DNA 
concentration of 1 mg/mL) using FD technique (Anchordoquy, Armstrong, & Molina, 2005). In 
another study, Veilleux et al. showed that CS/pDNA polyplexes can be concentrated up to 20-fold 
(to ~1 mg/mL) using this method, while maintaining isotonicity (Veilleux et al., 2016). Excipients 
are used in FD in order to increase the stability and to protect NPs against either freezing or drying 
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stresses, called cryoprotectants and lyoprotectants respectively. The commonly used excipients for 
FD are sugars such as sucrose, trehalose and glucose. Moreover, in order to control pH during 
freezing, buffers such as histidine (Veilleux et al., 2016), phosphate and citrate can be used 
(Abdelwahed et al., 2006). A maximum concentration limit, difficulties of carrying FD and 
subsequent rehydration in large scales and maintaining the isotonicity of solutions after rehydration 
are among limitations of lyophilization technique for concentration purposes. Moreover, FD is not 
applicable for purification of materials. 
2.5.5 Ultrafiltration 
Filtration is a pressure driven process of separating the components of a solution based on their 
size and charge differences using a membrane. Filtration is an important process in 
biopharmaceutical industry which is also used to concentrate the products to the desired final 
concentration. In contrast to the above mentioned techniques (dialysis, gel separation and 
ultracentrifugation), ultrafiltration is a fast and highly cost effective purification method for 
processing large batches of solutions, thus, suitable to implement in industrial processes (Sweeney 
et al., 2006). Based on the direction of the fluid flow on the filter membrane, filtration can be of 
two different types: 1) Normal Flow Filtration (NFF) and 2) Tangential Flow Filtration (TFF). 
2.5.5.1 Normal Flow Filtration 
In NFF, also know as dead end filtration, the fluid flows directly towards the filter under the 
influence of pressure. Normal flow indicates that the fluid flow is perpendicular (normal) to the 
filter surface and there is no recirculation of the feed stream. Basically, particles that are smaller 
than the pore size of the filter pass through the membrane, and all of the particles that are larger 
accumulate on the surface of the filter, as their size prevents them from passing through the filter 
medium. The normal pressure of the flow pushes the particles on the surface. As the process 
continues, more particles accumulate on the filter. The trapped particles start to build up a “filter 
cake” on the membrane, thus the filtration flow rate per unit membrane area decreases over time 
(Figure 2.6b). Although more efficient than other conventional purification techniques, NFF can 
cause aggeregation of NPs. Cake formation, fouling and concentration polarization are the main 
concerns in a TFF process (Dalwadi et al., 2005).  
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Figure 2.6 Comparison of NFF and TFF. Due to tangential movement of flow over the membrane, 
risk of cake formation, fouling and concentration polarization in a TFF process is much lower than 
a NFF process. Taken from Spectrumlabs filtration handbook (Ballew, Martinez, Markee, & 
Eddleman, 2002) with permission.  
 
2.5.5.2 Tangential Flow Filtration  
TFF, sometimes referred to as cross flow filtration, generally involves the circulation of the fluid 
parallel to the surface of a semi-permeable filter under pressure. Filtrate is pushed through the 
membrane by the pressure applied on the feed. While some of the feed solution passes through the 
membrane filter, most of the solution is circulated back to the feed tank. The solution retained by 
the membrane is known as the concentrate (or retentate) and the solution that passes through the 
membrane is known as the permeate (or filtrate). Figure 2.6 illustrates the fluid flow in TFF mode 
compared to the NFF mode. In TFF equipment, a pump is used to supply enough pressure on the 
feed flow and to generate feed recirculation. In each pass of the feed fluid over the surface of the 
filter, the applied pressure forces a portion of the fluid through the filter to the permeate stream, 
thus concentrating the solution. The continuous movement of the feed solution across the 
membrane surface helps to remove the built-up cake on the surface. During TFF molecules smaller 
than membrane pores (sugar, salt and water) pass simply through the membrane and larger 
molecules (e.g. NPs) are retained and re-circulated in the system until the desired concentration of 
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the solution is reached. TFF overcomes the main limitations of the NFF such as rapid flux decrease 
over time and particle trapping on the surface of the filter (Ralf Kuriyel, 2008). TFF is usually used 
in biopharmaceutical downstream processes including concentration, clarification, and 
fractionation (Ralf Kuriyel, 2008), and to concentrate, and separate proteins (Millipore, 2003). As 
NPs are in the same size range as proteins, TFF has been studied as a possible concentration and 
purification method for NPs (Anders et al., 2012; Correa et al., 2016; Dalwadi et al., 2005; Dalwadi 
& Sunderland, 2007; Hammady et al., 2006; Limayem et al., 2004; Robertson et al., 2016; Sweeney 
et al., 2006; Trefry et al., 2010; Zaloga et al., 2015). Unlike the other purification techniques, TFF 
can be automated by controlling the pump. This is a very important feature of TFF which stands it 
out as a convienent technique for large scale applications. TFF in concentration mode is 
schematically shown in Figure 2.7. 
 
Figure 2.7 Schematic of a TFF system in concentration mode. During recirculation, the permeate 
is being generated (blue liquid), therefore, the volume of the sample reduces and the retentate (red 
liquid) becomes concentrated. Taken from Spectrumlabs filtration handbook (Ballew et al., 2002) 
with permission.  
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2.5.5.3 Diafiltration 
It is possible to use a TFF system for purification or buffer exchange instead of concentration mode. 
When a new buffer is added into the feed tank while permeate is removed continuously from the 
system, the process is refered to as diafiltration. Diafiltration is a technique which uses 
ultrafiltration membranes to completely remove, replace, or lower the concentration of salts or 
solvents from solutions containing proteins, peptides, nucleic acids, and other biomolecules (L. 
Schwartz, 2003). Diafiltration technique involves washing out the original buffer in the sample 
(retentate) by adding water or a new buffer to the sample continuously at the same rate as permeate 
is being removed from the system. In processes where the products of interest are in the retentate, 
diafiltration washes and removes other components out of the retentate into the permeate, thus 
exchanging buffers and gradually reducing the concentration of impurities. The sample volume 
and product concentration do not change during a diafiltration process. Using diafiltration, the 
unwanted molecules will be washed out and their concentration is lowered. If a buffer is used for 
diafiltration aiming buffer exchange, the new buffer concentration will increase gradually at a rate 
inversely proportional to that of the initial buffer being removed. The amount of buffer exchange 
is directly related to the permeate volume generated. The permeate volume generated is usually 
referred to as “diafiltration volumes” (DV). With diafiltration, salt or solvent removal as well as 
buffer exchange can be performed quickly and conveniently. Another very important advantage of 
TFF is that the sample can be concentrated on the same system, minimizing the risk of sample loss 
or contamination. Figure 2.8 illustrates a schematic view of a TFF system in diafiltration mode. 
When the volume of permeate collected equals the starting retentate volume, one DV has been 
processed. The number of DV needed for a complete buffer exchange directly depends on the 
permeability of the molecules of the buffer through the chosen membrane.  
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Figure 2.8 Schematic of a TFF system in diafiltration mode. While the permeate leaves the system, 
the new buffer is replaced based on the established vacuum. Taken from Spectrumlabs filtration 
handbook (Ballew et al., 2002) with permission.  
 
Theoretically, there will be a linear decrease in solute content in the concentration mode, and an 
exponential decrease in diafiltration mode. This model is applicable for all solutes to be eliminated, but 
with different slopes depending on the permeability of the solute. 100% permeability means that all 
solute freely passes through the membrane, which is the case for salts, solvents and buffers (L. 
Schwartz, 2003). Permeability can be determined by measuring the concentration of the unwanted 
molecule in the permeate compared to its concentration in the retentate. According to the technical 
reports of the TFF instrument from Pall Corporation, greater than 99.5% of a 100% permeable 
solute can be removed and replaced with a new buffer by washing through 6 diafiltration volumes 
(6DV). Also, greater than 99.5% of a solute with a 75% permeability can be removed and replaced 
with the new buffer by washing through 8 diafiltration volumes (8DV) (L. Schwartz, 2003). 
Permeability can be affected by such factors as transmembrane pressure (TMP), crossflow rate, 
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retentate concentration, pH, and ionic strength. Therefore, the permeability may change during the 
process. 
2.6 Parameters that influence a TFF process 
TFF is the method that was used here for purification and concentration of CS-based polyplex 
solutions, hence, more details on this technique will be reviewed in this section. Parameters that 
influence the performance of this technique include membrane properties (material, cut-off, and 
geometry), as well as operational parameters (cross flow rate and trans-membrane pressure). These 
parameters are reviewd in the following sections. 
2.6.1 Membrane material and molecular weight cut off 
Choosing a membrane with appropriate retention characteristics is critical to ensure a high product 
yield. TFF membranes are rated by molecular weight cut off (MWCO) that refers to the average 
molecular weight of solutes for which 90% of solute is retained by the membrane. Generally, the 
membrane for concentration is selected based on its rejection characteristics of the sample to be 
processed. To assure complete retention, MWCO of the membrane should be 1/6th to 1/3rd of the 
molecular weight of the molecule to be retained (L. Schwartz, 2003). The closer the MWCO is to 
that of the sample, the greater the risk of losing some small product out of the concentrate. 
Ultrafiltration membranes for TFF are commercially available in a wide range of nominal MWCO 
from 1-1000 kDa (pore sizes between 0.001 and 0.1 micron). TFF membranes are commercially 
available in a variety of polymeric materials or ceramic for certain applications. The membranes 
are constructed from materials with high mechanical strength, chemical and physical compatibility, 
with the lowest levels of extractable and/or toxic compounds (Cross flow filtration Method 
Handbook, 2014). Some polymers have modified surfaces to improve their performance (i.e. 
increased hydrophilicity, lower binding). The common materials used for TFF are: i) polysulfone 
(PS), ii) cellulose based membranes, iii) polyethersulfone (PES), and iv) modified PES (mPES). 
Polymeric membranes are usually stored in sodium hydroxide solution. PS is hydrophilic 
membrane with low binding properties. It is more resistant to acids, bases and surfactants than 
other membrane chemistries. PS filters are common in applications like NP processing and 
diafiltration. Cellulose based membranes offer high flux and selectivity and because of its 
hydrophilic nature, this membrane is optimal for processes involving very hydrophilic materials 
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such as protein. PES membranes are stable against biological and physical degradation due to the 
unique chemical properties of PES. Due to their extremely low binding properties, PES membranes 
are significantly resistant to fouling, thus provide with higher recovery yields. Their fouling 
resistant properties allow higher flux rates and a shorter processing time (Novasep, 2016; "Why 
You Should Consider Hollow Fibres for Ultrafiltration," 2015). PE, PES, and Cellulose based 
hollow fibers are limited commercially in terms of cut-off availability. mPES has advanced 
hydrophilic membrane filtration chemistry. Compared to other membrane chemistries, mPES 
provides excellent selectivity for separation applications, higher flux rates for faster processing 
times, and low protein binding for higher product yields. mPES is slightly negatively charged, but 
due to the modifications it is very close to neutral. mPES hollow fibers are commercially available 
in a broad range of cut-offs, from 1 kDa to 0.2 µm. Table 2.1 summarizes the performance and 
limitations of common TFF membranes. 
Table 2.1 Common membrane materials used for TFF, their physical and performance attributes 
and limitations 
Material Physical attribute Performance attribute Limitations 
Cellulose base 
Most neutral 
membrane 
Charge has little effect 
on separation 
No storage in NaOH 
  High filtration flux  
Polyethersulfone 
(PES) 
Negatively charged 
Charge can affect 
separation 
Protein passage, 
   variable 
Polysulfone 
(PS) 
Negatively charged 
Can absorb endotoxins, 
low flux 
Hollow fiber most 
common 
   Lower permeate rate 
modified 
Polyethersulfone 
(mPES) 
Mix of cellulose & 
PES attributes 
High permeate flux 
Depends on the specific 
modification 
2.6.2 Membrane geometry 
Generally, two different filter configurations are used in TFF processes, cassette filters and hollow 
fiber filters. Cassette filters refer to filter units containing few sheets of membrane that are held 
apart in parallel and from the cassette housing by means of supports (called screens). Basically, the 
feed stream passes into the space between the sheets and the generated permeate is collected from 
the other side of the membrane. Cassettes are characterized by the thickness of the screen, as well 
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as the flow path length.  On the other hand, hollow fiber filters (also called as cartridge filters), 
encompass several hollow fibers that are supported next to each other (see Figure 2.9A). In this 
configuration, the feed stream passes into the fibers and the permeate is collected from outside of 
the fibers, Figure 2.9B). Hollow fibers are characterized by their length, diameter, as well as 
number of fibers in a cartridge (Cross flow filtration Method Handbook, 2014). Hollow fibers are 
less expensive than cassette geometry since packaging of membranes in a module compartment is 
more cost effective. Moreover, there is no need of a holder in hollow fiber technology which also 
reduces the capital cost. In addition, hollow fibers are more user friendly as the modules are pre-
assembled, pre-sterilized, and disposable ("Why You Should Consider Hollow Fibres for 
Ultrafiltration," 2015). It is known that for filtration of particles, the tubular geometry of hollow 
fibers is more beneficial than the cassette geometry. This is due to the migration of particles to the 
center of the hollow fiber where the flow velocity is the highest. This phenomenon is known as 
“tubular pinch effect” (Serway & Tamashiro, 2010; Veeken, 2012). 
 
 
Figure 2.9 Schematic of a typical hollow fiber module (A), and the performance of a hollow fiber 
membrane (B) 
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2.6.3 Cross flow rate 
Cross flow rate is the recirculating volumetric flow rate in a TFF process. Cross flow rate, also 
referred to as retentate flow rate, is simply the rate of the fluid that passes parallel to the filter 
membrane surface. This parameter is important since it produces the force required to sweep away 
the molecules which tend to accumulate on the filter and cause fouling, thereby restricting the 
filtrate flow. For hollow fiber filters, the cross flow rate through the fibers is expressed as the shear 
rate in units of per second (s-1), which is a function of the flow rate per fiber as well as the fiber 
diameter (d). 
𝑦 =
32𝑞
𝜋.𝑑3
 , where 𝑞 is the retentate flow rate in each fiber     Eq. 2.3 
Shear rates are not applicable for cassettes geometry, since calculation is complicated due to the 
influence of the support screen (Cross flow filtration Method Handbook, 2014). Shear rate plays 
an important role in scale up or down analysis between the modules. By expressing cross flow rate 
as shear rate, it would be possible to approximate the flow rate which results in the same shear rate 
at different scales. 
2.6.4 Trans-membrane pressure 
Trans-membrane pressure (TMP) is the pressure acting across the membrane which drives the fluid 
to the permeate side, carrying all permeable components. TMP is basically an average difference 
in pressure from the feed to the permeate. TMP is defined as follows: 
TMP = 
Pfeed+Pretentate
2
− Ppermeate           Eq. 2.4 
As the filtration driving force, TMP plays a very critical role in a TFF process. There is no filtration 
when the TMP is at zero as a given cross flow rate (no net pressure across the membrane), see 
Figure 2.10A. As soon as TMP applies across the membrane, permeable components pass through 
the pores to generate the permeate solution, and the higher the TMP, the higher permeate flux. This 
is the safe condition during a TFF process, confirming no clogging of the membrane (Figure 2.10B) 
(H. F. Liu, Ma, Winter, & Bayer, 2010). If a TMP higher than required level is applied, more gel 
layer and fouling occur on the membrane, which eventually, causes a drop in the TMP and permeate 
flux (Figure 2.10C). This is associated with high concentration of retained species at the membrane 
wall (Cross flow filtration Method Handbook, 2014; Paulena, Fikara, Foleyb, Kovácsc, & 
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Czermakc, 2012). Thus, selecting the optimum operating TMP must be determined through 
experimentation to prevent membrane fouling and to have an efficient TFF operation through a 
controlled TMP (Cross flow filtration Method Handbook, 2014; Jornitz, Jornitz, & Meltzer, 2007; 
Millipore, 2013).  
 
Figure 2.10 TFF performance when TMP=0 (A), TMP is balanced in a range where the is a linear 
trend between TMP and permeate flux (B), TMP is above the optimal threshold which causes 
membrane fouling. 
Like any other processes, TFF operational parameters (i.e. TMP, shear rate, and permeate flux) 
must be optimized for a robust process, and to have consistent and high product recovery yield. 
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Despite its high importance, there is no report on a systematic study of these operational 
parameters. This potentiats lack of consistency, significant drop in permeate flux during the 
process, and finally low product yield. Therefore, it would be relevant to validate the safe TFF 
operational parameters prior to its application.
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CHAPTER 3 APPROACH OF THE RESEARCH WORK AND 
GENERAL STRUCTURE OF THE THESIS 
The next two chapters, which represent the body of the thesis, will cover the research carried out 
in order to achieve the objectives of the thesis (see section 1.1). The results and their interpretation 
are presented in the form of a published article summarizing the in-line mixing system for large 
scale production of chitosan-based polyplexes (chapter 4), and a chapter describing purification of 
polyplexes via TFF, and coating of the chitosan-based polyplexes using hyaluronic acid (chapter 
5). The document finishes with a general discussion (chapter 6), followed by a conclusion and 
recommendations on future work (chapter 7). 
Chapter 4 presents the study on the development of an automated in-line mixing system for the 
large scale production of CS-based polyplexes. Mixing parameters such as mixing speed, mixing 
concentration, mixing length, as well as mixing pattern were studied for production of CS/pDNA 
and CS/siRNA polyplexes. The optimal operation conditions were established to reproducibly 
deliver small sized homogenuous CS/pDNA and CS/siRNA polyplexes. Size, size distribution 
(PDI), as well as zeta potential of polyplexes were studied by Dynamic Light Scattering (DLS). 
The morphology of the polyplexes was studied by transmission electron microscopy (TEM). In 
vitro transfection efficiency of CS/siRNA formulations was measured by quantitative real time 
polymerase chain reaction (qPCR), quantifying the knockdown percentage of Apolipoprotein B 
(ApoB) mRNA in the HepG2 hepatocellular carcinoma cell line. This study was published: Ashkan 
Tavakoli Naeini, Ousamah Younoss Soliman, Mohamad Gabriel Alameh, Marc Lavertu, Michael 
D. Buschmann, “Automated in-line mixing system for large scale production of chitosan based 
polyplexes”, J Colloid Interface Sci, vol. 500, pp. 253-263, 2017. 
Chapter 5 presents the work done to purify, concentrate, and modify CS-based polyplexes using 
tangential flow filtration. Optimized mixing conditions, from chapter 4, were used to produce large 
batches of polyplexes. TFF operational parameters (i.e. TMP, permeate flux, and shear rate) were 
studied in order to establish a safe operational zone where the TMP and permeate flux stay as 
constant (indicating maximum recovery of polyplexes post-filtration). Since for the TFF 
optimization study large volumes of polyplexes were needed, double stranded 
oligodeoxynucleotide (dsODN, 21 bp) encoding the same sequences and mimicking siRNA eGFP 
physico-chemical properties was used as a lower-cost alternative. Under the established TFF 
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operational conditions, polyplexes preserved their physico-chemical properties when concentrated 
up to sevenfold. Furthermore, using the safe operational conditions, the optimized number of 
diafiltration volumes (DV) for purification of polyplexes (unbound CS removal) was identified at 
5 DV. Upon establishement of TFF operational conditions as well as the number of diavolumes, 
CS/siRNA polyplexes were purified. Size, PDI, as well as zeta potential (ZP) of polyplexes post-
diafiltration were studied by Dynamic Light Scattering (DLS). The morphology of the polyplexes 
was studied by transmission electron microscopy (TEM). Silencing efficiency of CS/siRNA 
formulations was measured in vitro on eGFP+ H1299 cells. The hemocompatibility of these 
formulations was evaluated as per ASTM guidelines. Purified polyplexes, were then coated by HA 
molecules using the in-line mixing system, and further purified using TFF to remove the unbound 
HA. Size, PDI, as well as ZP of HA-coated polyplexes post filtration were studied by DLS. The 
morphology of the polyplexes was studied by transmission electron microscopy (TEM). Finally, 
the in vitro silencing efficiency of CS/siRNA formulations was measured on eGFP+ H1299 cells, 
and finally, the hemocompatibility of these formulations was evaluated. 
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CHAPTER 4 ARTICLE 1: AUTOMATED IN-LINE MIXING SYSTEM 
FOR LARGE SCALE PRODUCTION OF CHITOSAN-BASED 
POLYPLEXES 
Journal of Colloid and Interface Science 
Ashkan Tavakoli Naeini a, Ousamah Younoss Soliman a, Mohamad Gabriel Alameh a, Marc 
Lavertu b, Michael D. Buschmann a,b,* 
a Institute of Biomedical Engineering, Polytechnique Montreal, Montreal, Quebec, Canada 
b Department of Chemical Engineering, Polytechnique Montreal, Montreal, Quebec, Canada 
 
4.1 Abstract 
Chitosan (CS)-based polyplexes are efficient non-viral gene delivery systems that are most 
commonly prepared by manual mixing. However, manual mixing is not only poorly controlled but 
also restricted to relatively small preparation volumes, limiting clinical applications. In order to 
overcome these drawbacks and to produce clinical quantities of CS-based polyplexes, a fully 
automated in-line mixing platform was developed for production of large batches of small-size and 
homogeneous CS-based polyplexes. Operational conditions to produce small-sized homogeneous 
polyplexes were identified. Increasing mixing concentrations of CS and nucleic acid was directly 
associated with an increase in size and polydispersity of both CS/pDNA and CS/siRNA polyplexes. 
We also found that although the speed of mixing has a negligible impact on the properties of 
CS/pDNA polyplexes, the size and polydispersity of CS/siRNA polyplexes are strongly influenced 
by the mixing speed: the higher the speed, the smaller the size and polydispersity. While in-line 
and manual CS/pDNA polyplexes had similar size and PDI, CS/siRNA polyplexes were smaller 
and more homogenous when prepared in-line in the non-laminar flow regime compared to manual 
method. Finally, we found that in-line mixed CS/siRNA polyplexes have equivalent or higher 
silencing efficiency of ApoB in HepG2 cells, compared to manually prepared polyplexes.  
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4.2 Graphical abstract 
 
Figure 4.1 Graphical abstract: large scale production of chitosan based polyplexes using the 
automated in-line mixing system 
4.3 Keywords 
In-line mixing, Chitosan, siRNA, Plasmid, Polyplex, Non-viral gene delivery, Bioactivity 
4.4 Introduction 
Non-viral gene delivery mainly relies on the use of cationic lipids and cationic polymers to bind 
and condense negatively charged nucleic acids (NAs). Complexes formed between a nucleic acid 
and polymers are referred to as polyplexes. Upon mixing, these oppositely charged species bind to 
each other by means of attractive electrostatic interactions, a process favored by a concomitant 
increase in entropy due to the release of low molecular weight counter-ions. In very dilute solutions, 
complex formation leads to nanoparticle suspensions at the colloidal level, while mixing in a 
concentrated regime results in macroscopically flocculated systems (Dautzenberg et al., 1996; 
Muller, 1974; Muller et al., 2011; Thunemann et al., 2004a). Nonetheless, higher mixing 
concentrations result in higher dose of NA in a given volume of the suspension, hence increasing 
the deliverable doses. 
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Chitosan (CS), a naturally derived polycation, is a biocompatible and biodegradable 
linear polysaccharide that has gained interest for safe delivery of NA. It has been demonstrated that 
CS-based delivery systems are efficient for delivery of plasmid DNA (pDNA) (Alameh, Jean, 
Dejesus, Buschmann, & Merzouki, 2010; Buschmann et al., 2013; Jean et al., 2012b; Jean et al., 
2009; Lavertu et al., 2006; Mao et al., 2001; Nimesh et al., 2010a; Thibault et al., 2010b), and 
siRNA (Alameh et al., 2012; Corbet et al., 2016; Gao et al., 2014; Holzerny et al., 2012; Howard 
et al., 2006a; X. Liu et al., 2007; Malmo et al., 2012a; S. Mao et al., 2010; Ragelle et al., 2014; 
Ragelle et al., 2013; Raja et al., 2015; Yang et al., 2015), both in vitro and in vivo. Manual mixing 
is the most commonly used method to produce CS-based polyplexes. However, this manual method 
varies in implementation which raises some concerns regarding comparability of the properties of 
such complexes. Classical pipetting is a frequently reported technique in the literature, where CS 
is promptly added into NA solution followed by pipetting the mixture up and down for 
homogenization (Alameh et al., 2012; Alameh et al., 2010; Jean et al., 2011; Jean et al., 2012b; 
Jean et al., 2009; Lavertu et al., 2006; MacLaughlin et al., 1998a; Nimesh et al., 2010a; Veilleux et 
al., 2016). One other manual approach is addition of NA into excess CS solution under stirring 
condition to allow formation of polyplexes (Howard et al., 2006a; X. Liu et al., 2007; Malmo et 
al., 2012a; Yang et al., 2015). Another technique is drop-wise addition of CS solution into equal 
volume of NA solution followed by quick mixing (Katas & Alpar, 2006), while similar method 
was reported with reverse order of addition (Holzerny et al., 2012). Addition of siRNA into CS 
followed by vortexing of the complex for a short period (30 seconds) is also a reported technique 
(Corbet et al., 2016; Ragelle et al., 2014). Properties of final polyplexes depend upon the mixing 
technique, experience of the operator (Lu et al., 2014), and order of addition of the two 
polyelectrolytes (Zhigaltsev et al., 2012a). Furthermore, independent of the adopted approach, 
conventional manual mixing is not only a poorly controlled method which may result in 
irreproducibility (Belliveau et al., 2012; Lu et al., 2014; Valencia, Farokhzad, Karnik, & Langer, 
2012), but it is also restricted to relatively small preparation volumes, that seriously limit 
applicability. Small scale manual preparation of complexes poses risks of batch to batch and inter-
user variability (Kasper et al., 2011; Lu et al., 2014; Zelphati et al., 1998), thus, a controlled and 
repeatable production process of polyplexes in large quantities is a prerequisite for their clinical 
applications (Valencia et al., 2012). Several mixing techniques and devices have been proposed in 
the literature to prepare large volumes of complexes. These techniques rely on in-line mixing in Y 
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or T-shaped connectors (Clement et al., 2005; Davies et al., 2010; Kasper et al., 2011; Zelphati et 
al., 1998) microfluidics (Balbino, Azzoni, & de la Torre, 2013; Belliveau et al., 2012; Grigsby, Ho, 
Lin, Engbersen, & Leong, 2013; A. K. Leung et al., 2012; Lu et al., 2014; Stroock et al., 2002; 
Valencia et al., 2012; Zhigaltsev et al., 2012a), as well as jet mixing (C. Ankerfors et al., 2010a; B. 
K. Johnson & Prud’homme, 2003). To the best of our knowledge, the very first in-line mixing 
system for complex production was designed by Zelphati et al., where syringes were used to drive 
pDNA and cationic lipids into a T-connector (Zelphati et al., 1998). Later, John and Prud’homme 
invented a Confined Impinging Jet mixing (CIJ) apparatus to generate two opposing high velocity 
linear jets of polyelectrolyte solutions, where the two streams collide in a chamber for a few 
milliseconds (rapid mixing takes place in a time less than the nucleation and growth time of 
complexes) (B. K. Johnson & Prud’homme, 2003). Ankerfors et al. applied the CIJ system to 
investigate the influence of mixing time on the size of produced Polyallylamine hydrochloride 
(PAH)/polyacrylic acid (PAA) complexes. They reported production of larger particles at reduced 
speeds of the polyelectrolyte streams (C. Ankerfors et al., 2010a). While establishment of a jet 
mixer is sophisticated, mixing in a Y or T-shaped connector is a simpler design. In 2005, Clement 
et al. introduced an in-line mixing platform (but not computer controlled) based on two peristaltic 
pumps and a Y-connector. They showed no difference in transfection efficiencies of manual and 
in-line mixed complexes (Clement et al., 2005), however, the impact of mixing conditions (e.g., 
speed and NA concentration) on physico-chemical properties of complexes was not studied. In 
2010, Davies et al. designed a novel mixing device based on a static mixer and a cylindrical 
pneumatic actuator connected via an adjustable regulator to a compressed air supply (Davies et al., 
2010). They were the first to reporting an in-line mixing device for the preparation of polyplexes 
(PEI/pDNA), however, their device was not easily scalable. In 2011, Kasper et al. claimed 
reproducible production of small and homogeneous PEI/pDNA polyplexes by means of an up-
scaled micro-mixer system, consisting of two syringes and a T-connector (Kasper et al., 2011). 
They reported a reduction in the size of polyplexes by increasing the mixing speed and reducing 
the concentration of pDNA. Finally, a chaotic mixer specified as “staggered herringbone 
microfluidic mixing device” was designed based on microfluidic mixing in a laminar regime to 
produce well-defined lipid nanoparticles (LNPs) (A. K. Leung et al., 2012; Stroock et al., 2002). 
This staggered herringbone pattern creates transverse flows in the microchannels to induce chaotic 
mixing at a low speed of the laminar regime. Belliveau et al. investigated the ability of SHM to 
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produce monodisperse LNP-siRNA complexes (Belliveau et al., 2012). While the size of LNPs 
remained fairly constant over the range of the tested flow rates, the lowest PDI for LNP-siRNA 
complexes was obtained at the highest tested mixing flow rate. In addition, reducing the 
concentration of siRNA resulted in a reduction in polydispersity. Although the above-mentioned 
methods were introduced for up-scaled mixing platforms, there has been no systematic study to 
date on the operational parameters of a fully automated in-line mixing system that can reproducibly 
prepare large batches of CS-based polyplexes with defined physico-chemical properties, and 
transfection efficiency.  
The main objective of this study was to develop a computer controlled in-line mixing platform for 
reproducible production of small sized homogeneous CS-based polyplexes, and examine the 
influence of mixing parameters on the properties of polyplexes. We hypothesized that reducing the 
NA concentration and increasing mixing speed would reduce the size and polydispersity of CS-
based polyplexes. Another objective was to assess the in vitro silencing efficiency of the CS/siRNA 
polyplexes, where we hypothesized equal or even better bioactivity for in-line CS/siRNA compared 
to manually prepared polyplexes. 
4.5 Material and Methods 
4.5.1 Materials 
Chitosan was obtained from Marinard. Trehalose dehydrate (Cat #T0167), L-histidine (Cat 
#H6034) were from Sigma. HepG2 (hepatocellular carcinoma) cells (Cat# HB-8065), and Eagle's 
Minimum Essential Medium (Cat #30-2003) were from American Type Culture Collection 
(ATCC). Dulbecco's Modified Eagle Medium, high glucose pyruvate (DMEM-HG, Cat #12800-
017) was from Gibco. Fetal bovine serum (FBS, Cat #26140) was from Thermo Fisher Scientific. 
Plasmid EGFPLuc (Cat #6169-1) was from Clontech Laboratories. siRNA targeting ApoB mRNAs 
(siRNA ApoB) contains sense sequence of 5’-GUCAUCACACUGAAUACCAAU-3’ and 
antisense 5’-AUUGGUAUUCAGUGUGAUGACAC-3’ was obtained from GE (Custom 
synthesis, A4 scale). Double stranded oligodeoxynucleotide (dsODN, 21 bp) encoding the same 
sequences and mimicking siRNA ApoB physico-chemical properties was obtained from Integrated 
DNA Technologies Inc, Coralville, IO. The commercially available liposome, DharmaFECT™2 
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was from Dharmacon RNAi Technologies and Diethyl pyrocarbonate (DEPC) from Sigma Aldrich 
(Cat #D5758). 
4.5.2 Preparation of CS, plasmid DNA and siRNA for mixing 
The plasmid eGFPLuc stock solution was prepared and characterized by UV spectrophotometry, 
as described in Lavertu et al (Lavertu et al., 2006). The plasmid DNA (pDNA) stock solution was 
diluted to 10, 50, 100, 200, and 300 µg/mL with Milli-Q water as well as sterile filtered trehalose 
and histidine (pH 6.5) solutions for having final concentration of 0.5% and 3.5mM, respectively 
(these are optimum concentrations of excipients for freeze-drying and stability of complexes over 
time that have been previously established) (Veilleux et al., 2016). The siRNA ApoB stock solution 
was prepared and characterized by UV spectrophotometry, then diluted to 10, 50, 100, 200, 300, 
and 400 µg/mL with RNase/DNase free water as well as the excipients as described for plasmid 
DNA. Commercial chitosan was first heterogeneously deacetylated to 92% using concentrated 
sodium hydroxide and was depolymerized to 10 kDa and 2 kDa using nitrous acid, as established 
and previously reported by our group (Lavertu et al., 2006). It has been reported that the 10 kDa 
chitosan with DDA of 92% (CS92-10) form stable complexes when prepared at molar ratio of CS 
amine to NA phosphate ratio of 5 (N:P=5), and also dissociates effectively upon release from 
lysosomes, maximizing the level of transfection (Thibault et al., 2010b). Degree of deacetylation 
(DDA) and number-average molar mass (Mn) of chitosan was confirmed by 1H NMR (Lavertu et 
al., 2003), and gel permeation chromatography multi-angle light scattering (Nguyen, Winnik, & 
Buschmann, 2009). A chitosan stock solution at 5 mg/mL was prepared from dry powder dissolved 
in 28 mM HCl overnight at room temperature (RT). The stock solution was sterile filtered, then 
diluted with Milli-Q or RNase free water (for siRNA applications), as well as excipients as 
described before for N:P=5, based on the concentration of nucleic acid (either pDNA or siRNA). 
4.5.3 Preparation of CS/NA polyplexes by Manual Mixing (classical pipetteing) 
CS/NA polyplexes were prepared by manual addition of CS (100 µL) to equal volume of NA 
(diluted to maintain N:P=5), following by immediate pipetting up and down repeated 10 times. 
Samples were then incubated for 30 minutes at RT before analyses or transfections. 
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4.5.4 Preparation of CS/NA polyplexes by In-line Mixing 
In addition to the manual mixing, both types of polyplexes (CS/pDNA and CS/siRNA) were 
produced via AIMS in the exact same formulation as for the manual mixing. Both initial and 
advanced versions of AIMS (configuration a and b of Figure 4.2) were tested. Prepared samples 
were incubated in the original collecting vessel for 30 minutes at RT before analyses or 
transfections. 
4.5.5 Polyplex Size, Polydispersity, and Surface Charge Analysis 
Hydrodynamic size and polydispersity index of the produced polyplexes were measured using 
dynamic light scattering (Zetasizer Nano ZSP- ZEN5600, Malvern Instruments, Worcestershire, 
UK). Samples were diluted by 4-5 fold by adding Milli-Q or RNase free water, then analyzed for 
three consecutive runs at 25°C. Zeta potential (ZP) measurements were made with the Malvern 
Zetasizer Nano ZSP using folded capillary cells. ZP value was calculated from the measured 
electrophoretic mobility 𝑢𝐸 by applying the Henry equation: 𝑍𝑃 =
3𝜂𝑢𝐸
2𝜀𝑓(𝜅𝑎)
, where UE is the 
velocity of the particle in the applied electric field (referred to as the electrophoretic mobility), ɛ 
and η are the dielectric constant and the viscosity of the medium, respectively. ƒ(𝜅𝑎) is the Henry’s 
function, where 𝑎 is the particles radius, and 1/𝜅 is the Debye length, thus 𝜅𝑎 is the ratio of particle 
radius to Debye length. For calculation of the ZP from electrophoretic mobility, a value of 3/2 for 
the Henry function was used so that 𝑍𝑃 =
𝜂𝑢𝐸
ɛ
 was used. This limiting case is referred to as the 
Smoluchowski equation, an approximation that is valid when the size of the particle is much larger 
than the Debye length (𝜅𝑎 ≫ 1), a condition generally satisfied in an aqueous media with moderate 
to high electrolyte concentration. For ZP measurements, each sample was diluted 8 fold to a final 
volume of 800 µL by adding 700 µL of buffer (trehalose 0.5%, and 3.5mM histidine) for a final 
ionic strength of about 1 mM. Each sample was analyzed for three consecutive runs at 25oC. 
4.5.6 Transmission Electron Microscopy Imaging 
Morphology of both in-line and manually produced polyplexes was studied using Transmission 
Electron Microscopy (TEM). On a carbon coated copper grid (200 mesh, Electron microscopy 
sciences), 5 µL drop of polyplex suspension was pipetted and allowed to evaporate for 30 minutes. 
To avoid drying artifacts, remaining solvent was removed by blotting using a filter paper. 5 µL of 
44 
 
2% phosphotungstic acid was placed on the grid. After 10 minutes the stain was removed as 
described above. The grid was washed two times with deionized water to avoid any salt 
contamination from the sample and air dried. TEM images were obtained using a Tecnai T12 
electron microscope operating at 120 keV. For each sample four random areas on the grid were 
imaged at different magnifications. 
4.5.7 Sterile and RNase free production via AIMS 
The AIMS system including the upstream vessels, collecting containers, as well as the tubing set 
were autoclaved for sterility. In order to maintain the sterility of AIMS, the entire tubing network 
is isolated from the environment where each vessel is open to atmosphere via a 0.22 µm syringe 
filter in order to maintain pressure during pumping and mixing. When working with siRNA, the 
closed system was treated with diethylpyrocarbonate (DEPC) in order to inactivate contaminant 
nucleases. 
4.5.8 Cell culture and transfection 
HepG2 cells were cultured in EMEM supplemented with 8% fetal bovine serum (FBS). One day 
prior to transfection, cells were seeded in a 24 well plate at 300,000 cells per well to reach ~80% 
confluence on the day of transfection. Prior to transfection, media over cells was aspirated and 
replenished with serum free DMEM-HG media (pH 6.5) supplemented with 0.976g/L MES and 
0.84g/L NaHCO3. In-line and manually mixed polyplexes were prepared as described above and a 
specific volume was pipetted into each well to reach a target siRNA concentration of 100nM/well 
(~0.66µg/500µL). FBS was added 5 hours post-transfection to reach a final concentration of 8%. 
Transfection media was aspirated 24 hours post transfection, replenished with complete EMEM 
and incubated for an extra 24 hours. DharmaFECT®2/siRNA lipoplexes were used as positive 
control and were prepared as per manufacturer recommendation. Lipoplex and naked siRNA 
transfection were performed at a final concentration of 100nM/well. Chitosan only and untreated 
cells were used as negative controls. 
4.5.9 Assessment of silencing efficiency 
Polyplex bioactivity was assessed using MIQE compliant quantitative real time PCR (qPCR) 
(Bustin et al., 2009). All primers and probes were intron spanning to avoid amplification of 
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potential genomic DNA contamination and in silico validated using the NCBI blast tool for 
specificity (Supp info). Total RNA extraction was performed 48 hours post transfection using the 
EZ-10 Spin column Animal total RNA extraction kit (BioBasic).  Total RNA was extracted as per 
manufacturer protocol and subjected to in-column DNase digestion (Qiagen, Cat#79254). The 
purity of the eluate was assessed using UV/VIS spectrometry at 260, 280, 230 and 340 (Nanodrop 
8000).  The integrity of extracted RNA was determined using the Agilent 2100 Bioanalyzer 
(Agilent technologies). Total RNA concentration was determined using the Qubit reagent (Life 
technologies, Cat# Q10210) as per the manufacturer’s protocol. For each condition tested, a total 
RNA quantity of 200ng/20µL reaction was reverse transcribed using the SuperScript VILO cDNA 
synthesis kit (Life technologies, Cat#11754250). Primer and probe efficiency was experimentally 
determined using the standard curve method on the same plate where target gene knockdown is 
being assessed (Supp info). Reference gene stability was validated using the GeNorm statistical 
package (Biogazelle NV) (Supp info) cDNA was amplified using TaqMan Fast Advanced Master 
Mix (Life technologies, Cat# 4444557) on a QuantStudio 12K flex system (ThermoFisher 
Scientific). All reactions were performed in a 384 well plate (ThermoFisher Scientific, Cat# 
4309849) using a final volume of 10µL (10ng of cDNA) and the following cycling conditions: 2 
minutes hold at 55°C, then 10 minutes hold at 95°C followed by 40 cycles at 95°C for 15 seconds 
and 60°C for 1 minute. Data was exported in RDML and analyzed using the Biogazelle qBase+ 
software package. 
4.5.10 Statistical analyses 
All experiments were repeated once with technical replicates within each for the transfections. 
Values are given as average ± standard deviation. For statistics and plotting, SigmaPlot 13.0 
package was used. One way ANOVA (at a significance level of 0.05) was applied and normality 
and other assumptions were validated. 
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4.6 Results and Discussion 
4.6.1 Design and Establishment of the Up-scaled Automated In-line Mixing 
System (AIMS) 
The in-line mixing setup uses peristaltic pumps to drive fluids based on pulsatile motion, where the 
natural oscillation of the fluids provides a wavy and stretched interface between the two streams, 
thus enhancing the mixing (Jackson et al., 2002; Truesdell, Vorobieff, Sklar, & Mammoli, 2003). 
A schematic of the in-line mixing is shown in Figure 4.2 
Figure 4.2 Schematic of Automated In-line Mixing System (AIMS): initial version (configuration 
a), and advanced version (configuration b). 
. Digital peristaltic pumps are programmed via LabVIEWTM to drive CS and NA solutions through 
either silicon or PharmaPure tubings that were connected to each other with a connector (Y, T or 
cross connector). The mixing system also comprises digital balances that record the masses of 
buffers (e.g., water) for calibration of the pump(s), and to monitor the volume/mass of payloads 
during mixing process. The whole closed tubing network was designed to be primed in order to 
remove air pockets trapped in streams as well as to pre-wet the inner walls of the tubings prior to 
the actual mixing. Pinch valves were programmed to switch from one stream to the other (i.e., in 
the downstream: from waste line to the collecting vessel, as well as in the upstream: from buffer 
line to the payloads after priming, and vice versa). Calibration of the pump(s) was done 
automatically via a sub-program developed in house by LabVIEWTM. Configuration (a) of Figure 
4.2 displays an overview of the initial version of AIMS which features: 1) two separate but inter-
connected peristaltic pumps where one drives NA and the other dispenses the CS solution, 
simultaneously, at the same flow rate; 2) priming of the tubings is done using the NA and CS 
solutions; 3) mixing takes place both during and after the acceleration phase of the pumps 
(acceleration phase refers to the period of time during which the pump head starts from stationary 
and reaches the target speed). Configuration (b) of Figure 4.2 displays the advanced version of the 
mixing system that features some technical, hardware and software improvements: 1) only one 
peristaltic pump with a dual channel head drives both CS and NA, simultaneously; 2) priming of 
the tubings is done with the buffer solution rather than the NA and CS solutions in order to 
minimize consumption of NA; 3) mixing takes place after the acceleration phase of the pump, 
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hence, polyplexes are mixed only at the target speed by switching the pinch valve from waste to 
the collection vessel once the final target speed was reached. 
 
Figure 4.2 Schematic of Automated In-line Mixing System (AIMS): initial version (configuration 
a), and advanced version (configuration b). 
4.6.2 Influence of mixing speed on the properties of CS/NA polyplexes 
In order to examine the impact of mixing speed on the size and polydispersity of final complexes, 
CS/NA polyplexes were mixed via AIMS using flow rates ranging from 2 to 300 mL/min (1.7 to 
253 cm/s given 1/16” as the tube inner diameter, ID). 300 mL/min is the maximum flow rate 
achievable using tubing ID=1/16”. Equal volumetric flow rates between the inlets was used in all 
mixing experiments. Production of polyplexes was done in duplicates for every mixing flow rate 
tested. The dimensionless Reynolds number (Re) was calculated in the outlet as Re = UD/ν, where 
U is fluid velocity, D is the tube inner diameter and ν represents the fluid kinematic viscosity. The 
Re range covered in this study was 26-4,000. In a cylindrical/tubular geometry with smooth walls, 
Re ~<2,000 and Re ~>4,000 are indicative of laminar, and turbulent flow regime, respectively 
(Green & Perry, 2007). 2,000<Re<4,000 corresponds to transitional flow regime, which has 
characteristics of both laminar and turbulent regime. However, these values may not accurately 
translate the flow regimes in our system, due to the presence of peristaltic motions. 
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Literature reveals that the size and polydispersity of manually mixed CS/pDNA and CS/siRNA 
polyplexes both increase significantly at NA concentrations higher than about 0.1 mg/mL, and 0.2  
mg/mL, respectively (Lavertu et al., 2006; Thunemann, 2004; Veilleux et al., 2016; Xu & 
Anchordoquy, 2011a), hence, these concentrations were taken to optimize the speed of mixing in 
AIMS. Both initial and advanced versions of AIMS were used for producing polyplexes by mixing 
2 mL of CS and 2 mL of NA with either LS14 (ID=1/16”) or LS13 (ID=1/32”) tubing. For 
comparison purposes, manual mixing was performed through classical pipetting by addition of 
100µL of CS into 100µL of NA followed by pipetting up and down ten times. 
 
Figure 4.3 Influence of mixing speed on size and polydispersity of CS/siRNA polyplexes (a) and 
CS/pDNA polyplexes (b) produced by initial and advanced versions of AIMS. pDNA and siRNA 
concentration prior to mixing were 0.1 mg/mL, and 0.2 mg/mL, respectively, at molar ratio of CS 
amine to NA phosphate ratio of 5 (N:P=5). In-line mixing was done using 2 mL of CS and 2 mL 
of NA. Manual mixing was done by addition of 100µL of CS into 100µL of NA, followed by 
pipetting up and down ten times. Error bars represent standard deviation between the duplicates. 
4.6.2.1 Faster mixing results in smaller and more homogenous CS/siRNA polyplexes 
As shown in Figure 4.3a, a marked reduction in size and polydispersity of CS/siRNA polyplexes 
was observed when Re increased. Z-average diameter and PDI dropped from 235 to 75nm, and 
from 0.40 to 0.17, respectively, using the initial version of AIMS in the Re range from 26 to 4,000. 
Similar trend was observed using the advanced version of AIMS in the same range of Re where Z-
average diameter and PDI were reduced further from 230 to 47nm, and from 0.44 to 0.12, 
respectively.  
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In a purely laminar flow regime with smooth walls (e.g., using syringe pumps), where the streams 
move in parallel with no transverse movements or vortex, mixing relies solely on diffusion (Jackson 
et al., 2002; Stroock et al., 2002). The speed of molecular diffusion is a constant and intrinsically 
slow process; hence relying on diffusion results in incomplete mixing before fluid enters the 
collecting vessel, and non-homogenous complexes due to concentration gradient. As mentioned 
previously, the natural peristaltic actions of the pump(s) promote(s) diffusion by stretching the 
interfacial area (Jackson et al., 2002; Truesdell et al., 2003). The stretched contact area is associated 
with shorter diffusion path so that at each snapshot of the mixture throughout the outlet tubing, the 
two polyelectrolytes are brought closer to each other to bind quickly and form the complex (B. K. 
Johnson & Prud’homme, 2003). Increasing the frequency of rotation of the peristaltic pump (faster 
mixing), augments the intensity of pulsatile effect which enhances the overall mixing process by 
further stretching the interface area which favors production of smaller and more homogenous 
polyplexes. Reduction in size and PDI of CS/siRNA polyplexes could be also due to introduction 
of chaotic advection (irregular/random transport of matter by flow) in the mixing process at high 
mixing flow rates. Chaotic advection can be introduced to a system by either implementing 
obstacles in the flow channel (Stroock et al., 2002), or non-aligned inputs that generates vertical 
flow in the mixer (Ansari, Kim, Anwar, & Kim, 2012), or turbulence and vortex by high speed 
streams (C. Ankerfors et al., 2010a; B. K. Johnson & Prud’homme, 2003). By folding the streams, 
chaotic advection offers enhanced mixing performance due to transverse components of flow. Not 
only intertwinement of the two streams by chaotic advection generates additional contact area, but 
also quickly alters and refreshes the interfacial area that accelerates diffusion. Here, it was revealed 
that by increasing the speed (Re>2,140), mixing efficiency increases and translates into smaller 
and more homogenous CS/siRNA polyplexes in non-laminar regime (Figure 4.3a).  
AIMS led to better reproducibility in production of CS/siRNA polyplexes versus the manual 
method except for the very low Re of 26. AIMS produced much smaller and more homogenous 
CS/siRNA polyplexes in the non-laminar regime (Re between 2,140 and 4,000) compared to 
manual polyplexes, with Z-average diameter and PDI from 84nm to 75nm and, 0.18 to 0.17 in the 
initial version of AIMS, and 65nm to 47nm and, 0.18 to 0.12 using the advanced version of AIMS, 
versus 101nm and 0.2, respectively for manual mixing. The largest improvement was at the highest 
Re=4,000 with the advanced version of AIMS to produce CS/siRNA polyplexes with Z-average of 
47nm, and PDI of 0.12, while manual mixing led to Z-average of 101nm, and PDI of 0.2. This 
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suggests that in-line mixing in a non-laminar regime is more efficient than manual mixing, which 
is likely due to the role of chaotic advection which offers enhanced mixing performance due to 
transverse components of flow.  
Moreover, as shown in Figure 4.3a, smaller and more homogenous CS/siRNA polyplexes were 
obtained using the advanced version of AIMS. In order to better understand the source of this 
reduction in size and polydispersity of polyplexes, each of the three modifications of the advanced 
version of AIMS (as described above) was isolated and studied separately, where oligonucleotide 
(ODN) was used to mimic siRNA as a lower-cost alternative. It was found that mixing during the 
acceleration phase of the pump was the source of increase in size and PDI of CS/ODN polyplexes 
(see supplementary material, Figure S1). This can be attributed to the fact that CS/siRNA 
polyplexes are sensitive to the speed Figure 4.3a, and mixing in the acceleration phase of the pump, 
where the mixing takes place at different speeds results in the formation CS/siRNA polyplexes with 
various sizes. 
4.6.2.2 CS/pDNA polyplexes properties are not very sensitive to mixing flow rate 
For 26<Re<4,000, Z-average diameter and PDI of CS/pDNA polyplexes varied only slightly 
between 186 and 112nm, and between 0.25 and 0.23, respectively. As shown in Figure 4.3b, size 
and PDI of CS/pDNA polyplexes change very smoothly throughout the tested range of Re. Davies 
et al. reported the same behavior for PEI/pDNA polyplexes in the moderate range of 568<Re<2,840 
when a static mixer was applied in the downstream (Davies et al., 2010). This suggests that the 
pulsatile action of the peristaltic pumps produces sufficient perturbation and interface stretching 
for efficient mixing and production of homogeneous small sized pDNA/CS polyplexes, even at 
very low speeds. Due to its high MW (~4MDa, with 6.4kbp), pDNA has a low diffusivity, hence, 
while pDNA has limited mobility, mostly CS molecules diffuse to contribute to complex formation. 
Once association starts on a pDNA supercoil, the chance of collision with subsequent CS is much 
higher than colliding with another pDNA molecule, which limits random bridging of polyplexes 
and heterogeneity. Rapid saturation of pDNA binding sites by CS molecules limits the 
heterogeneity of the CS/pDNA polyplexes, even when advection is limited as pDNA does not 
diffuse quickly.  
On the other hand, the stronger dependence of CS/siRNA polyplexes size upon the mixing speed 
is likely due to high diffusivity of siRNA molecules. siRNA as a much smaller molecule 
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(MW~14kDa with only 21 bp duplex) has a characteristic diffusion time scale much shorter than 
that of pDNA. Hence, in addition to CS, siRNA diffusion significantly contributes to the complex 
formation. Thus, in order to achieve efficient mixing, stronger advection is required to eventually 
saturate siRNA with excess CS molecules rather than colliding with another siRNA.  
It was also observed that in-line CS/pDNA polyplexes (regardless of the AIMS configuration) have 
similar properties and similar reproducibility to the manually prepared polyplexes (Figure 4.3b). 
This could be again explained by low diffusivity of pDNA and limited sensitivity of CS/pDNA 
polyplexes to the mixing speed, suggesting that even the low advection provided by manual mixing 
is sufficient for having an efficient mixing. 
4.6.3 Mixing patterns and tube length have no impact on the properties of 
CS/NA polyplexes 
Two other mixers were tested at relatively low speed (Re=266), as well as in the highest mixing 
speed (Re=4,000): Y-connector was replaced by either a T-connector or a cross connector. 
Moreover, five mixing lengths with the output downstream after the connector, were tested (25, 35, 
45, 55, and 65cm) at the highest speed, Re=4,000. We found that the mixing pattern and mixing 
length have no effect or a very slight effect on polyplex properties (data not shown), suggesting 
that pulsatile actions and transverse advection are sufficient for mixing over 25cm. 
4.6.4 Influence of NA concentration on the properties of CS/NA polyplexes 
Based on the results of Figure 4.3, the highest Re (4,000) was chosen for further mixings and 
investigation of the impact of NA concentration on properties of polyplexes. Here, NA 
concentration was varied from 0.01 to 0.4 mg/mL. Equal flow rate between the inlets was 
maintained. Both configurations of AIMS were tested. For comparison purposes, manual mixing 
was done at every concentration by pipetting, as described in the method section. Polyplexes were 
prepared in duplicate for each mixing condition.  
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Figure 4.4 Influence of NA mixing concentration on size and polydispersity of CS/siRNA 
polyplexes (a) and CS/pDNA polyplexes (b) produced manually and by AIMS (using both initial 
and advanced versions), at molar ratio of CS amine to NA phosphate ratio of 5 (N:P=5). In-line 
mixing was done using 2 mL of CS and 2 mL of NA at Re=4,000. Manual mixing was done by 
addition of 100µL of CS into 100µL of NA, followed by pipetting up and down for ten times. 
CS/pDNA polyplexes severely aggregate at ≥0.4 mg/mL. Error bars represent standard deviation 
between the duplicates. 
4.6.4.1 Mixing in dilute regime results in small and homogeneous polyplexes 
As shown in Figure 4.4, regardless of the type of NA (siRNA or pDNA), mixing method (manual 
or in-line), and configuration of AIMS (initial or advanced), concentration of NA prior to mixing 
increases the size and PDI of polyplexes. The increase in polyplex size and PDI with increasing 
NA concentration has been reported in the literature (Belliveau et al., 2012; Kasper et al., 2011; 
Zelphati et al., 1998), Z-average diameter for CS/siRNA polyplexes produced with AIMS varied 
from 53 to 95nm in the concentration range of 0.01 to 0.4 mg/mL (Figure 4.4a), while for CS/pDNA 
Z-average diameter increased from 80 to 261nm in the concentration range of 0.01 to 0.3 mg/mL 
(Figure 4.4b), respectively. The small increase in Z-average and PDI of polyplexes prepared at the 
very lowest NA concentration (0.01 mg/mL) compared to 0.05 mg/mL can be explained by the low 
intensity of the scattering signal. When the number of particles is very low, the particle count 
(particles recognized by the DLS instrument) is too low for the instrument to derive a precise size 
distribution. Independent of the mixing method, macroscopic flocculation in CS/pDNA polyplexes 
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was observed at 0.4 mg/mL, however, such behavior was not found for CS/siRNA polyplexes up 
to the highest concentration tested (0.4 mg/mL). It is already reported in the literature that for 
production of stable and small size homogenous complexes, the mixing of two polyelectrolytes has 
to be done in dilute regime (Klausner et al., 2010; Lavertu et al., 2006; Malmo et al., 2012a; Mao 
et al., 2001). In fact, there is a significant difference between the characteristics of a dilute polymer 
solution (where polymer chains are completely separated) and a semi-dilute to concentrated 
solution (where polymer chains are overlapped). Generally, the transition concentration of 
polyelectrolyte solutions from dilute to semi-dilute regimes is defined as the overlap concentration 
(C*) (de Gennes, 1979). The closer the starting concentration of polyelectrolytes to their C*, the 
bigger the size and increased polydispersity of the final complexes.  
The maximum concentration of pDNA for the preparation of small size uniform polyplexes is 
reported as ~0.1 mg/mL (Xu & Anchordoquy, 2011a), while production of small sized lipoplexes 
using relatively high concentration of siRNA (0.59 mg/mL) was reported by Belliveau et al. 
(Belliveau et al., 2012). As shown in Figure 4.4b, regardless of the mixing method (manual vs in-
line) and configuration of AIMS (initial vs advanced), the onset pDNA concentration for increasing 
size and PDI of CS/pDNA polyplexes is clearly 0.1 mg/mL. However, with siRNA AIMS allowed 
production of relatively small and homogeneous CS/siRNA polyplexes at increased concentrations 
of 0.3 mg/mL and even 0.4 mg/mL. The possibility of producing CS/siRNA polyplexes at higher 
concentrations could be attributed to the smaller size of siRNA (higher C*) as compared to pDNA. 
Several techniques are used to measure the overlap concentration C* of polymeric solutions, such 
as small angle light scattering, osmometry, viscometry, light scattering and nuclear magnetic 
resonance (Wandrey, 1999; Zhu & Choo, 2008). According to our calculations, while C* for CS 
92-10 and pDNA are close to each other and fairly low (C* ~3.6 mg/mL and ~1.36 mg/mL for 
chitosan 92-10 and pDNA, respectively), C* for siRNA is relatively high at ~790 mg/mL, which 
permits increased siRNA mixing concentration before reaching flocculation (see supplementary 
material for C* calculations). 
In order to further investigate the impact of C* on the highest possible mixing concentrations, a 
smaller CS molecule (Mn= 2 kDa) was used to prepare CS/siRNA polyplexes. Being a smaller 
chain, CS92-2 has a smaller radius of gyration (Rg), hence, has a higher C*. It was shown that 
CS92-2 allows for production of small size homogeneous polyplexes at increased concentrations 
of siRNA, up to 0.6 mg/mL (see supplementary material, Figure 4.10), confirming the direct impact 
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of chain length on the mixing concentrations. Using manual method, the maximum siRNA 
concentration for producing relatively small size polyplexes is clearly 0.2 mg/mL, where a sharp 
increase in size of polyplexes was observed at higher concentrations. However, using the advanced 
version of AIMS small and monodisperse polyplexes were successfully prepared at elevated 
concentration of 0.4 mg/mL. 
4.6.4.2 CS/siRNA polyplexes are smaller than CS/pDNA polyplexes 
At a given concentration, CS/siRNA polyplexes were generally smaller than CS/pDNA polyplexes. 
For example, at an NA mixing concentration of 0.1 mg/mL, CS/siRNA and CS/pDNA polyplexes 
have Z-average of 40nm and 112nm, respectively. This is most probably due to the fact that pDNA 
is a larger molecule compared to siRNA, which naturally leads to larger complexes. Yet, the larger 
size of CS/pDNA polyplexes could be attributed to the slower diffusion of pDNA molecules that 
leads to broader distribution of pre-complexes which therefore induces formation of polyplexes 
with more than one pre-complex (C. Ankerfors et al., 2010a). As shown in Figure 4.4b, the 
configuration of AIMS has no significant influence on the properties of CS/pDNA polyplexes. This 
was also observed previously in Figure 4.3b where the properties of CS/pDNA polyplexes are 
independent of the AIMS configuration. However, in the case of CS/siRNA polyplexes (Figure 
4.4a), the advanced version of AIMS produced smaller and more monodisperse CS/siRNA 
polyplexes at the given concentrations, which again confirms their sensitivity to mixing speed as 
described in Figure 4.3a. Compared to manual mixing, production of CS/siRNA polyplexes with 
AIMS at Re=4,000 (regardless of the AIMS configurations) provided better reproducibility, smaller 
size, lower PDI, and production of small size homogeneous polyplexes at elevated concentrations. 
4.6.5 Surface charge density of CS/NA polyplexes increases with NA mixing 
concentration 
Independent of the type of NA, concentration of polyelectrolytes prior to mixing also influenced 
the zeta potential (ZP) of polyplexes: the higher the NA concentration prior to mixing, the higher 
the electrophoretic mobility/calculated ZP of final complexes (Figure 4.5). In-line CS/siRNA had 
ZP varying between +10.5 and +21 mV in the concentration range of 0.01 to 0.4 mg/mL Figure 
4.5a), whereas for in-line CS/pDNA the recorded ZP was from +5 to +16.5mV in the concentration 
range of 0.01 to 0.3 mg/mL (Figure 4.5a). As shown previously in Figure 4.4, polyplex size 
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increases with increasing NA concentration, so both ZP and size increase with mixing 
concentration. It is worth mentioning that for the polyplexes tested and analysis conditions used in 
this study, the ratio of the particle size to the Debye length changes with particle size and in all 
conditions, does not strictly meet the criteria for Smoluchowski model to apply precisely (i.e. 𝜅𝑎 ≫
1, and the Henry function is not exactly 1.5 as explained in the methods). In order to examine if 
size variations could account, at least partially, for the observed ZP variations, calculations using 
the complete Henry function were also performed (data not shown). These calculations reveal that 
even if the calculated ZP changes slightly versus that obtained with the Smoluchowski equation, 
the general trend observed is unchanged, namely, ZP increases as mixing concentration increases. 
Therefore, although ZP is not a direct measurement of surface charge (Doane, Chuang, Hill, & 
Burda, 2012), our results indicate that the surface charge density of the polyplexes increases with 
mixing concentration, suggesting that more chitosan is incorporated in polyplexes when mixing 
concentration is higher. This could be the result of faster association kinetics at higher mixing 
concentrations. 
 
Figure 4.5 Influence of NA mixing concentration on zeta potential of CS/pDNA polyplexes (a) and 
CS/siRNA polyplexes (b). In-line mixing was done using the advanced version of AIMS: 2 mL of 
CS and 2 mL of NA at Re=4,000. Manual mixing: pipetting 100µL of CS into 100µL of NA. Zeta 
potential measurements were done in 0.5% trehalose and 3.5mM histidine (Ionic strength =1mM). 
Error bars represent standard deviation between the duplicates. 
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4.6.6 Morphology of the CS/pDNA and CS/siRNA polyplexes 
Morphology of polyplexes was assessed by Transmission Electron Microscopy (TEM). CS/pDNA, 
and CS/siRNA polyplexes were prepared both manually and in-line using the advanced version of 
AIMS at NA starting concentrations of 0.1 mg/mL and 0.2 mg/mL, respectively. TEM images show 
CS/pDNA polyplexes with mixed morphology (spherical, toroidal and rod like) when produced 
both manually and using the AIMS (Figure 4.6a and b). This morphology of CS/pDNA polyplexes 
was reported in literature (Danielsen, Varum, & Stokke, 2004; Strand et al., 2005). On the other 
hand, CS/siRNA polyplexes were generally spherical regardless of the method of preparation 
(Figure 4.6c and d). The spherical shape of CS/siRNA polyplexes was also reported previously 
(Holzerny et al., 2012; Howard et al., 2006a; X. Liu et al., 2007). However, CS/siRNA polyplexes 
produced using AIMS (Figure 4.6d) were smaller and more uniform than those prepared manually 
(Figure 4.6c), in agreement with DLS results. 
  
Figure 4.6 Transmission Electron Microscopy (TEM) images of CS/pDNA polyplexes (a and b) 
and CS/siRNA polyplexes (c and d), produced both manually (a and c) and using the advanced 
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version of AIMS (b and d). pDNA and siRNA concentration prior to mixing were 0.1 mg/mL and 
0.2 mg/mL, respectively. In-line mixing was done by mixing 2 mL of CS and 2 mL of NA at 150 
mL/min. Manual mixing was done by pipetting 100µL of CS into 100µL of NA. 
4.6.7 CS/siRNA polyplexes produced in-line are as bioactive as manual 
polyplexes 
In order to test the suitability of AIMS to produce bioactive CS/siRNA polyplexes, the 
hepatocellular carcinoma cell line HepG2 was transfected in vitro and Apolipoprotein B (ApoB) 
mRNA knockdown assessed using quantitative real time polymerase chain reaction (qPCR). Cells 
were transfected with polyplexes prepared using the advanced version of AIMS at Re=4,000, and 
different siRNA mixing concentration (0.05-0.4 mg/mL). Manually prepared polyplexes were also 
transfected for comparison purposes. DharmaFECT®2, a commercially available lipoplex, was 
used as positive control. Naked siRNA, mock chitosan and non-treated cells were used as negative 
controls. 
ApoB mRNA knockdown reached 40-55% when produced via AIMS (Figure 4.7). Statistical 
analysis revealed no significant effect of mixing siRNA concentrations on gene knockdown. 
Compared to the in-line mixed polyplexes, manually prepared polyplexes resulted in slightly lower 
ApoB mRNA knockdown (~30-45%). These results are consistent with a previous study where 
CS/siRNA polyplexes achieved ApoB mRNA knockdown of ~50% in HepG2 when prepared 
manually at N:P 5 and siRNA concentration of 0.05 mg/mL (Alameh et al., 2010). Although 
manually prepared polyplexes at siRNA concentration of 0.2 mg/mL showed the lowest 
transfection efficiency (~30%), analysis of variance did not show statistical significance compared 
to other siRNA mixing concentrations. CS-based polyplexes achieved comparable knockdown 
efficiency to DharmaFECT®2 (Figure 4.7), independent of the mixing method. We have previously 
shown that manually prepared polyplexes achieve comparable knockdown efficiencies to 
DharmaFECT®2 but with lower toxicity (Alameh et al., 2012; Alameh et al., 2017; Jean et al., 
2012b). Nanoparticle size and surface charge are cited in the literature to be important parameters 
for nanoparticle uptake and bioactivity (Nel et al., 2009; Son, Tkach, & Patel, 2000). 
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Figure 4.7 Bioactivity of In-line and manually mixed CS/siRNA polyplexes. HepG2 cells were 
transfected with either inline or manually mixed anti-ApoB CS/siRNA polyplexes at a final siRNA 
concentration of 100 nM/well. Apob mRNA knockdown was assessed by qPCR using geometric 
averaging of the most stable reference genes (GAPDH and B2M) and expressed relative to non-
treated cells. Data represent the mean of two independent experiments (N=2) with two technical 
replicate per experiment (n=2). Analysis of Variance (ANOVA) was performed using the 
SigmaPlot 13.0 statistical package. 
In our study, polyplex size correlated moderately (r2= 0.376) with knockdown efficiency (Figure 
4.8a), with smaller sized polyplexes inducing higher knockdown efficiency. This trend can be seen 
from results presented in Figure 4.4a and Figure 4.7 where in-line mixed polyplexes demonstrate 
a smooth reduction in size with decreasing siRNA concentration and a generally better efficiency 
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at knocking down ApoB mRNA in vitro. The slight correlation suggests that uptake of smaller 
polyplexes could be higher, but determining if it is really the case would require further 
investigation and is beyond the scope of this study. Interestingly, our results also indicate that ZP 
does not correlate (r2= 0.060) with improved bioactivity (Figure 4.8b). The slight correlation 
between size and knock-down as well as the lack of correlation between ZP and knock-down could 
be explained by serum dependent size stabilization of polyplexes occurring through rapid protein 
corona formation, which will also rapidly alter their surface charge and ZP (Albanese & Chan, 
2011; Nimesh et al., 2010a). The aggregation due to protein binding upon transfection, might either 
inhibit, or facilitate the cellular uptake (Saptarshi, Duschl, & Lopata, 2013). It is worth mentioning 
that ZP was measured in low ionic strength (1mM) buffer and not at ~ 150 mM as in culture 
medium, and it could contribute to the lack of correlation between ZP and knock-down. 
Additionally, the somewhat limited range of both size and ZP values tested could also explain the 
limited correlations observed.  
 
Figure 4.8 Correlation between bioactivity and physico-chemical parameters of in-line and 
manually prepared polyplexes. a) correlation between ApoB mRNA knockdown (average) and 
polyplexe size (average). b) correlation between ApoB mRNA kncockdown (average) and 
polyplexe zeta potential (average). Regression and pearson correlation analysis was performed with 
SigmaPlot 13.0 statistical package. 
Altogether our data show that AIMS is able to produce small sized polyplexes that retain their 
physico-chemical integrity and bioactivity as demonstrated by equal or superior performance to 
manually prepared polyplexes. 
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4.7 Conclusion 
A fully automated in-line mixing platform was developed for production of large batches of CS-
based polyplexes to overcome the drawbacks of conventional manual mixing methods that are not 
only poorly controlled but also restricted to small volumes. This scaled-up platform addresses the 
risk of batch to batch inter-user and intra-user variability, resulting in a controlled quality of large 
quantities of polyplexes. While manual mixing cannot practically deliver more than 2 mL of 
product, polyplexes prepared via AIMS are expected to have similar physico-chemical properties 
and bioactivity when produced in batch sizes up to a litre, 10 L, and 100 L. Size and polydispersity 
of CS/siRNA polyplexes can be simply controlled via the mixing flow rate and mixing 
concentrations. We found that by increasing NA concentration, Z-average diameter and the PDI of 
the polyplexes increase. Moreover, AIMS is capable of production of smaller and more 
homogeneous CS/siRNA polyplexes using a non-laminar flow regime compared to manual 
polyplexes. The established AIMS allowed production of well-defined CS/siRNA polyplexes with 
maintained bioactivity at every siRNA mixing concentration tested, demonstrating the suitability 
of this system for large scale production of polyplexes intended for pre-clinical and clinical 
applications. 
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4.9 Supplementary material 
4.9.1 Investigation of the impact of mixing in the acceleration phase of the 
peristaltic pump 
Mixing CS and NA solutions using AIMS can take place in two different scenarios: either 1- during 
and after the acceleration phase of the peristaltic pump, or 2- only after the acceleration phase of 
the pump. In order to better examine the differences between the properties of polyplexes produced 
in these two scenarios, ODN/CS polyplexes were prepared at the target flow rate of 150 mL/min 
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in both scenarios, at four different starting concentrations of ODN solution (0.1 mg/mL, 0.2 
mg/mL, 0.3 mg/mL, 0.4 mg/mL). Z-average diameter and PDI of the polyplexes were recorded 
using DLS and shown in Figure 4.9. According to our calculations, for the type of peristaltic pump 
we used (Masterflex L/S Digital Drive), the acceleration period (the time it takes from stationary 
to reach the maximum flow rate, 150 mL/min = 2.5 mL/s) is 610ms. During the acceleration phase 
of the pump, mixing takes place in different speeds. On the other hand, mixing after the acceleration 
period takes place only at the target speed. In order to avoid collecting the polyplexes during the 
acceleration phase, water was first pumped to the waste container, before switching (using a pinch 
valve) to the collection vessel once the final target speed was reached.It was shown that at a given 
concentration, mixing of CS and ODN solutions only after completion of the acceleration phase of 
the pump produced smaller and more homogenous polyplexes compared to polyplexes produced 
both during and after the acceleration phase (Figure 4.9). This is consistent with the influence of 
speed on polyplex size (as shown in Figure 4.3), since mixing in the acceleration phase of the pump 
involves a range of uncontrolled speeds with direct impact on the size and PDI of these polyplexes. 
 
Figure 4.9 Influence of mixing during and after (white circles), and only after (black circles) the 
acceleration phase of the peristaltic pump on size and PDI of ODN/CS polyplexes produced using 
AIMS. In-line mixing was done using 2 mL of CS and 2 mL of NA at 150 mL/min. Error bars 
represent standard deviation between the duplicates. 
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4.9.2 Calculation of overlap concentration (C*) for pDNA, siRNA, CS solutions 
The overlap concentration of a polymer is expressed as shown in the equation below: 
𝐶∗ =
3𝑀
4𝜋𝑁𝐴×𝑅𝑔
3            Eq. 4.1 
where M is the Molar Mass of polymer, NA stands for Avogadro’s number, and Rg is the radius of 
gyration of the polymer. While the molecular weights for different polymers (pDNA, siRNA, and 
CS) are known, the challenge is to estimate the Rg value of each polymer in order to calculate the 
C*. 
4.9.2.1 pDNA overlap concentration 
The plasmid pEGFPLuc used in this study comprises 6.4 kbp, with a corresponding molar mass of 
3.94 MDa. Latulippe et al. reported the Rg values of plasmid DNA of various sizes, some with 
molar masses close to that of pEGFPLuc used in this study (Latulippe & Zydney, 2010). More 
specifically, they reported Rg values of 102 ± 2 and 117±3 nm for plasmids of 5.76 and 9.80 kbp, 
respectively. From a simple linear interpolation between the Rg values of these two plasmid DNA 
we estimated the Rg value of pEGFPLuc (6.4kbp) to 105nm. C* was calculated accordingly: 1.3 
mg/mL. 
4.9.2.2 siRNA overlap concentration 
In this study, siRNA with 21bp, and molar mass of 13,974 Da was used. Pavan et al. reported a Rg 
value 1.91nm for a 21bp siRNA (Pavan et al., 2010). C* was calculated accordingly: 790 mg/mL. 
4.9.2.3 Chitosan overlap concentration 
Rg of chitosan depends on its DDA and Mw. Relatively few studies have derived relations to 
estimate the Rg value of chitosan molecules for given DDA and Mw (Brugnerotto, Desbrieres, 
Roberts, & Rinaudo, 2001; Rinaudo, 2006). Brugrenotto et. al. correlated Rg values (obtained by 
Static Light Scattering) for different chitosan molecules (different DDA and Mw) in a Mark–
Houwink equation, Rg=𝑘𝑀𝑤𝑎 (Brugnerotto et al., 2001). The chitosan used in this study had a 
Mn=10,000 Da, Mw=15,000Da, DDA= 92%. Mark–Houwink parameters (k and a) for the exact 
DDA of 92% were applied to estimate the Rg of a 15,000Da chitosan. Rg (nm) = 0.062 
(15000)0.546= 11.8 nm. C* was calculated accordingly: 3.6 mg/mL. 
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4.9.3 Verification of the effect of overlap concentration (C*) on the maximum 
NA starting concentration to produce homogeneous small sized 
polyplexes 
The data obtained for manually mixed CS92-10-based polyplexes indicate that the maximum 
mixing concentration for siRNA and pDNA to produce homogeneous small sized polyplexes is 0.2, 
and 0.1 mg/mL, respectively. As discussed, since the C* value for pDNA and chitosan 92-10 are 
relatively low and close to each other, the maximum concentration of pDNA to prepare 
homogeneous small sized polyplexes is limited. However, C* for siRNA is significantly higher, 
thus we hypothesized that if a CS with a higher overlap concentration C* is used, it would be 
possible to mix with siRNA at higher concentrations before a sharp increase in size and PDI of 
polyplexes occurs. In other words, a lower molecular weight chitosan should favor production of 
homogeneous small sized polyplexes at higher siRNA starting concentrations. In order to further 
investigate the impact of C* on the highest possible mixing concentrations, a smaller CS but with 
the same DDA (Mn= 2 kDa, DDA=92%) was chosen to be mixed with siRNA at elevated 
concentrations. 
 
Figure 4.10 Influence of chitosan C* on size and PDI of siRNA/CS polyplexes produced manually. 
Two CS with the same DDA (92%), but different molecular weights (10 kDa and 2 kDa) were 
tested 
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As shown in Figure 4.10, while the maximum siRNA concentration for preparation of 
homogeneous small sized CS/siRNA polyplexes is 0.2 mg/mL using CS92-10, this concentration 
for CS2-10 is 0.6 mg/mL. This suggests that the molecular weight and consequently C* of CS 
solution have a direct influence on the maximum possible starting concentration of nucleic acid for 
production of homogeneous small sized polyplexes. Note that manual mixing of CS92-10 at siRNA 
starting concentration of 0.3 mg/mL results in irreproducible size records with PDI>0.2. Also, 
mixing CS92-2 at siRNA starting concentration of 0.8 mg/mL is associated with limited 
macroscopic flocculation. 
4.9.4 MIQE compliant qPCR 
4.9.4.1 Transcript structure analysis 
The analysis of the region containing the amplicon was performed using m-fold (version 2.3). The 
default setting of 60oC was selected to mimic the temperature at which qPCR is performed and 
only the most stable structure was analyzed. No secondary structures hindering the amplicon were 
detected. 
4.9.4.2 Details of the qPCR assay 
The sequence of the forward, reverse and the probe for each assay used in this manuscript is listed 
in Table 4.1. The NCBI ref_sequence ID and the position of the forward, reverse, the probe and the 
anti-ApoB siRNA relative to the ref_sequence is also given. 
4.9.4.3 Efficiency of the assays 
Assay efficiency was determined using the standard curve method. In each experiment, a 6 log 10-
fold dilution curve was constructed by plotting the quantification cycle (Cq) versus Log 
complementary DNA (cDNA) concentration and linearly regressed to fit the data. PCR reaction 
efficiency was estimated by using  𝐸 = 10
(−
1
slope
)
− 1. The efficiency of all assays for the two 
experiments (shown in  
Table 4.2) was within the acceptable range of 95-105%. The inter-experiment variability or 
difference in efficiency was ≤ 3% indicating reproducibility and robustness of the assays.   
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Table 4.1. The sequence of the forward, reverse and the probe for each assay used 
Assay name Sequence (5’ to 3’) Position Ref_Seq 
IDT_ApoB 
Forward GAC ACA CCA AAG ATC AGC 996-1016 
NM_000384.2 
Reverse GAG AGT CTT CAA AAC AGC TTC G 1115-1094 
Probe 
/5’6-FAM/CAC CAA ATC/ZEN/CAC ATC ACC 
TCC AAA GC/3’IABkFq 
1064-1089 
UPL_ApoB 
Forward GAC GAC TTT TCT AAA TGG AAC TTC TAC 
12177-
12203 
Reverse CTC AGT TTT GAA TAT GGT GAG TTT TT 
12254-
12229 
Probe TCCTCTCC (UPL probe #55, Cat #04688520001)  
IDT_GAPDH 
Forward ACA TCG CTC AGA CAC CAT G 173-191 
NM_002046.5 
Reverse TGT AGT TGA GGT CAA TGA AGG G 315-294 
Probe 
5’6-FAM/AAG GTC GGA/ZEN/GTC AAC GGA 
TTT GGT C /3’IABkFq 
201-225 
ABI_B2M 
Forward 
Information not publically available. TaqMan Assay 
ID: Hs00984230_m1 
 NM_004048.2 
Reverse   
Probe   
ApoB siRNA 
Sense GUC AUC ACA CUG AAU ACC AAU 
10167-
10187 
NM_000384.2 
Anti-
sense 
AUU GGU AUU VAG UGU GAU GAC AC 
10187-
10165 
 
Table 4.2 Assay efficiency for the two experiments 
Assay 
name 
Experiment 1 Experiment 2 
Difference 
(%) in E 
between 
experiments 
E 
Standard 
Error E 
Rsqrt 
Slope 
(error) 
Intercept 
(error) 
E 
Standard 
Error E 
Rsqrt 
Slope 
(error) 
Intercept 
(error)  
(%)     (%)     
IDT_
ApoB 
95.2 0.024 0.997 
-3.4413 
(0.0633) 
17.318 
(0.1205) 
95 0.0228 0.996 
-3.458 
(0.0610) 
19.779 
(0.1044) 
0.2 
UPL_
ApoB 
96% 0.0178 0.998 
-3.4214 
(0.0461) 
17.985 
(0.0789) 
95 0.0111 0.999 
-3.455 
(0.0296) 
19.651 
(0.0506) 
1 
IDT_
GAP
DH 
102.2 0.0255 0.996 
-3.2685 
(0.0585) 
22.291 
(0.1001) 
99.5 0.0205 0.997 
-3.332 22.341 
(0.0848) 
3 
-0.0495 
ABI_
β2M 
96.4 0.0135 0.999 
-3.4112 
(0.0348) 
19.997 
(0.059) 
96.4 0.012 0.999 
-3.412 
(0.0310) 
20.439 
(0.0531) 
0 
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4.9.4.4 Reference gene stability 
The reference genes used in this study viz. human glyceraldehyde-3-phosphate (GAPDH) and 
human β-2 microglobulin (β2M) were selected from a pilot study where the stability of references 
genes was assessed using a panel of 10 reference genes and 8 treatment conditions including 
DharmaFECT®2- lipoplexes, chitosan based polyplexes prepared at different DDA and N:P ratios, 
concentration of chitosan/well and cell lines (Alameh et al., 2017). In this study, the stability of 
GAPDH and β2M was re-validated using the geNorm statistical package.  The M score for both 
reference genes, computed from all treatment conditions viz. in-line (0.05 to 0.4 mg/mL), manual 
(0.05 to 0.4 mg/mL), DharmaFECT®2, Mock chitosan, naked siRNA and non-treated, was ≤ 0.25. 
As a consequence, these two reference genes were deemed stable. The suitability of these reference 
genes was not only decided based on their stability vis-a-vis treatment conditions but also to the 
fact that they are on two different cellular pathways and cannot be co-regulated. 
4.9.4.5 RNA quality, integrity, and quantity 
Total RNA quality, integrity, and quantity was assessed using the UV-Vis (Nanodrop 8000), 
Agilent Bioanalyzer 2100 and Qubit assay, respectively.  
The results of one technical replicate from each experiment is shown in Table 4.3. The UV 260/280, 
260/230 and 340 ratios were above 2, 1.8 and equal to 0 respectively indicating high purity and 
absence of contamination with guanidium salts and/or other compounds i.e. silica. RNA integrity 
of all extracted samples was above 9, indicative of intact RNA. 
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Table 4.3 Total RNA quality, integrity, and quantity for the two experiments 
Sample/parameter 
Experiment 1 Experiment 2 
[RNA] 
(ng/µL) 
UV 
260/280 
UV 
260/230 
UV 
340 
RIN 
[RNA] 
(ng/µL) 
UV 
260/280 
UV 
260/230 
UV 
340 
RIN 
InL 0.05 mg/mL 121.5 2.1 1.9 
-
0.007 
9.6 183.8 2.13 1.97 
-
0.061 
9.8 
InL 0.10 mg/mL 114.7 2.1 1.9 
-
0.012 
9.6 149.8 2.12 1.97 
-
0.027 
9.7 
InL 0.20 mg/mL 134 2.1 2 0.006 9.8 195.2 2.09 1.91 
-
0.042 
9.8 
InL 0.30 mg/mL 150.1 2.1 1.4 
-
0.029 
9.8 192 2.11 1.97 0.011 9.8 
InL 0.40 mg/mL 123.9 2.1 1.9 
-
0.011 
9.7 168.4 2.12 1.99 0.003 9.8 
Man 0.05 mg/mL 60.2 2.1 1.9 
-
0.083 
9.8 142.8 2.13 2 
-
0.004 
9.7 
Man 0.10 mg/mL 109.1 2.1 1.9 
-
0.043 
10 160.2 2.12 2.02 0.016 9.7 
Man 0.20 mg/mL 129.3 2.1 1.9 
-
0.004 
9.9 159 2.12 1.86 -0.06 9.7 
Man 0.30 mg/mL 124.7 2.1 1.9 0.023 9.9 169.6 2.12 1.94 
-
0.039 
9.8 
Man 0.40 mg/mL 134.1 2.1 2 
-
0.013 
9.9 214 2.1 1.97 
-
0.049 
9.8 
DharmaFECT® 2 113.9 2.1 2 0.032 10 127 2.11 1.96 
-
0.055 
10 
Naked siRNA 133 2.12 2.01 0.01 10 163 2.08 1.9 0.02 9.5 
Mock chitosan 127.2 2.12 1.88 
-
0.097 
9.9 120.8 2.12 1.94 
-
0.006 
9.9 
Non-treated cells 138.9 2.1 2.1 0.03 9.9 176.6 2.12 1.95 
-
0.006 
9.8 
4.9.4.6 Controls 
No reverse transcription control (NRTC) and no template control (NTC) were used as controls. 
There was no amplification in controls. 
4.9.4.7 Comparison between the two assays used 
The two probes used in this study detect the ApoB mRNA at two different regions. The Integrated 
DNA (IDT) and Universal Library (UPL) probes detect and amplify sequences on the ApoB cDNA 
that are around 10kbp apart. The IDT and UPL assays are located at the 5’ and 3’ sides of the ApoB 
mRNA respectively. The data in Figure 4.11 show that the two assays were in agreement indicating 
a true knockdown of the target gene, demonstrating that the knockdown assay is not dependent on 
the probe position.  
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Figure 4.11 Comparison of knockdown detected by two different primer-probe pairs targeting the 
ApoB mRNA. The IDT primer-probe pair detect the ApoB mRNA at 996-1115 (amplicon 120 bp). 
The UPL primer-probe pair (#55) detect the ApoB mRNA at 12177-12254 (amplicon 78 bp).  
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CHAPTER 5 PURIFICATION AND MODIFICATION OF CHITOSAN-
BASED POLYPLEXES USING TANGENTIAL FLOW FILTRATION 
5.1 Objective 
The first objective of this chapter is to establish TFF technique and optimize its operational 
conditions for purification and concentration of CS-based polyplexes. The second objective is to 
develop HA-coated complexes, upon purification of polyplexes, to enhance their 
hemocompatibility for intravenous clinical applications. 
5.2 Summary 
Chitosan(CS)-based polyplexes are produced by electrostatic association of positively charged CS 
and nucleic acids (NAs) upon mixing, while CS is in excess versus NA. The final solution includes 
polyplexes with positive surface charge as well as unbound CS molecules. However, due to 
interactions with negatively charged blood components, the unbound CS as well as the positive 
surface of polyplexes limit the applicable dosage of these therapeutics for intravenous (IV) 
administrations. Hence, clinical application of this technology requires the development of 
hemocompatible formulations for IV delivery systems. One approach to tackle such drawbacks is 
to purify (remove the unbound CS), then coat the polyplexes with hyaluronic acid (HA) through 
electrostatic interactions between the anionic groups of HA and the cationic groups of CS on the 
surface of the polyplexes. Here, we introduced tangential flow filtration (TFF) for purification of 
CS-based polyplexes. Using 100 kDa mPES hollow fibers, TFF operational conditions were 
established at trans-membrane pressure (TMP) of 0.9-1.0 psid, and relatively low shear rates of 
7000-11000 s-1. Thereafter, the optimal number of diafiltration volumes (DV) for purification of 
polyplexes was established at 5 DV. We demonstrated that at shear rate of 7000 s-1 (TMP=0.9 psid), 
98% of the unbound CS was removed, while 81% of the polyplexes were recovered. No marked 
change in physico-chemical properties and morphology of polyplexes was observed post-
diafiltration. Purified CS/siRNA eGFP polyplexes were then coated by a library of HA molecules 
with different molecular weights and degrees of sulfation, at different phosphate to carboxyl ratios 
(C:P). Our data revealed that C:P≥ 2 is needed to effectively coat the polyplexes and sign reversal 
of the surface of complexes. It was also demonstrated that regardless of C:P ratio, addition of a 
high molecular weight HA (866 kDa) results in macroscopic flocculations. Furthermore, we 
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showed that low molecular weight (10 kDa and 12 kDa) HA-coated CS/siRNA complexes have 
equivalent or increased silencing efficiency of eGFP in H1299 cells, with improved 
hemocompatibility as compared to uncoated polyplexes. Finally, it was shown that although both 
sulfated and non-sulfated HAs resulted in small sized, homogenous, and bioactive coated 
complexes, sulfated HA molecules presented higher stability during filtration process, indicating 
their stronger binding affinity to polyplexes. Development of these modified formulations represent 
an important step forward to the clinical use of CS-based complexes for IV applications. 
5.3 Introduction 
In the past decade, chitosan (CS)-based formulations have gained increasing interest for safe 
delivery of nucleic acids (NAs). We have already demonstrated reproducible production of 
CS/pDNA and CS/siRNA polyplexes using an Automated In-line Mixing System, AIMS (Tavakoli 
Naeini, Soliman, Alameh, Lavertu, & Buschmann, 2017). CS/NA polyplexes are produced by 
electrostatic-mediated association of CS and NA solutions upon mixing, while CS is used in excess 
versus NA, typically, 5X higher in molar charge concentration (Alameh et al., 2017; Jean et al., 
2012b; Jean et al., 2009; Lavertu et al., 2006; Tavakoli Naeini et al., 2017; Thibault et al., 2010b; 
Veilleux et al., 2016). Since CS is in excess, a significant portion of this molecule remains free 
(unbound to polyplexes) in the solution. Despite the potential of these polyplexes in vivo (Alameh 
et al., 2017; Corbet et al., 2016; Gao et al., 2014; Howard et al., 2006a; Nielsen et al., 2010; Yang 
et al., 2015), intravenous (IV) administration remains problematic due to hemolysis and 
haemagglutination of erythrocytes in contact with both bound and unbound CS (Carreno-Gomez 
& Duncan, 1997). CS binds to the red blood cells (RBCs) and causes haemagglutination, even at 
very low concentrations (Rao & Sharma, 1997). The interactions between CS molecules and the 
anionic charges on the surface of the erythrocytes induces stresses to the cell membranes which 
eventually leads to their rupture (Carreno-Gomez & Duncan, 1997; Rao & Sharma, 1997). Thus, 
CS-based formulations need to be modified before transferring for IV administrations of especially 
higher doses. Modification of polyplexes involves neutralization or coating the polyplexes with 
another molecule in order to eliminate the interactions with blood cells, and finally enhance the 
pharmacokinetics of polyplexes (Buschmann et al., 2013). Several surface modification approaches 
have been suggested in literature (Buschmann et al., 2013). One approach pursued here is to coat 
the CS/NA polyplexes using hyaluronic acid (HA) through electrostatic interactions between the 
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cationic groups of CS and the anionic groups of HA. HA is a highly hydrophilic, non-toxic and 
hemocompatible glycosaminoglycan which is widely distributed throughout extracellular matrices. 
Another important feature of HA which nominates this molecule as a great therapeutic targeting 
agent is that it binds to the CD44 receptor, which is overexpressed in a wide variety of cancer cells 
(Dosio et al., 2016; Karbownik & Nowak, 2013; Platt & Szoka, 2008). HA is available in a wide 
range of molecular weight (Karbownik & Nowak, 2013; Tripodo et al., 2015). The carboxyl groups 
on the D-glucuronic acid residues have pKa value ~3-4, hence, these functional groups are ionized 
at physiological pHs (Dosio et al., 2016). HA can also be modified by the insertion of ionic sulfate 
(SO3–) groups in the polysaccharide chain. Sulfated HAs have been reported with different degrees 
of sulfation, ranging from 1 to 4 sulfate groups per disaccharide (Magnani et al., 1999). Stronger 
binding affinity, and slower degradation of sulfated HA by hyaluronidase was reported in the 
literature (Feng et al., 2017; Magnani et al., 1999). HA chains (either non-sulfated or sulfated) can 
simply form electrostatic bonds with CS molecules on the surface of the polyplexes to improve 
their pharmacokinetics and hemocompatibility. However, before CS-based polyplexes can be used 
for further surface modifications, they must be purified. Purification of CS-based polyplexes relies 
on elimination of the unbound chitosan molecules from the polyplex solution. Appropriate 
purification techniques are required to effectively purify the polyplexes post-mixing. Conventional 
techniques used for purification of nanoparticles (NPs) such as ultrafiltration, dialysis and gel 
filtration are associated with several drawbacks when it comes to their application in purification 
of gene loaded NPs. These methods are mainly used for “hard” NPs such as gold NPs, and cannot 
be easily applied to “soft” NPs (Robertson et al., 2016). The conventional techniques are either 
invasive, expensive, time-consuming, relatively inefficient, and more importantly difficult to scale-
up. Ultracentrifugation is associated with irreversible aggregation of NPs due to centrifugal forces 
(Dalwadi et al., 2005), and becomes much more problematic when transitioning from small scale 
to large scale purifications (Correa et al., 2016). Dialysis involves the risk of product loss during 
manual manipulations, requires a large amount of exchange buffer which produces large volumes 
of aqueous waste, and can take up to several days (Sweeney et al., 2006). Moreover, due to the 
lengthy process, dialysis can result in release of NP’s payload (Dalwadi et al., 2005). Gel filtration 
is relatively a faster process; however, a small volume of NP solution can be processed at a time. 
Moreover, irreversible adsorption of molecules onto the column and not a perfect selectivity of 
small and bigger NPs can restrict the application of this approach for purification of drug or gene-
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loaded particulates (Dalwadi et al., 2005). Tangential Flow Filtration (TFF), on the other hand, 
overcomes the main limitations of the conventional techniques. By re-circulation of the fluid 
parallel to the surface of the filter, TFF inhibits built-up cake on the surface of the membrane. 
During TFF, molecules smaller than membrane pores pass through the membrane (generating the 
permeate) and larger molecules are retained and re-circulated in the system (generating the 
retentate) until the desired concentration is reached. Diafiltration is a TFF process that involves 
washing out the original buffer by continuously adding a new buffer to the sample at the same rate 
as permeate is being removed from the system (L. Schwartz, 2003). As a membrane-based method, 
pore size dictates the retention of particles of interest in the sample during re-circulation, thus, 
diafiltration offers to combine purification and size separation into a single process. Due to simple 
equipment requirements and the scalability of the technique, diafiltration can be performed quickly 
and conveniently (Sweeney et al., 2006). Another important advantage of diafiltration is that the 
sample could be concentrated in the same system, minimizing the risk of sample loss or 
contamination (Limayem et al., 2004). Diafiltration has been used in separation of proteins that 
differ by only a single charged amino acid residue (Ebersold & Zydney, 2004), purification of 
polymeric nanocapsule suspensions (Limayem et al., 2004), gold NPs (Sweeney et al., 2006), silver 
NPs (Anders et al., 2012), NP suspension (Dalwadi et al., 2005), PEGylated NPs (Dalwadi & 
Sunderland, 2007), and drug loaded layer by layer complexes (Correa et al., 2016). However, the 
application of diafiltration for CS-based polyplexes has not been reported yet. Here, we specifically 
describe, for the first time, the approach to adopt and optimize the TFF technique for processing 
CS-based polyplexes. Optimization of a TFF process was executed by examination of the 
interdependence of TMP, shear rate and permeate flux, which is known as TMP scouting (Cross 
flow filtration Method Handbook, 2014; Millipore, 2013). Afterwards, the capability of TFF for 
concentration and diafiltration of these polyplexes in the established operational conditions is 
demonstrated. Thereafter, diafiltered polyplexes were coated by different HA molecules to deliver 
a layer by layer complex. Finally, to highlight the compatibility of TFF technique to safely process 
CS-based polyplexes, bioactivity and hemocompatibility of the purified CS/siRNA polyplexes, as 
well as HA-coated complexes were examined. 
73 
 
5.4 Materials and Methods 
5.4.1 Materials 
Chitosan was obtained from Marinard. Custom synthesized siRNA targeting EGFP (siRNA EGFP) 
contains sense sequence of 5' GAC GUA AAC GGC CAC AAG UUC 3' and antisense 5' ACU 
UGU GGC CGU UUA CGU CGC 3' (Howard et al., 2006a) was obtained from GE. Custom made 
double stranded oligodeoxynucleotide (dsODN, 21 bp) encoding the same sequences and 
mimicking siRNA EGFP physic-chemical properties was obtained from Integrated DNA 
Technologies Inc, Coralville, IO. The commercially available liposome, DharmaFECT 2 was from 
Dharmacon RNAi Technologies. A human non-small lung carcinoma (H1299) cell line stably 
expressing enhance green fluorescence protein (eGFP+ H1299) was donated by Dr Jorgen Kjems 
(AARHUS University, Denmark) upon approval of Dr Anne Chauchereau. Stanbio hemoglobin 
standards (Cat #SB 0325 006) was from Fisher Scientific. RPMI 1640 (Cat #31800-022), Fetal 
Bovine Serum (FBS, Cat #26140), GlutaMAX 100X (Cat #35050-061) were from ThermoFisher 
Scientific. Trehalose dihydrate (Cat #T0167), L-histidine (Cat #H6034), triton X-100 (Cat 
#T8532), poly-L-Lysine hydrobromide (PLL, Cat #P1399), polyethylene glycol (PEG 8 kDa, Cat 
#P1458), orange II sodium salt (Cat #195235), 1N hydrochloric acid solution (Cat #318949), 
glacial acetic acid (Cat #338826), sodium acetate trihydrate (Cat #S7670), 1N sodium hydroxide 
solution (Cat #319511) were from Sigma Aldrich (Cat #D5758). DC protein assay kit (5000111), 
and fetal bovine serum (FBS, Cat #26140) were from LifeTechnologies. Modified polyethersulfone 
(mPES) MWCO of 100 kDa (part #C02-E100-05-N) and 300 kDa (C02-E300-05-N) were obtained 
from Spectrum Labs, MicroKros Class. Non-sulfated sodium hyaluronate (MW=866 kDa, Cat 
#HA1M-1), Non-sulfated sodium hyaluronate (MW=10 kDa, Cat #HA10K-1), Non-sulfated 
sodium hyaluronate (MW= 40 kDa, Cat #HA40K-1), was from Lifecore Biomedical. Sulfated 
sodium hyaluronate (MW=184 kDa with degree of sulfation=2.0, Cat # FP-RD009-26), Sulfated 
sodium hyaluronate (MW=154 kDa with degree of sulfation=1.0, Cat # FP-RD009-27), Sulfated 
sodium hyaluronate (MW=148 kDa with degree of sulfation=0.6, Cat # FP-RD009-29), and 
Sulfated sodium hyaluronate (MW=12 kDa with degree of sulfation=1.4, Cat # FP-RD009-33) 
were from HTL Biotechnology. 
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5.4.2 Preparation of CS, ODN, and siRNA formulations for mixings 
ODN ApoB, and siRNA ApoB stock solutions were prepared and characterized by UV 
spectrophotometry, then diluted to 200 µg/mL with RNase/DNase free water, as well as sterile 
filtered trehalose and histidine (pH 6.5) solutions for having final concentration of 0.5% w/v and 
3.5mM, respectively (these are optimum concentrations of excipients for freeze-drying and stability 
of complexes over time that have been established within our group (Veilleux et al., 2016)). 
Commercial chitosan was first deacetylated to 92% using concentrated sodium hydroxide and was 
depolymerized to Mn=10 kDa using nitrous acid, as previously described (Lavertu et al., 2006). It 
has been repeatedly shown that the 10 kDa chitosan with DDA of 92% (CS92-10) form stable 
polyplexes with bigh transfection efficiency, when prepared at molar ratio of CS amine to NA 
phosphate ratio of 5 (N:P=5). Number-average molecular mass (Mn) as well as degree of 
deacetylation (DDA) of CS were confirmed by gel permeation chromatography multi-angle light 
scattering (Nguyen et al., 2009), and 1H NMR (Lavertu et al., 2003), respectively. CS stock 
solution was prepared at 5 mg/mL from dry powder dissolved in 28 mM HCl overnight at room 
temperature (RT). Dry HA was dissolved in DNase/RNase free water at RT, to a stock solution 
concentration of 1 mg/mL. CS and HA stock solutions were then sterile filtered, and diluted with 
DNase/RNase free water, as well as excipients (trehalose and histidine) for the target N:P and C:P 
ratios, respectively. 
5.4.3 Preparation of polyplexes by in-line mixing  
CS/ODN and CS/siRNA polyplex solution were produced at N:P=5 via the advanced version of 
Automated In-line Mixing System (AIMS) with Re=4000 (300 mL/min), tubing size=1/16” (LS14) 
as described by Tavakoli et al. (Tavakoli Naeini et al., 2017).  
5.4.4 Preparation of HA-coated polyplexes by manual mixing 
HA-coated polyplexes were formed by adding HA to diafiltered polyplexes at carboxyl to phosphate 
ratio (C:P) of  1.0, or 1.5, or 2.0, or 3.0. HA was added to the uncoated diafiltered polyplexes in a 
HA:polyplex volumetric ratio of 1:2. Manual mixing was done by pipetting up and down of the final 
solution for approximately 10 times.  
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5.4.5 Preparation of HA-coated polyplexes by in-line mixing 
HA-coated polyplexes were formed by adding HA to diafiltered polyplexes at carboxyl to phosphate 
ratio (C:P) of  3 using the Automated In-line Mixing System, AIMS (Tavakoli Naeini et al., 2017). 
PharmaPure tubing, size=1/16” (LS-14) was used. In order to maintain the HA:polyplex volumetric 
ratio of 1:2, polyplexe solution was pumped at Re=2000 (150 mL/min), while the HA solution was 
dispensed at Re=1000 (75 mL/min).  
5.4.6 Tangential flow filtration 
Polyplex solution was transferred to a three-port cap 50 mL or 250 mL conical vessel (Corning), 
and connected to the TFF system (KrosFlo Research IIi; Spectrum Labs). All connections were 
made using MasterFlex PharmaPure tubing, LS-14, size=1/8”. Filer modules composed of 
modified polyethersulfone (mPES), either 100 kDa or 300 kDa (MicroKros class by Spectrum 
Labs) were used. The digital TFF pump was programmed using LabViewTM software. Feed, 
permeate, and retentate pressure values were monitored and recorded by the transducers. The mass 
of permeate was also monitored using a programmed digital balance. The permeate flow rate (Qp) 
was being calculated in real time via the software (mass of permeate collected in every 20 seconds 
and converted to mL/min). Knowing the feed flow rate (Qf, set by the user), the retentate flow rate 
(Qr) was calculated by simple subtraction of Qp from Qf. 
5.4.6.1 Normalized water permeability 
Normalized water permeability measures the flow rate of water through the membrane under an 
applied trans-membrane pressure (TMP). Water flow rate gives an indication of the performance 
of a filter. By tracking the water permeability before and after filtration, it is possible to determine 
if a filter is clogged. Water permeability is usually carried out when the filter is new and after each 
use. Water permeability test was done by placing the permeate and retentate tubings into two 
separate waste containers. Permeate containers was placed on a digital balance that was 
programmed and recorded the mass every 20 seconds. The pump was first adjusted at 10 mL/min. 
Feed, retentate, and permeate pressures (Pf, Pr, Pp) were recorded by the transducers while all of 
the streamlines were open. TMP was then calculated in real time by the software; 
TMP=[(Pf+Pr)/2]-Pp . Upon stablization of the pressures, permeate flow rate was calculated by the 
the permeate mass collected in two minutes. The permeate flow rate was then translated in flux, 
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permeate flow rate in litre per hour per m2 of the membrane, represented as litre/m2/h (LMH). The 
calculated permeate flux corresponded to the recorded TMP. This was the first point of the 
normalized water permeability curve. The same procedure was done for four extra feed flow rates 
(20, 30, 40, and 50 mL/min). The slope of the generated curve defined the permeability of the 
membrane.  
5.4.6.2 Equilibration of the hollow fibers prior filtration 
Before use, every hollow fiber was equilibrated by passing 200 mL of diafiltration buffer through 
the membrane. Following steps were taken: both retentate and permeate streams were directed to a 
waste container, then the feed flux was adjusted at 200 to 300 LMH. Ratio of permeate to retentate 
flow rate was adjusted at 40%-50%. When half the buffer mixture has been flushed, the system 
was put in total recirculation mode (TRM) where the permeate and retentate lines were put back in 
the feed vessel, for 15 minutes.  
5.4.7 Polyplex size, polydispersity, and surface charge analysis 
Hydrodynamic size and polydispersity index of the produced polyplexes were measured using 
dynamic light scattering (Zetasizer Nano ZSP- ZEN5600, Malvern Instruments, Worcestershire, 
UK). Samples were diluted 4 folds by adding Milli-Q or RNase free water, then analyzed for three 
consecutive runs at 25°C. Zeta potential (ZP) measurements were made via laser Doppler 
velocimetry with the Malvern Zetasizer Nano ZS using folded capillary cells. For ZP 
measurements, samples were diluted by 8 fold to a total volume of 800 µL using RNase free water. 
Each sample was analyzed for three consecutive runs at 25oC. Electrophoretic mobility was 
calculated based on the Smoluchowski model. 
5.4.8 Orange II assay 
The concentration of free (unbound) CS in permeate and retentate solutions was determined by 
Orange II assay, established by Drogoz et al. (Drogoz, David, Rochas, Domard, & Delair, 2007). 
Polyplex samples were first ultracentrifuged (Optima MAX-E, TLA-110 fixed rotor, Beckman 
Coulter, Brea, CA, USA) for 45 min at 60000 rpm to spin down polyplexes. A supernatant aliquot 
of 20 μL was collected for each sample. Supernatants were diluted 20 fold with 50 mM acetic 
acid/sodium acetate buffer at pH 4.0. Supernatants from the permeate samples were not diluted as 
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they were already very dilute for CS. Orange II dye was prepared at a concentration of 1 mM in 
the acetic acid/sodium acetate buffer, and was added to supernatants, at a volumetric ratio of 1:32 
(ensuring Orange II sulfonic acid groups are in excess relative to fully protonated CS amine groups 
during the assay), and mixed by vortexing. Samples were incubated 5 min to allow formation of 
CS/Orange II complexes, which were then precipitated by centrifugation (IEC Miromax, 891 rotor, 
Thermo Fisher Scientific, Waltham, MA, USA) at 15000 rpm for 45 min. 200 μL of the final 
supernatant (containing the unbound Orange II) was transferred to each well of a 96-well 
microplate and the absorbance was measured at 484 nm by Infinite M200 microplate reader (Tecan, 
Mannedorf, Switzerland). The free CS content was calculated using a calibration curve obtained 
from CS standard dilutions (in the range of 2-20 µg/mL) prepared in the same procedure as the 
samples. 
5.4.9 Transmission electron microscopy imaging 
Morphology of both uncoated, and HA-coated polyplexes (pre- and post-diafiltration) was studied 
using Transmission Electron Microscopy (TEM). On a carbon coated copper grid (200 mesh, 
Electron microscopy sciences), 5 µL drop of polyplex suspension was pipetted and allowed to 
evaporate for 30 minutes. Remaining solvent was removed by blotting using a filter paper. 5 µL of 
2% phosphotungstic acid was placed on the grid. After 10 minutes the stain was removed as 
described above. The grid was washed two times with deionized water to avoid any salt 
contamination from the sample and air dried. TEM images were obtained using a Tecnai T12 
electron microscope (FEI, Hillsboro, OR, USA) operating at 120 keV. For each sample four random 
areas on the grid were imaged at different magnifications. 
5.4.10 Cell culture and transfection 
eGFP+ H1299 cells were cultured in RPMI-1640 media supplemented 10% FBS, 1% GlutaMAX® 
and 500 µL/ mL of G418 antibiotic at 37°C in 5% CO2. For target gene knockdown cells were 
seeded in 96 well plates at a density of 7500 cells per well to reach 75-85 % confluence on the day 
of transfection. Prior to transfection, cells were washed once with 500 µL of warm Ca2+/Mg2+ free 
PBS and replenished with complete RPMI-1640 adjusted at pH of 6.5 (5mM MES, 10 mM sodium 
bicarbonate, pH 6.5).  
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2.7μL of uncoated polyplexes, or 4 μL of HA-coated complexes were added to each well prefilled 
with 197.3 μL and 196 μL of transfection medium (pH 6.5), respectively, to reach a final siRNA 
concentration of 100 nM (0.268 μg of siRNA per well). In the case of purified CS/siRNA (uncoated 
polyplexes post-diafiltration), after 15 minutes, 2.7 μL of pure CS solution at 0.2 mg/mL was added 
to the designated wells for CS rescue (note that the addition of chitosan is to compensate the 
diafiltered free chitosan as it was previously shown to be necessary for endosomal release of the 
payload) (Thibault et al., 2010b). Cells were incubated for 24h, then medium was aspirated and 
replenished with 200 μL of culture medium. Cells were incubated again for extra 24 hours before 
analysis. 
DharmaFect® 2/siRNA nanoparticles were prepared by diluting siRNA stock solution to 0.025 
mg/mL (4 μM) in Opti-MEM® serum free media and complexed to the lipid component as per 
manufacturer recommendation; a volume of 6.4 μL of DharmaFect® 2 in 153.6 μL Opti-MEM® 
was used for complexation. Untreated and naked siRNA at a final concentration of 100nM were 
used as negative controls.  
5.4.11 Assessment of in vitro silencing efficiency 
Before analysis, eGFP+ H1299 cells were washed twice with 200µL ice cold Ca2+/Mg2+ free PBS, 
lysed by addition of 200 µL of PBS containing 1% NP-40 and incubated at room temperature for 
10 minutes to allow complete membrane disintegration. Lysates were homogenized by pipetting, a 
volume of 100 µL transferred in a black 96 well assay plate, and EGFP fluorescence measured at 
510 nm using a TECAN Infinite® F-500 microplate system (Tecan, Mannedorf, Switzerland). 
Total protein content of the lysate was assessed using the BioRad DC Protein assay as per 
manufacturer recommendation. For assessment of gene knockdown, EGFP fluorescence was 
background subtracted and normalized to total protein content and expressed relative to non-treated 
cells. The assay was performed in duplicate. 
5.4.12 Hemocompatibility assays 
Hemolytic and hemagglutinative properties of both uncoated and HA-coated polyplexes were 
tested according to ASTM E2524 ("Standard Test Method for Analysis of Hemolytic Properties of 
Nanoparticles," 2013) and the method described by Evani and Ramasubramanian (Evani & 
Ramasubramanian, 2001), respectively. CS/siRNA polyplexes both pre- and post-diafiltration were 
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diluted to final siRNA concentrations of 0.1, 0.05, and 0.025 mg/mL. Also, the HA-coated 
polyplexes pre- and post-diafiltration were diluted to final siRNA concentration of 0.0667, 0.0335, 
and 0.0167 mg/mL. Negative controls included 40% w/v polyethylene glycol (PEG, 8 kDa), 20% 
w/v trehalose, 1 mg/mL HA, 0.1 mg/mL siRNA, and PBS pH 7.0. Positive controls included 10 
mg/mL poly-L-lysine (PLL), and 10% v/v Triton X-100. Sodium citrate anti-coagulated whole 
blood (collected from a subject who had responded positively to an Informed Consent Form) was 
diluted with PBS pH=7.0 to adjust total blood hemoglobin concentration to 10 mg/mL. 100 µL of 
each test sample, positive or negative control was mixed with 700 µL of PBS pH 7.0, and 100 µL 
of diluted blood. The mixture was then incubated for 3 hours in a water bath at 37oC. Supernatant 
was collected following centrifugation for 15 min at 800 g and used for colorimetric measurement 
of hemoglobin content (absorbance read at 540 nm) using Stanbio™ hemoglobin (Fisher, Product 
No SB 0325). A calibration (standard) curve was generated to calculate the hemoglobin 
concentration in the supernatant of each sample. The percentage of hemolysis for each sample was 
calculated as: % Hemolysis =
Hemoglobin conc.in the sample
Hemoglobin conc.in diluted blood
× 100. %Hemolysis above 5% 
indicates the test material causes damage to red blood cells. Hemagglutination was assessed 
qualitatively by incubation of 200 µL of each sample-PBS-diluted blood mixture for 3 hours at 
37oC in a round-bottomed (U-shaped) 96-well plate. Hemagglutination occurs if a granular or 
irregular ring of erythrocytes covered more than half of the well bottom. 
5.4.13 Statistical analysis 
Unless otherwise indicated, data were expressed as mean value ± standard deviation (n = 2). Sigma 
Plot 13.0 was used to generate curves and standard deviation calculations. Also, for 
hemocompatibility results, Sigma Plot 13.0 was used to generate the four parameter logistic (4PL) 
regression curves and calculate values. 
5.5 Results and discussion 
5.5.1 Establishment of TFF operational parameters 
Choosing a membrane with appropriate retention characteristics is an important and integral part 
of the establishment of a membrane filtration to ensure high product yield. Here, we picked mPES 
membrane due to its advanced hydrophilic chemistry, almost neutral charge, and low binding 
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properties which yields higher product recovery. Working with nanoparticles, hollow fiber 
geometry was chosen as it has been demonstrated that the tubular geometry of hollow fibers is 
more beneficial than the cassette geometry for filtration of particles, which is attributed to 
migration of particles to the center of the hollow fiber where the flow velocity is the highest 
(tubular pinch effect) (Serway & Tamashiro, 2010). To assure complete retention of NPs, the 
molecular weight cut-off (MWCO) of the membrane should be 1/6th to 1/3rd of the molecular 
weight of the molecule to be retained: 3-6X rule (L. Schwartz, 2003). The closer the size of the 
particles to that of the membrane pores, the greater the risk for loss of some small particles (L. 
Schwartz, 2003). For retention of ODN/CS and siRNA/CS NPs (with a hydrodynamic size of 45-
60 nm), and permeation of CS molecules (<5 nm), mPES membranes with MWCO of 300 kDa 
and 100 kDa were deemed to be suitable (according to the manufacturer, 100 kDa and 300 kDa 
have pores nominally in the range of 5-7 nm and 13-15 nm, respectively). Identical operational 
conditions were applied for both membranes (shear rate of 11000 s-1, and TMP of 1.0 psid). 
CS/ODN polyplexes were diafiltered up to 5DV. Optical density at 260 nm for each solution 
(initial polyplex sample, retentate, permeate, and cleaning solutions after diafiltration) was 
recorded then translated to concentration. Based on the volumes, the mass of polyplexes present 
in each solution was calculated. Loss on membrane was then computed by simple subtraction. It 
was found that while using 100 kDa membrane it is possible to recover up to 85% of the 
polyplexes, 300 kDa membrane retains only 57% of polyplexes (Figure 5.1). It should be noted 
that in the applied conditions, 13% of the polyplexes were permeated using 300 kDa. Interestingly, 
this value was reduced to only ~1% when 100 kDa membrane was used. This suggest that due to 
bigger pore sizes, polyplexes can partially cross the 300 kDa membrane. Moreover, higher risk of 
deposition of polyplexes on the 300 kDa membrane surface was observed (25% of initial 
polyplexes). The significant drop in the normalized water permeability of 300 kDa membrane post 
filtration (to 62% of its original value) also advocats the high risk of penetration of polyplexes 
into the pores of the membrane. Normalized water permeability of 100 kDa membrane changed 
slightly to 89% of its original value, confirming very lower risk of clogging the membrane. 
Altogether of data, 100 kDa membrane is a better pick for filtration of CS-based polyplexes with 
the size range of 45-50 nm.  
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Figure 5.1 Distribution of CS/ODN polyplexes post-diafiltration by 300 kDa mPES (A), and 100 
kDa mPES (B) membranes. Diafiltration was done at shear rate of 11000 s-1, and TMP of 1.0 psid 
at 5DV. 
 
Therefore, 100 kDa mPES membrane was picked for further optimizations. TFF operational 
parameters include TMP, permeate flux, as well as cross flow rate (CFR), which is expressed as 
shear rate in the case of hollow fibers. Shear rate produces the force required to sweep away the 
molecules which tend to accumulate on the filter. Optimization of a TFF process involves the 
examination of the interdependence of these parameters, which is known as TMP scouting (Cross 
flow filtration Method Handbook, 2014; Millipore, 2013). In a safe operational condition, there is 
no risk of forming a gel layer on the membrane, hence, the permeate flux varies linearly by TMP 
(Cross flow filtration Method Handbook, 2014; Millipore, 2013). Despite its high importance, a 
systematic optimization approach for TFF operational parameters prior to its application is not 
often found in literature and not available for CS-based NPs. This may result in lack of 
consistency, significant drop in permeate flux during the process, and finally low product yield. 
For instance, Limayem et.al., reported 85% drop in the permeate flux after 170 minutes of both 
concentration and diafiltration of indomethacin loaded NPs. This flux drop is due to the 
continuous fouling of the membrane which is likely due to running the system in a suboptimal 
condition. Other studies just reported the applied conditions with no clear justification (Anders et 
al., 2012; Correa et al., 2016; Dalwadi et al., 2005; Dalwadi & Sunderland, 2007; Limayem et al., 
2004; Robertson et al., 2016; Trefry et al., 2010). For the determination of the safe operational 
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conditions for filtration of CS-based polyplexes, TMP scouting was executed for five shear rates: 
7000 s-1, 11000 s-1, 16500 s-1, 22000 s-1, 30000 s-1. Since for the TFF optimization study large 
volumes of polyplexes were needed, ODN encoding the same sequences and mimicking siRNA 
eGFP physico-chemical properties was used as a lower-cost alternative. 60 mL CS/ODN 
polyplexe solution was prepared at ODN concentration of 0.2 mg/mL and N:P=5 via AIMS. 10mL 
of CS/ODN polyplex sample was loaded into the feed vessel. In order to maintain the 
concentration and total volume of the CS/ODN starting solution during TMP scouting, the system 
was kept in total recirculation mode (TRM). TMP was increased very gradually from very low 
values (as low as 0.2 psid). In order to control the permeate and retentate flow rates, a needle valve 
was used in each stream. For each shear rate tested (each curve), a fresh polyplex solution (10 
mL) was loaded and a brand new 100 kDa hollow fiber was used.  
 
Figure 5.2 Relationship between permeate flux and TMP at five different shear rates using 100 kDa 
mPES hollow fibers. CS/ODN polyplexe solution prepared at ODN concentration of 0.2 mg/mL 
and N:P=5 via AIMS. Filtration of polyplexes was kept in total recirculation mode (TRM). For 
each curve, a fresh polyplex solution (10 mL) was loaded and a brand new 100 kDa hollow fiber 
was used. 
As shown in Figure 5.2, there is a general trend in the curves for all of the shear rates tested. The 
curves started with a linear behavior confirming the proportional increase in permeate flux by TMP 
up to a threshold (knee point). The linearity of permeate flux and TMP shows that the polyplex 
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solution represents the same behavior as pure water which ensures low concentration gradient of 
polyplexes on the membrane (indicating the safe operational zone). However, when TMP passes 
the knee point, permeate flux is no longer proportional to TMP, as it reaches a plateau, confirming 
high concentration gradient on the membrane. This is due to accumulation of polyplexes on the 
surface of membrane which limits generating of permeate. At higher TMPs the flux even drops, 
confirming blockage of filter pores which is due to formation of a gel layer on the surface that 
prevents liquid passage across the membrane. Furthermore, as shown in Figure 5.2, the higher the 
applied shear rate, the broader the linear zone. TMP values at the knee points were 0.9 psid, 1.4 
psid, 1.6 psid, 2.3 psid, and 2.6 psid for 7000 s-1, 11000 s-1, 16500 s-1, 22000 s-1, 30000 s-1 shear 
rates, respectively. This expected behavior can be simply explained by the increased sweeping 
actions at higher shear rates which reduce the concentration gradient on the membrane, and lower 
the chances of gel layer formation on the membrane. Generally, the linear part of the curves is 
considered as the safe operational zone for filtration of particles. Among the five shear rates tested, 
the lowest, 7000 s-1 shear rate, demonstrated closest behavior to the linear trend of water (red 
points). Moreover, working with shear sensitive materials (i.e. soft polyplexes with not a very high 
surface charge), it is always recomended to apply lower shear rates, when possible. Hence, the two 
lowest shear rates were picked for diafiltration optimization. 
5.5.2 Diafiltration of CS-based polyplexes is optimized at 5 diavolume 
When the volume of permeate collected equals the starting feed volume, one diafiltration volume 
(also refered to as diavolume, DV) has been processed. The number of DV needed for a complete 
buffer exchange is a key parameter in a diafiltration process which directly depends on the 
permeability of the molecules of the buffer through the chosen membrane. In order to establish the 
optimum DV for purification of CS-based polyplexes (removal of unbound CS), diafiltration of 20 
mL of ODN/CS polyplexes was done using 100 kDa mPES hollow fibers in ten different DVs 
(from 1DV to 10DV). Diafiltration process was performed against the buffer mixture (trehalose 
0.5% and 3.5mM histidine: the mixture in which the polyplexes were prepared) at the two lowest 
shear rates (at a TMP close to the knee point): 7000 s-1 (at TMP=0.9 psid), and 11000 s-1 (at 
TMP=1.0 psid). Although, it is also possible to run the system in lower TMPs (in the linear part of 
the TMP scouting curves), performing filtration in a TMP close to the knee point ensures higher 
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permeate flux, and shorter filtration time (Cross flow filtration Method Handbook, 2014; Millipore, 
2013). 
 
Figure 5.3 Mass percentage of chitosan removed, and mass percentage of polyplexes recovered (a), 
as well as the size and PDI of polyplexes (b) at each diavolume. Diafiltration was performed using 
100 kDa mPES hollow fibers at shear rates of 7000 s-1 (TMP=0.9 psid) and 11000 s-1 (TMP=1.0 
psid). CS/ODN polyplexe solution prepared at ODN concentration of 0.2 mg/mL and N:P=5 via 
AIMS.  
In order to evaluate the recovery of polyplexes, and the amount of free CS remained in the polyplex 
solution, UV absorbance and Orange II measurements were performed on the retentate solution at 
each DV. As shown in Figure 5.3a, by increasing the DV, more CS was removed from the polyplex 
solution. However, increased DV was associated with a reduction in recovery yield (Figure 5.3a), 
and an increase in the size and PDI of polyplexes (Figure 5.3b). The increase in size and PDI of 
polyplexes by increasing the DV is likely due to the increased processing time, during which the 
polyplexes are pushed toward each other under pressure on the membrane during re-circulation. 
Figure 5.3a suggest removal of CS up to 98% and 92% at 5DV diafiltration, for shear rates of 7000 
s-1 and 11000 s-1, respectively. Diafiltration at 11000 s-1 reaches 98% only after 9DV. These results 
indicate that CS removal at lower shear rate (7000 s-1) is more efficient, which is due to lower re-
circulation rate that lets CS molecules pass across the filter more quickly. While there is not a 
significant difference in recovery yield of polyplexes at 5DV at the shear rates of 7000 s-1 and 
11000 s-1 (81%, and 85% respectively), diafiltration at lower shear rate is faster. Higher recovery 
at higher shear rate can again be explained by stronger sweeping actions on the membrane surface. 
Normalized water permeability of hollow fibers was reduced to 86%, and 89% of the original value 
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post-diafiltration for 5DV at shear rates of 7000 s-1 and 11000 s-1, respectively. The small change 
in the permeability of membrane post-diafiltration is an indication that filtration was done with 
very low risk of clogging of the membrane. 
5.5.3 TFF is capable in concentration of CS-based polyplexes 
In order to examine the capability of TFF in concentration of CS-based polyplexes in the 
established operational zone, CS/ODN polyplexes were concentrated using 100 kDa mPES hollow 
fibers in shear rate=7000 s-1, TMP=0.9 psid. 60 mL of polyplexes were loaded into the TFF system. 
The volume of the polyplex was reduced to 30 mL, 20 mL, 15 mL, 12 mL, 10 mL, and 8.5 mL to 
achieve volume concentration factors (VCF) of 2, 3, 4, 5, 6, and 7, respectively. Since the system 
hold-up volume (including tubings and the module) was 7.6 mL, the concentration process was 
stopped at seven-fold before introduction of air into the TFF closed loop. VCF only mirrors the 
concertation of the sample at each stage when no loss of material during the concentration process. 
In order to confirm the actual concentration factor (CF), optical density (OD) of the samples at each 
VCF was recorded using UV spectroscopy at 260 nm. CF was then calculated as following: 
𝐶𝐹 =
𝑂𝐷 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑡 𝑒𝑎𝑐ℎ 𝑉𝐶𝐹
𝑂𝐷 𝑜𝑓 𝑡ℎ𝑒 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒
 
 
Figure 5.4 Z-average and PDI of uncoated CS/ODN polyplexes at each VCF (a), Deviation between 
volume concentration factor (VCF) and the real concentration factor (CF) (b). Concentration of 60 
mL of CS/ODN polyplexes was done up to sevenfold using 100 kDa mPES hollow fibers in shear 
rate=7000 s-1, TMP=0.9 psid.  
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As shown in Figure 5.4a, physico-chemical properties of polyplexes (Z-average and PDI) was 
maintained during the concentration process, since there was no marked change is the size and PDI 
of polyplexes (Figure 5.4a). Moreover, during the concentration process, VCF was equal to CF 
indicating the capability of the TFF system to concentrate the polyplexes, in the applied operational 
conditions, with no loss of up to seven-fold (Figure 5.4b). Normalized water permeability of hollow 
fiber was reduced to 81% of the original value after this concentration process which confirms that 
concentration was done in conditions with very low risk of clogging of the membrane. 
5.5.4 Influence of molecular weight and degree of sulfation of HA, as well as the 
mixing C:P ratio on the physico-chemical properties of complexes   
Upon establishment of the TFF process for filtration of CS/ODN polyplexes, ODN was replaced 
with siRNA for further HA-coatings. 15 mL of CS/siRNA polyplexes were prepared at N:P=5, 
using AIMS, then diafiltered at shear rate of 7000 s-1 (TMP=0.9) against HCl at pH=4 (low pH was 
chosen to ensure that the CS molecules are fully ionized for maximum repulsion during filtration, 
and fully charged for further HA-coating). TMP was stable during diafiltration, indicating no gel 
layer creation of the membrane. UV abs showed >95% recovery of CS/siRNA polyplexes. 
Diafiltered CS/siRNA polyplexes were then transferred for HA-coating. In order to examine the 
influence of HA molecular weight (MW), degree of sulfation (DS), as well as the C:P ratios of 
carboxyl of HA (C) to the phosphate of NA (P) on the properties of final complexes, seven HAs 
with different MW and DS including three non-sulfated (10 kDa, 40 kDa, and 866 kDa), as well as 
four sulfated (12 kDa with DS=1.4, 148 kDa with DS=0.6, 154 kDa with DS=1.0, and 184 kDa 
with DS=2.0) were tested.  
Before addition of HAs to the purified CS/siRNA polyplexes, the amount of bound CS on the 
surface of the polyplexes was investigated. In order to dissociate the CS and siRNA, the diafiltered 
polyplexes were first treated with 10X Tris-Acetate-EDTA (TAE) buffer, which contains 400 mM 
Tris, 200 mM acetic acid, and 10 mM EDTA. TAE 10X buffer was added polyplex solution in 
equal volumes for a final TAE concentration of 5X. Final sample was then centrifuged at 21 kg for 
20 minutes to pellet down the precipitated CS. The supernatant was pipetted out very slowly, and 
the precipitated CS was dissolved back in acetic acid pH=4. Orange II assay was then performed 
to quantify the bound CS. Our data showed that the bound N:P ratio in the diafiltered CS/siRNA 
polyplexes is 1.7. Also, no CS and no siRNA was detected in the supernatant and precipitate, 
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respectively. Thus, it is assumed that the diafiltered polyplexes have a net positive charge of 0.7. 
Therefore, HA could be added at C:P ≥  0.7 to the purified polyplexes. Accordingly, HA solutions 
were added at four different C:P ratios of 1.0, 1.5, 2.0, and 3.0. In order to save on polyplexes, HA-
coating was done by manual addition of small volumes (200 µL of HA into 400 µL of diafiltered 
polyplexes). Preparation of HA-coated complexes was done in duplicates for each condition. 
5.5.4.1 HA-coating of polyplexes requires C:P ≥ 2.0 
Our data showed that regardless of MW and DS, addition of HA at C:P of 1 and 1.5 resulted in 
either macroscopic flocculations or complexes with sizes similar to CS/siRNA polyplexes, with no 
change in their ZP (data not shown). This suggests that although theoretically addition of HA at 
C:P>0.7 should neutralize and reverse the charge sign of the surface (from positive to negative), 
use of HA in excess is required to fully condense and coat the polyplexes. At higher C:P ratios (2 
and 3) a size increase (Figure 5.5a), and a clear switch in ZP (Figure 5.5b) was observed, suggesting 
availability of enough HA molecules to effectively coat the polyplexes.  
 
Figure 5.5 Effect of HA molecular weight, HA degree of sufation, and C:P ratio on the size and 
PDI (a), as well as zeta potential (b) of polyplexes post HA-coating. Uncoated CS/siRNA 
polyplexes were prepared at N:P=5, then diafiltered against HCl at pH=4 to remove the unbound 
CS. Diafiltered polyplexes were then coated by different HAs. HA was added manually to the 
polyplex solutions (200 µL of HA into 400 µL of diafiltered polyplexes). Error bars represent 
standard deviation between the duplicates. 
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5.5.4.2 Low and moderate MW HA result in small sized and homogeneous coated complexes 
Addition of the high MW HA (866 kDa) to the purified CS/siRNA polyplexes resulted in 
macroscopic flocculations, which occurred at all of the tested C:P ratios. However, when mixing 
was done at C:P of 2 or 3 with relatively moderate MWs (148 kDa, 154 kDa, and 184 kDa) and 
low MWs (10 kDa, 12 kDa and 40 kDa) of HAs, this parameter (C:P ratio) had no marked influence 
on the size of the HA-coated complexes with z-average between 125 and 133 nm (Figure 5.5a). 
Nonetheless, the lowest MW HA 10 kDa resulted in the most homogenous coated complexes (PDI 
of 0.08-0.1). Upon addition of different HAs at C:P of 2 or 3, the ZP of the polyplexes reversed 
from +22mV to negative values ranging from -13mV to -26mV. There is not a clear correlation 
between the ZP of the coated complexes and the MW and DS of the HAs, nevertheless, the non-
sulfated HA10 kDa and the non-sulfated HA40 kDa resulted in complexes with the lowest ZP (-
13mV) and the highest ZP (-26mV), respectively (Figure 5.5b). 
5.5.4.3 DS has no or negligible influence on the size, PDI and ZP of coated complexes 
As shown in Figure 5.5, there is no marked difference in the size, PDI and ZP of the HA-coated 
complexes prepared with three HAs having similar MWs of 148 kDa, 154 kDa, and 184 kDa but 
different DS of 0.6, 1.0, and 2.0. They all were added at the fixed C:P of 2. Z-average, PDI, and 
ZP of the HA-coated polyplexes were in the small ranges of 133 to 138 nm, 0.17 to 0.2, and -18 to 
-21mV, respectively. The data suggests that the charge density (represented by DS) has no effect 
on the size, PDI and ZP of the coated complexes (when C:P ratio is high enough (≥2) for an 
effective binding of HA molecules to the surface of polyplexes), however, their stability and 
circulation time in physiological conditions might be different. 
5.5.4.4 Only complexes coated with sulfated HA remained stable post diafiltration 
The two low MW HAs (non-sulfated 10 kDa, and sulfated 12 kDa with 1.4 DS) were chosen for 
large scale production of HA-coated complexes. 10 mL of diafiltered polyplexes were mixed with 
5 mL of HA at C:P=3 using AIMS as described in methods. The HA-coated polyplexes produced 
via AIMS were smaller and more homogenous than manually prepared complexes: 119 nm (PDI 
of 0.07) versus 127 nm (PDI of 0.10) for non-sulfated HA10 kDa, and 100 nm (PDI of 0.18) versus 
125 nm (PDI of 0.19) for sulfated HA12 kDa 1.4 DS. The smaller size and PDI of polyplexes 
produced via AIMS versus manual method was also reported by Tavakoli Naeini et al. for 
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CS/siRNA production (Tavakoli Naeini et al., 2017). Due to similar conditions of HA-coated 
complex solution to the uncoated polyplexes (both have unbound excess materials, at ~10-12 kDa), 
same operational conditions were applied for diafiltration of HA-coated complexes upon mixing: 
shear rate=7000 s-1, and TMP=0.9 psid. In order to keep the HA molecules fully ionized, 
diafiltration of HA-coated complexes was done against HCl at a pH=5 (well above their pKa, but 
low enough to still keep the CS molecules charged). 
 
Figure 5.6 Effect of diafiltration on the size and PDI (a), and zeta potential (b) of HA-coated 
complexes prepared at C:P=3. Both non-sulfated 10 kDa and sulfated 12 kDa HAs were tested. 
Diafiltration of HA-coated complexes was done at 5DV against HCl at pH=5 using 100 kDa mPES 
hollow fibers at shear rate=7000 s-1, and TMP=0.9 psid. Error bars represent standard deviation 
between the duplicates. 
As shown in Figure 5.6, diafiltration of complexes coated with non-sulfated HA 10 kDa was 
associated with a drastic increase in size, Z-average from 119 nm to ~600 nm (Figure 5.6a), and a 
ZP closer to neutral, from -18mV to -9mV (Figure 5.6b) indicating aggregation of complexes. In 
contrast, the size, PDI, and ZP of complexes coated with the sulfated HA 12 kDa was maintained 
over the course of diafiltration: small increase in size from 100 nm to 128 nm, and PDI from 0.18 
to 0.20 (Figure 5.6a). Moreover, as shown in Figure 5.6b, ZP of sulfated HA-coated complexes 
was almost unchanged after diafiltration (-22mV versus -23mV pre-diafiltration). Higher stability 
of complexes coated with sulfated HA could be explained by the increased charge density of the 
sulfated HA, and its enhanced binding affinity to polyplexes, which protects complexes from 
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dissociation by external shear (due to recirculation and filtration pressure), and pH change (during 
diafiltration). Stronger binding affinity of the sulfated HA compared to non-sulfated HA was also 
reported previously (Feng et al., 2017; Magnani et al., 1999).  
5.5.5 Morphology of the uncoated and HA-coated CS/siRNA polyplexes 
Morphology of uncoated CS/siRNA polyplexes as well as HA-coated complexes was assessed by 
Transmission Electron Microscopy (TEM). TEM images show similar spherical morphology of 
CS/siRNA polyplexes pre- and post-diafiltration (Figure 5.7a and Figure 5.7b). The spherical shape 
of CS/siRNA polyplexes was reported previously (Holzerny et al., 2012; Howard et al., 2006a; X. 
Liu et al., 2007; Tavakoli Naeini et al., 2017). Figure 5.7c, and Figure 5.7e show the HA-coated 
complexes produced by non-sulfated 10 kDa HA and sulfated 12 kDa 1.4DS, respectively. 
Generally, HA-coated complexes are noticeably larger than uncoated polyplexes, due to the 
presence of HA. However, HA corona is more evident when non-sulfated HA was used. Stronger 
binding of sulfated HA molecules to the surface of polyplexes results in more compact complexes 
(Figure 5.7e). Morphology of the complexes post-diafiltration is shown in Figure 5.7d (non-
sulfated) and Figure 5.7f (sulfated). As can be clearly seen, the size of non-sulfated HA-coated 
complexes increased post-diafiltration. In contrast, sulfated HA-coated complexes maintained their 
morphology and size during diafiltration which could be attributed to their initial compact 
morphology. This is in agreement with DLS results, which again suggests higher stability of 
complexes produced by sulfated HA. 
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Figure 5.7 TEM images of uncoated polyplexes (prepared at N:P=5), pre-diaifltration (a) and post-
diafiltration agiast HCl at pH=4 (b). HA-coated complexes were prepared using the diafiltered 
polyplexes via AIMS at C:P=3 (c is non-sulfated 10 kDa HA, and e is sulfated 12 kDa HA with 
1.4DS). HA-coated complexes were diafiltered against HCl at pH=5 (d is non-sulfated 10 kDa HA, 
and f is sulfated 12 kDa HA with 1.4DS). Diafiltration of HA-coated complexes was done at 5DV 
using 100 kDa mPES hollow fibers at shear rate=7000 s-1, and TMP=0.9 psid. 
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5.5.6 HA-coated complexes are as bioactive as uncoated CS/siRNA polyplexes 
In order to test the suitability of TFF to maintain the bioactivity of CS/siRNA polyplexes, the eGFP+ 
H1299 cells were transfected in vitro and eGFP+ knockdown was assessed by fluorescence 
measurement at 510 nm, and normalized to total protein content and expressed relative to non-
treated cell. Cells were transfected with uncotaed CS/siRNA polyplexes prepared at N:P=5, both 
pre-diafiltration and post-diafiltration. HA-coated complexes (prepared by either non-sulfated or 
sulfated HAs) were also transfected, both pre- and post-diafiltration. DharmaFECT®2, a 
commercially available lipoplex, was used as positive control. Naked siRNA, and non-treated cells 
were used as negative controls. 
eGFP knockdown reached ~55% and 60% when uncoated polyplexes were transfected pre-
diaifltration and post-diafiltration, respectively (Figure 5.8). Compared to the uncoated polyplexes, 
HA-coated complexes, resulted in slightly higher eGFP knockdown (~75% with non-sulfated 10 
kDa HA, and 81% with sulfated 12 kDa HA 1.4 DS). Higher eGFP knockdown with HA-coated 
complexes could be possibly explained by protection of polyplexes from interactions with 
negatively charged molecules in the serum. Moreover, since HA binds to the CD44 receptor, which 
is overexpressed on the surface of H1299 cells, it can act as the addressing molecule of polyplexes, 
and increases receptor mediated endocytosis. 
As shown in Figure 5.8, bioactivity of non-sulftaed HA-coated complexes reduced significantly 
post-diafiltration (to ~30%). In contrast, complexes prepared using sulfated HA preserved their 
bioactivity at the same level upon filtration (82-84%). Consistant bioactivity of sulfated HA-coated 
complexes upon filtration confirm high stability of these formulations, which is aligned with the 
DLS data (Figure 5.6), and morphology of complexes (Figure 5.7). 
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Figure 5.8 Bioactivity of CS/siRNA polyplexes as well as HA-coated complexes both pre-
diafiltration and post-diafiltration. eGFP+ H1299 cells were transfected with either uncoated or HA-
coated anti-eGFP CS/siRNA polyplexes at a final siRNA concentration of 100 nM/well. eGFP 
silencing was assessed by fluorescence measurement at 410 nm, and normalized to total protein 
content and expressed relative to non-treated cell. Data represent the mean of two independent 
experiments (N=2) with three technical replicates per experiment (n=3). 
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5.5.7 HA-coated complexes have increased hemocompatibilty 
None of the formulations induced hemolysis (see Table 5.1).  
 
Table 5.1 Hemolysis (%) and hemagglutination of RBCs following incubation with serial dilutions 
of uncoated CS/siRNA polyplexes (N:P=5), and HA-coated (sulfated or non-sulfated) both pre- 
and post-diafiltration. Maximum final siRNA concentration was of 0.1 mg/mL and 0.066 mg/mL 
for uncoated and HA-coated complexes, respectively. siRNA (0.1 mg/mL), HAs (1 mg/mL), and 
PEG (40% w/v) were used as negative controls. PLL (10mg/mL) and TX-100 (10% v/v) were used 
as positive controls. Uncoated polyplexes at N:P=5 and HA-coated polyplexes  were all 
nonhemolytic (< 2% hemolysis) for all the concentrations. Mean ± standard deviation (n = 2). 
 
 
However, uncoated polyplexes induced hemagglutination at the highest concentration tested, 0.1 
mg siRNA/mL (see Figure 5.9), whether pre-diafiltration (with unbound CS) or post-diafiltration 
(without unbound CS). It suggests that although the unbound CS is removed upon diafiltration, 
this is not sufficient to prevent hemagglutination in these formulations due to their positive 
surface charge. Hemagglutination of CS-based polyplexes at elevated concentrations (1 mg 
siRNA/mL) was previously reported (Veilleux, 2016). On the other hand, HA-coated complexes 
(weather with sulfated or non-sulfated) did not cause hemagglutination up to the highest 
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concentration tested, 0.0667 mg siRNA/mL (see Figure 5.10 and Figure 5.11), which suggest that 
HA corona reduces the interactions of polyplexes with red blood cells. 
 
Figure 5.9 Hemagglutination assay of uncoated CS/siRNA polyplexes prepared at N:P=5 at 0.1, 
0.05, and 0.025 mg siRNA/mL pre-diafiltration (A, B, C), and post-diafiltration (D, E, F). Note 
that 1 mg siRNA/mL equals to 1 mg/kg injectable dose for a mouse of 10g (for an injection of 10 
µL/g). Highest dose of uncoated polyplexes cuased hemagglutination both pre- (A) and post-
diafiltration (D). 
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Figure 5.10 Hemagglutination assay of non-sulfated HA-coated complexes prepared at P:C=3 at 
0.067, 0.0335, and 0.0167 mg siRNA/mL pre-diafiltration (A, B, C), and post-diafiltration (D, E, 
F). Note that 1 mg siRNA/mL equals to 1 mg/kg injectable dose for a mouse of 10g (for an injection 
of 10 µL/g). None of the samples caused hemagglutination. 
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Figure 5.11 Hemagglutination assay of sulfated HA-coated complexes prepared at P:C=3 at 0.067, 
0.0335, and 0.0167 mg siRNA/mL pre-diafiltration (A, B, C), and post-diafiltration (D, E, F). Note 
that 1 mg siRNA/mL equals to 1 mg/kg injectable dose for a mouse of 10g (for an injection of 10 
µL/g). None of the samples caused hemagglutination. 
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5.6 Conclusion 
To tackle the limitations of CS-based polyplexes for intravenous delivery, TFF was applied, for the 
first time, to purify CS-based polyplexes from the unbound CS. Through TMP scouting analysis, 
safe TFF operational conditions were established. It was shown that polyplexes preserved their 
physico-chemical properties, morphology, and bioactivity after the TFF process. Purified 
CS/siRNA eGFP polyplexes were then coated by different HA molecules. Our study examined the 
impact of HA molecular weight and degree of sulfation, as well as C:P ratio on the physicochemical 
properties of coated complexes. We found that regardless of the degree of sulfation, low molecular 
weight HA at C:P ratios above 2 is needed to effectively coat the polyplexes and surface charge 
reversal. Additionally, it was shown that the HA-coated CS/siRNA complexes have even higher 
knockdown efficiency of eGFP in H1299 cells (75-82%), compared to uncoated polyplexes (53-
63%), which is likely due to 1) improved protection of polyplexes by HA corona, and 2) increased 
receptor mediated endocytosis by the HA-coating through the CD44 receptor on the surface of the 
cells. Our data indicated that although both sulfated and non-sulfated HAs result in small sized and 
homogenous coated complexes, only complexes prepared with sulfated HA preserved their 
physico-chemical properties and bioactivity post filtration, indicating their stronger binding affinity 
to polyplexes. Finally, we showed that the HA-coated complexes eliminated hemagglutination and 
hemolysis. Improved bioactivity and hemocompatibility of these modified formulations are 
promising for the clinical use of CS-based complexes for IV applications. 
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CHAPTER 6 GENERAL DISCUSSION 
The published study (Chapter 4) aimed to develop a fully automated in-line mixing system (AIMS) 
that is capable in reproducible production of large batches of CS/NA polyplexes. We started the 
work by designing a mixing platform based on two peristaltic pumps. The choice of peristaltic 
pumps was to drive fluids based on pulsatile motion, where the natural oscillation of the fluids 
provides a wavy and stretched interface between the two streams, thus enhancing the mixing. In 
order to have an automated system, digital peristaltic pumps were programmed via LabView 
software, to simultaneously drive CS and NA solutions (at a flow rate set by the user), and mix 
them in a Y, or T, or cross connector. For maxium precision on dispensed volumes, a sub-program 
was desgined to calibrate the pumps using digital balances before actual mixing. Balances were 
also used to monitor the volume/mass of payloads during mixing process. The whole system was 
closed to maintain sterility. The primary design (named "initial version" throughout the text) was 
further improved, aiming to enhance the quality of products (smaller size and more homogeneous), 
and to reduce the capital cost, and save space. The new design (named "advanced version" 
throughout the text) features (1) only one peristaltic pump with a dual channel head that drives both 
CS and NA, simultaneously; (2) priming of the tubings with water rather than the NA and CS 
solutions in order to minimize consumption of payloads; (3) mixing after the acceleration phase of 
the pump to produe the polyplexes only at the target speed set by the user.  
In order to optimize the mixing process for production of small size and uniform polyplexes, the 
influence of mixing parameters (i.e. mixing speed, mixing concentrations, mixing pattern and 
length) on physico-chemical properties of CS/pDNA and CS/siRNA were studied for both initial 
and advanced versions of AIMS. Increasing mixing concentrations was directly associated with an 
increase in size and polydispersity of both CS/pDNA and CS/siRNA polyplexes. We found that 
regardless of the mixing method (manual versus in-line) and configuration of AIMS (initial versus 
advanced), the maxium concetration for reproducible production of small and homogeneous 
CS/pDNA is 0.1 mg/mL. However, AIMS allowed production of relatively small and homogeneous 
CS/siRNA polyplexes at increased concentrations of 0.3 mg/mL and even 0.4 mg/mL (using the 
advanced version). The possibility of producing CS/siRNA polyplexes at higher concentrations 
could be attributed to the higher C* of siRNA as compared to pDNA. While C* for CS and pDNA 
are close to each other and relatively low (3.6 mg/mL and 1.36 mg/mL for chitosan 92-10 and 
pDNA, respectively), this value is 790 mg/mL for siRNA which gives a lattitude in siRNA mixing 
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concentration before reaching flocculation (up to the tested concentraion of 0.4 mg/mL), 
nevertheless, the increased siRNA mixing concentration is associated with an increase in size and 
PDI of final polyplexes. Additionally, we found that ZP increases as mixing concentration 
increases. This behavior was found for the both type of NAs. This result suggests that when mixing 
concentration is higher, more chitosan is incorporated in polyplexes which could be the result of 
faster association kinetics at higher mixing concentrations. 
The speed of mixing found to have a negligible impact on the properties of CS/pDNA polyplexes: 
for 26 < Re < 4000, z-average diameter and PDI of CS/pDNA polyplexes varied only slightly 
between 186 and 112 nm, and between 0.25 and 0.23, respectively. It seems that even at very low 
speeds, the pulsatile action of the peristaltic pumps generates sufficient perturbation and interface 
stretching for efficient mixing and production of homogeneous small sized pDNA/CS polyplexes. 
pDNA is a relatively big molecule with a low diffusivity, thus, at the time of mixing, mostly CS 
molecules diffuse to contribute to complex formation. Once association of CS molecules starts on 
a pDNA supercoil, the chance of collision with another pDNA molecule is much lower than 
colliding with a subsequent CS. This limits bridging of polyplexes and potential heterogeneity, 
even at low mixing speeds. Similar physico-chemical properties of manual and in-line CS/pDNA 
polyplexes (regardless of AIMS version), in a given concentration, could be explained by low 
diffusivity of pDNA and limited sensitivity of these polyplexes to the mixing speed, suggesting 
that even the low advection provided by manual mixing is sufficient for having an efficient mixing. 
However, interestingly, the size and polydispersity of CS/siRNA polyplexes are influenced by the 
mixing speed: the higher the speed, the smaller the size and polydispersity. This is likely due to 
high diffusivity of siRNA molecules. As a very small molecule, in addition to CS, siRNA 
significantly contributes to the complex formation. Thus, in order to achieve homogeneous 
polyplexes, stronger advection is required to eventually saturate siRNA with excess CS molecules 
rather than colliding with another siRNA. Accordingly, it is not surprising that compared to manual 
method, AIMS (both initial and advanced versions) provided with smaller and more homogenous 
CS/siRNA polyplexes when mixing was done at a high speed (Re≥ 2140, non-laminar flow 
regime). Compared to manual CS/siRNA polyplexes (z-average diameter and PDI of 101 nm and 
0.2), for Re between 2140 and 4000, the initial version of AIMS produced polyplexes with z-
average diameter and PDI from 84 nm to 75 nm and, 0.18 to 0.17; and the advanced version 
produced polyplexes with z-average diameter and PDI from 65 nm to 47 nm and, 0.18 to 0.12, 
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respectively. Knowing the fact that CS/siRNA polyplexes are sensitive to mixing speed, and since 
in the advanced version of AIMS mixing only takes place in the target speed, it was expected that 
this version provides with smaller CS/siRNA polyplexes with lower PDI, as compared to the initial 
version (where mixing starts at a low speed and ends at the target speed). We also found that the 
mixing pattern (Y, T, or a cross connector), and mixing length (from 25cm to 65cm) had no effect 
or a very small effect on polyplex properties. This suggests that no matter what mixing pattern is 
chosen, the pulsatile actions and transverse advection inside the 25cm outlet is sufficient for a 
complete mixing. 
TEM images show that regardless of the mixing method (AIMS versus manual), CS/pDNA 
polyplexes have a mixed morphology (spherical, toroidal and rod like). This was expcted as was 
previously reported in literature. CS/siRNA polyplexes, on the other hand, were generally 
spherical. In agreement with DLS data, TEM images revealed smaller and more uniform CS/siRNA 
polyplexes when produced via AIMS versus manual method. Finally, it was demonstrated that 
CS/siRNA polyplexes produced via AIMS had equivalent or higher silencing efficiency of ApoB 
in HepG2 cells: 40-55% ApoB mRNA knockdown as compared to manual polyplexes (30-45%). 
Chapter 5 aimed to establish TFF technique for concentration and purification of CS-based 
polyplexes. Hollow fiber geometry was taken as it has been demonstrated that the tubular geometry 
of hollow fibers is more beneficial than the cassette geometry for filtration of particles, which is 
attributed to migration of particles to the center of the hollow fiber where the flow velocity is the 
highest (tubular pinch effect). Moreover, hollow fibers are less expensive than cassette geometry 
and are available as pre-sterilized single use modules, which reduces the risk of cross 
contamination, cleaning labour, and time needed for system overhaul. mPES membranes are 
extremely hydrophilic, and almost all of the commercially available hollow fibers for ultrafiltration 
purposes are made form modified Polyethersulfone (mPES). According to the size range of 
polyplexes (45-60 nm aimed to retentate), and the chitosan molecules (~5 nm aimed to permeate), 
and based on the data obtained from manufacturer on the pore size of different cut-offs, mPES 
hollow fibers at 100 kDa and 300 kDa were selected for filtration of CS-based polyplexes. Our 
results showed that filtration of polyplexes using a 300 kDa membrane was associated with a very 
low recovery (57%) versus the 100 kDa membrane with 85% recovery (both tested at the shear rate 
of 11000 s-1, and TMP=1.0 psid). This was due to partial penetration of polyplexes into bigger 
pores of 300 kDa membrane (data showed higher deposition of polyplexes on the 300 kDa 
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membrane surface (25% of the initial polyplexes). Altogether, 100 kDa membrane was found as a 
better pick for filtration of CS-based polyplexes. Thereafter, optimal TFF operational conditions 
were established using 100 kDa mPES hollow fibers. TMP scouting revealed that for filtration of 
CS-based based polyplexes, TMP had to be generally maintained lower than 1.0 psid. Among the 
shear rates tested (between 7000 s-1 and 30000 s-1), the lowest shear rate (7000 s-1) demonstrated 
closest behavior to the linear trend of water, suggesting a very low concetration gradient on the 
surface of the membrane (no excessive pressure and enough shear rate to sweep the polyplexes 
away). In order to reduce the processing time at a given feed flow rate, TMP should increase, which 
requires higher shear rate to sweep away the polyplexes more efficiently to keep the concentration 
gradient on the membrane surface as low as possible. However, higher TMP is always associated 
with the risk of membrane fouling as it is the pressure that pushes the polyplexes on the membrane. 
Moreover, working with shear sensitive materials (i.e. soft polyplexes with not a very high surface 
charge), it is always recomended to apply lower shear rates, when possible. Hence, the two lowest 
shear rates were picked for further diafiltration optimizations. We found that by increasing the DV, 
more chitosan was removed from the system, at the cost of recovery yield, and a gradual increase 
in the size and PDI of polyplexes. The increase in size and PDI of polyplexes by increasing the DV 
is likely due to the increased recirculation of polyplexes in the system where they were pushed 
toward each other under pressure on the membrane. Our data suggest that at 5DV up to 98% and 
92% of CS was removed, when shear rate was set at 7000 s-1 and 11000 s-1, respectively. Removal 
of CS at 11000 s-1 reached 98% only after 9DV. These results indicate that CS removal at lower 
shear rate (7000 s-1) is more efficient, which is due to lower re-circulation rate that lets CS 
molecules pass across the filter more quickly. Recovery yield of polyplexes at 5DV was 81%, and 
85%, for shear rates of 7000 s-1 and 11000 s-1 respectively. The slight higher recovery at higher 
shear rate (11000 s-1) can be explained by stronger sweeping actions on the membrane surface. 
However, achieving a certain purity is faster and less expensive (less buffer usage) at lower shear 
rate. Upon establishment of the TFF operational conditions, polyplexes were concentrated up to 
sevenfold while preserving their physico-chemical properties (shear rate=7000 s-1 at TMP=0.9 
psid). 
The final objective of the thesis was to modify the surface of the polyplexes upon purification. A 
library of HA molecules was used to coat the polyplexes to enhance their hemocompatibility for 
IV administration. HAs with different molecular weights (from 10kDa to 866 kDa) and degrees of 
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sulfation (from 0.6 to 2.0), at different carboxyl to phosphate ratios (C:P from 1.0 to 3.0) were 
tested. We initially found that high molecular weight HA (866 kDa) results in macroscopic 
flocculations at every C:P ratio tested. Moreover, it was demonstrated that C:P≥ 2.0 is needed to 
effectively coat the polyplexes and switch the surface charge of complexes. It was shown that 
polyplexes coated with lower molecular weight HAs, non-sulfated 10kDa and sulfated 12kDa (z-
average of 125-129nm, PDI of 0.09-0.18, and average zeta potential of –17 mV) have have even 
higher knockdown efficiency of eGFP in H1299 cells (75-82%), compared to uncoated polyplexes 
(53-63%). This is likely due to the improved protection of polyplexes by HA corona in serum, and 
the increased receptor mediated endocytosis by the HA-coating through the CD44 receptor on the 
surface of the cells. Our data indicated that although both sulfated and non-sulfated HAs result in 
small sized and homogenous coated complexes, only complexes prepared with sulfated HA 
preserved their physico-chemical properties and bioactivity post filtration, indicating their stronger 
binding affinity to polyplexes. We finally showed that hemagglutination and hemolysis induced by 
uncoated polyplexes were completely eliminated by HA-coating (using both sulfated and non-
sulfated HAs).   
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CHAPTER 7 CONCLUSION AND RECOMMENDATIONS 
This work allowed to develop an automated in-line mixing system (AIMS) for reproducible 
production of large batches of CS-based polyplexes with equivalent bioactivity as compared to 
manually prepared polyplexes. We found that the mixing speed has not a significant impact on the 
physico-chemical properties of CS/pDNA polyplexes. However, mixing at higher flow rates 
resulted in smaller and more homogenous CS/siRNA polyplexes. In additions, it was shown that 
reducing the concentration of both pDNA and siRNA, results in a reduction in size, PDI and zeta 
potential of polyplexes. The type of mixer and mixing length showed no or negligible effect on the 
properties of CS-based polyplexes. AIMS enabled to eliminate day to day small volume 
preparations, and the risks of batch to batch and inter-user variability. 
In a subsequent study, for the first time, tangential flow filtration technique was adopted and 
optimized to purify large batches of CS-based polyplexes. First, we found that 100 kDa mPES 
hollow fiber is a proper membrane for permeation of CS molecules (Mn =10 kDa) from polyplexes 
(z-average = 45-55 nm). We demonstrated that generally TMP has to be maintained below 1.0 psid 
to prevent clogging of the membrane during the filtration process. Upon establishment of the 
operational conditions, it was demonstarted that TFF is capable in concentration of polyplexes up 
to sevenfold while preserving their physico-chemical properties. Furthermore, we demonstrated 
that a diafiltration volume of 5 is enough to remove up to 98% of free CS (TMP= 0.9 psid, shear 
rate = 7000 s-1). Our results suggest that CS removal at a low shear rate (7000 s-1 with 98% CS 
removal at 5 DV) is more efficient than a higher shear rate (11000 s-1 with 92% CS removal at 5 
DV), while there is not a significant difference in recovery yield of polyplexes at 5DV at the shear 
rates of 7000 s-1 and 11000 s-1 (81%, and 85% respectively). Also, diafiltration at a lower shear rate 
is faster due to higher permeate flux. TFF was found suitable for removal of unbound chitosan from 
the polyplexes while preserving their physicochemical properties, and their biological activity. 
Finally, decorating the purified polyplexes with HA led to the development of a new class of 
bioactive complexes with improved hemocompatibility.  
This work allowed to develop an automated method for reproducible production of CS-based 
polyplexes in large batches with equivalent or even improved qualities as compared to manually 
prepared polyplexes. Establishment of tangential flow filtration technique for purification and 
concentration of large batches of CS-based polyplexes while preserving their physicochemical 
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properties and biological activities was another achievement of this work. Finally, this work 
demonstrated that HA-coating of purified polyplexes led to the development of new formulations 
with increased bioactivity and hemocompatibility. The accomplishments of this work represent 
important steps towards future clinical use of CS-based intravenous gene therapies. 
Although beyond the scope of this work, the following recommendations are worth considering in 
the future: 
1. Integration of AIMS and TFF – In this study, polyplexes were first produced via AIMS, 
then transferred to the TFF system for either purification or concentration. We programmed 
and automated both AIMS and TFF via the LabView software. One recommendation is to 
integrate them (by a sub-program) to a bigger platform as a complete production and 
purification/concentration line. The output vessel of AIMS can be the input (feed) container 
of the TFF system. This will eliminate manual works, and the risk of contamination. 
2. Optimization of TFF conditions for HA-coated polyplexes – The main purpose of 
establishing TFF in this work was to purify the CS/siRNA polyplexes before addition of 
HA. We also used this technique for filtration of HA-coated complexes in the conditions 
that were optimal for uncoated polyplexes. Although the size of 10 kDa and 12 kDa HA 
molecules are close to the CS used (10 kDa), the size range and the viscosity of HA-coated 
sample is different from the one of uncoated polyplexes. Therefore, it is recommended to 
investigate the TFF operational parameters (e.g. membrane cut-off, TMP, and shear rate 
needed) for processing of HA-coated complexes.  
3. Assess the colloidal stability of HA-coated complexes – HA-coated complexes 
demonstrated excellent hemocompatibility and bioactivity in vitro. One recommendation is 
to test their colloidal stability in physiological conditions (e.g. 150 mM NaCl, 25mg/mL 
BSA or 90% serum), prior transferring them for in vivo and clinical administration.  
4. Freeze-dry the purified uncoated and HA-coated samples and check their stability – For 
long term storage, HA-coated complexes need to be freeze-dried before delivery to the end 
user. A recommendation here would be to evaluate their physico-chemical properties, 
bioactivity and hemocompatibility post freeze-drying. 
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